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FR901464 is a natural product that elicits anticancer activity via inhibition of pre-mRNA 
splicing, a novel therapeutic approach. Through structure-activity relationship (SAR) studies on 
FR901464, the Koide group reported a potent stable synthetic analogue of FR901464, 
meayamycin B (GI50 4 – 211 pM).  
An objective of this thesis was to probe electrophilic sites of meayamycin B through SAR 
anaylsis. This studies in this thesis provided insights into the effects of cis-C2´-C3´ enamide and 
epoxide moieties. A newly synthesized inhibitor, in which the epoxide was replaced with a 
ketone, exhibited elevated inhibition against cellular proliferation. Cell growth assays illustrated 
that this analogue inhibited the proliferation of cells in an irreversible manner.  
Addtionally, an in vivo study led to the development of meayamycin C which, although 
less potent than meayamycin and meayamycin B, exhibited single digit nanomolar GI50 values 
and selectivity to inhibit the proliferation of certain human cancer cells. 
Continuing with the design of pre-mRNA splicing inhibition tools, we also report the 
preparation and evaluation of two tetraethylene-linked derivatives of meayamycin. These two 
derivatives inhibited the proliferation of human cell lines and pre-mRNA splicing in cells. 
Structurally, one of the derivatives is far less complex than tetraethylene glycol-linked 
meayamycin, though still retained sufficient inhibitory activity towards cell proliferation and pre-
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mRNA splicing. These two compounds have the potential serve as starting points for 
conjugatable FR901464 analogues. 
Furthermore, a new synthetic route for meayamycin is described. The new route consists 
of 8 steps to prepare the western fragment, followed by a final cross metathesis interchange 
strategy between the right half and FR901464 to yield meayamycin. This is the shortest synthetic 
approach to prepare meayamycin.  
Finally, a study was begun on TMC-205, which was discovered in 2001 in a similar 
manner to FR901464. The work in this dissertation reports the first synthesis of TMC-205 and 
developed analogues, including alcohol 3.21, an eight-fold more potent analogue of TMC-205. 
Importantly, there is a range of TMC-205 and analogue 3.13 concentrations where the 
compounds activate an SV40-controlled gene without detectable antiproliferative activity. 
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1.0  BACKGROUND 
1.1 EUKARYOTIC GENE EXPRESSION 
The classic central dogma of molecular biology shows the order of genetic information 
from DNA → RNA → protein (Figure 1-1). While DNA is being transcribed to produce 
messenger pre-RNA (pre-mRNA), several essential co-transcriptional processing events take 
place that ultimately control the localization, stability and translation of mature mRNAs. These 
events include capping the 5´ end of mRNAs, poly-adenylation of the 3´ end of mRNAs and 
precursor mRNA (pre-mRNA) splicing. Pre-mRNA splicing is a critical step during the 
expression of eukaryotic genomes in which the intervening sequences, introns, regions of pre-
mRNA that are removed before the mRNA is translated into protein. Removal of intron 
sequences produces mRNA substrates that are exported to the cytoplasm for subsequent protein 
translation. Incorrect splicing can be caused by mutations in the pre-mRNA or mutations in 
trans-acting factors, proteins that bind pre-mRNA sequences to control gene expression, and are 
implicated in an array of human diseases.1 Recently, it has been shown that small molecules that 





Figure 1-1 Pictorial presentation of eukaryotic gene expression. 
 
The pre-mRNA that results from DNA transcription serves as a binding platform for a 
highly coordinated series of RNA-RNA and RNA-protein interactions that are critical for the 
accurate removal of intron sequences. Additionally, conserved cis-RNA sequences, DNA 
sequences in the vicinity of the structural portion of a gene required for gene expression, within 
the pre-mRNA serve as the biological catalyst of intron removal. Eukaryotic cells have 
developed an elaborate machinery known as the spliceosome, to facilitate the two chemical steps 
of the splicing reaction of each intron. Spliceosomes are assembled from key building blocks, 
which include five uridine-rich snRNP (small nuclear ribonucleoprotein complexes), specifically 
U1, U2, U4, U5 and U6.8 Together, these compounds play critical roles in identifying conserved 
cis-RNA sequences, assembling the catalytic spliceosome, and facilitating splicing chemistry. 
1.1.1 Chemistry of splicing 
RNA transcripts undergo multiple changes before they can be used as templates in 
protein production. One of the initial steps is the transcription of DNA into pre-mRNA. Pre-
 3 
mRNA is composed of introns and exons and approximately 40% of the human genome consists 
of introns.9 The removal of introns and the ligation of exons occur through a process of two 
trans-esterification reactions (Figure 1-2). In the first reaction, the 2’-OH of an adenosine in the 
intron, termed the branchpoint A, attacks the phosphate bond at the 5’ splice site (5’ SS). This 
results in a free 5’ exon and the 5’ SS is ligated to the branchpoint A, forming a lariat structure. 
During the second trans-esterification reaction, the 3’-OH of the 5’ exon attacks the 3’ splice site 
(3’SS). This nucleophilic attack causes the 5’ exon to become ligated with the 3’ exon and 
releases the intervening intron.8 
 
 
Figure 1-2 Chemical mechanism of the pre-mRNA splicing reaction. Red and blue structures 
represent exons and black structures represent intron. 
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1.1.2 Spliceosome components and stepwise recognition of intron 
The accurate and efficient catalysis of the two chemical steps in splicing is essential for 
proper cellular activity. The correct recognition and catalysis of splicing is carried out by the 
spliceosome, a large protein-RNA complex.8 The spliceosome is comprised of five snRNPs and 
each snRNP consists of one snRNA (small nuclear RNAs).  
 
 
Figure 1-3 Model of human spliceosome assembly. 
 
The snRNAs of the snRNPs play roles in intron recognition and splice site definition and 
intimately involved in spliceosomal catalysis. The pre-mRNA splicing involves the step-wise 
assembly of the spliceosome onto the pre-mRNA.8 There are four main complexes that are 
 5 
formed, denoted spliceosomal complexes E, A, B, and C, respectively (Figure 1-3).8 Their 
involvement is as follows:8 Complex E, the commitment complex, is created when U1 joins with 
pre-mRNA, attaching at the 5’ intron/exon boundary. Complex A is created when U2 binds to 
the complex at the branch point adenosine. Complex B is created when the triple complex U5, 
U4 and U6 assembles onto the pre-mRNA. Complex C, the active spliceosome, is created when 
U4 dissociates, allowing U6 to base pair with snRNA in U2. Pre-mRNA splicing occurs, 
resulting in the separation of the 5’ exon/intron boundary and formation of the lariat. The joined 
exons dissociate from the spliceosome/intron complex, leaving the lariat structure behind and the 
spliceosome dissociates followed by the recycling of snRNPs (Figure 1-3).8  
1.1.3 Alternative splicing 
With the sequencing of a variety of genomes has come the realization that the number of 
genes does not seem to correlate with the complexity of the organism. One explanation for how 
these organisms increase in complexity despite a limited genomic set is through the use and 
regulation of alternative splicing. 
Alternative splicing occurs when one pre-mRNA is spliced into multiple mRNAs and, 
hence, encodes multiple proteins accordingly. There are four patterns of alternative splicing: (1) 
exon skipping, (2) intron retention, (3) alternate 5’SS, and (4) alternate 3’SS (Figure 1-4). The 
most common form of alternative splicing in humans is exon skipping.10 The regulation of 
alternative splicing occurs through the activity of alternative splicing factors. The presence or 
absence of these proteins affects the recognition of a particular splice site. If the protein is acting 
as an enhancer, it will recruit members of the spliceosome to the adjacent splice site. However, if 
the factor is a splicing silencer, it will inhibit members of the spliceosome from recognizing a 
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splice site.10 Alternative splicing of pre-mRNA is a flexible point of gene control in humans. It 
provides cells with the opportunity to create isoforms of differing, even opposing, functions from 
a single gene.10  
 
 
Figure 1-4 Alternative splicing variations. 
1.1.4 Splicing and disease 
Approximately 15% of single base pair mutations that cause human genetic diseases are 
linked to pre-mRNA splicing defects. Many of these genetic mutations cause inappropriate exon 
skipping, which ultimately causes defects in protein expression.11 Other mutations also lead to 
alternative splice site selection, thus resulting in inclusion or exclusion of more RNA and longer 
or shorter exons. This in turn leads to the addition of one or more amino acids, or more 
commonly reading frame shift.11 Given that the majority of human genes contain introns, and 
that most pre-mRNAs undergo alternative splicing, it is not surprising that disruption of normal 
splicing patterns can cause human diseases such as cancer.12  
Cancer cells exploit alternative splicing to produce proteins that promote growth and 
survival.11,13 Three different approaches could be used to target the pre-mRNA splicing process 
in cancer. 13  
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a. Precisely control alternative pre-mRNA splicing by identifying specific splice sites 
and block their use. 
b. Characterize splice-variant proteins that may be responsible for the malignant 
phenotype, and identify differences from their normal protein counterpart. 
c. Since cancer cells in general have higher metabolic rates than normal cells, and hence 
increased splicing rates, they are more responsive to pre-mRNA splicing inhibitors. 
 
An example of the second approach was demonstrated by Peter Laverman and coworkers 
in a strategy to eradicate colon and pancreatic cancer;14 gastrin, a 33-amino acid peptide 
hormone, binds to cholecystokinin, a receptor, and participates in gastric motility. Recently, a 
splice variant of cholecystokinin has been discovered in human colorectal and pancreatic cancer 
but not in normal tissue. This splice-variant receptor was involved in the development of 
colorectal and gastric cancer, which makes this receptor a potential therapeutic target. The same 
group developed a peptide radiolabelled with 111In to target the splice variant of cholecystokinin, 
although the radiolabelled peptide has some affinity for the normal receptor.  
Despite the numerous advances in oncology over the past fifty years, cancer is still the 
second leading cause of death in the United States.15 American men and women have a 38 – 44% 
chance respectively, of developing cancers during their lifetime and, in 2010, more than 500,000 
Americans died from cancer.15 Currently, there is a grave need for new therapies from new 
sources utilizing novel modes of action to complement already established treatments for cancer. 
Such approach is targeting the splicing of pre-mRNAs, which is novel and just being recognized 
as a viable approach to targeting cancer.13 
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 Worldwide efforts in the isolation of new natural products have been an important source 
for novel structures and successful therapeutics.16 In the search for new small molecules to treat 
cancer, researchers have begun to investigate new compounds from natural sources with new 
modes of action. The result of such an investigation is FR901464, an anticancer compound and 
pre-mRNA splicing inhibitor, and is the motivation for the development of a first in-class of 
FR901464-like compounds with novel chemotherapeutic effects. 
1.2 FR901464 
1.2.1 Discovery of FR901464 
In the pursuit for natural anticancer therapeutics with new modes of action, researchers at 
Fujisawa Pharmaceutical Company discovered and isolated FR901463 (512 mg), FR901464 
(819 mg), and FR901465 (70 mg) (Figure 1-5) from the fermentation broth of Pseudonomas sp. 
No. 2663 as novel SV40 promoter-dependant transcriptional activators that cause cell cycle 
arrest at G1 and G2/M phases.5 All three compounds isolated exhibited potent antitumor activity 
against a number of human cancer cell lines with IC50 (concentration required to inhibit 50% of 
cell growth) values ranging from 0.2 – 1.7 ng/mL (Table 1-1), in which mouse bone marrow 






Figure 1-5 Chemical structures of FR901463, FR901464 and FR901465. 
 
Table 1-1 Antiproliferative activity of FR901463, FR901464 and FR901465 in various human 
cancer cell lines. 
  IC50 (ng/mL)  
 FR901463 FR901464 FR901465 
MCF-7 0.46 0.91 0.59 
A549 0.35 0.66 0.44 
HCT116 0.22 0.31 0.34 
SW480 0.40 0.51 0.53 
P388 0.82 1.69 0.48 
BM  2.03 5.01 1.91 
MCF-7 = human breast adenocarcinoma cells. A549 = human lung adenocarcinoma cells. 
HCT116 = human colon carcinoma cells. SW480 = human colon adenocarcinoma cells. P388 = 
lymphocytic leukemia cells. BM = mouse bone marrow cells. 
 
The antitumor activities of the three compounds were then evaluated in mice bearing 
P388 tumors. The compounds were administered intraperitoneal (ip) once a day for 4 days. 
Antitumor activity was measured as percentage (%) of median survival time of treated group (T) 
versus control (C), shown in equation 1.1 (the length of the study was not reported). 
Equation 1.1    
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Of the three compounds, FR901465 was the least effective, T/C(%) of 127 at 0.032 
mg/kg. Higher dosages were reported to be toxic. FR901463 displayed a T/C(%) of 160 at 1.0 
mg/kg and FR901464 showed T/C(%) of 145 at 0.1 mg/kg. Antitumor effects of FR901463 and 
FR901464 were then measured in A549 xenografts. The efficacy was determined by a measure 
of percentage of mean tumor weight of the treated (T) group to that of control (C) group, 
equation 1.2. 
Equation 1.2    
 
FR901464 showed significant GI at dosages of 0.1 to 0.56 mg/kg, GI = 60 – 83%, while 
FR901463 displayed weaker antitumor effect, a maximum GI of 61%. FR901464 showed 
prominent antitumor effects against Colon38 and Meth A (3-methylcholanthrene-induced 
sarcoma) as well, GI = 38 to 86% at dosages between 0.1 to 1.0 mg/kg.5 These data strongly 
suggest that FR901464 or its analogues have promising clinical applications. Despite its high 
potency in inducing SV40 promoter, this compound lowers the mRNA levels of several cancer-
related genes, including p53, p21, c-myc, and E2F-1 in MCF7 cells at 20 nM and induces 
apoptosis in MCF7 cells at LC50 (lethal concentration to kill 50% of the tested population) of 0.5 
nM.5,17,18 Recent work has identified the biosynthetic gene cluster of FR901464, which sets the 
stage for engineering the pathway for the development of novel analogues.19 An important final 
note, however, is that FR901464 is not a compound designed or optimized for clinical use due to 
its instability (discussed below). It is instead a great lead compound that suggests superior 
analogues could be developed based on this lead. 
Synthetically, the complexity of this compound has led to three total syntheses. The first 
and only member of the FR90146 family to succumb to synthesis was FR901464, which was 
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completed by Jacobsen and coworkers in 2001.20 Kitahara and coworkers completed the second 
total synthesis of FR901464 in the same year,21 followed by the Koide group, which completed 
the most concise synthesis in 2006.22 These syntheses were each an impressive feat but their 
lengths make them ineffective in their present form as a source of clinical material. 
1.2.2 FR901464 structure activity relationship (SAR) studies by Jacobsen, Kitahara 
Koide, and Takahashi  
Due to FR901464’s antiproliferative activity in mammalian cancer cells, medicinal 
chemistry efforts have been performed to explore the SAR of FR901464. During early synthetic 
studies undertaken by the Jacobsen group to establish the absolute stereocenters of FR901464, 
the epoxide moiety was found to be a crucial functional group, most likely acting as a reactive 
electrophile (Figure 1-6, compound 1.3, Table 1-2).20 The epimer of the epoxide, 1.2, was only 
2-fold less active than the natural one (GI50 = 400 nM in Tag Jurkat cells), confirming which 
epimer is the naturally occurring one.20 Furthermore, Kitahara and coworkers reported one of 
their synthetic precursors, alkene 1.5, also exhibited no activity for CMV promoter 
activation.23,24 Finally, the Koide group also investigated the epoxide moiety. It was not clear 
whether the loss of activity of cyclopropane 1.3 and alkene 1.5 was due to loss of oxygen atom 
or the electrophilicity of the epoxide. To address these questions, Koide and colleagues prepared 
non-epoxy analogues 1.7, 1.8 and 1.9, where the oxygen atom at C3 is retained. All non-
epoxy/non-electrophilic analogues were inactive,23,24 which further supports that the 




Figure 1-6 Chemical structures of epoxy analogues and their parent compounds (FR901464, 











Table 1-2 Antiproliferative activity of epoxy-analogues and their parent compounds. 
  IC50 (nM)  
compound Tag Jurkat cells Promoter activation MCF7 cells 
1.1 2 ++++ 1.1 
1.2 400 ND ND 
1.3 >5000 ND ND 
1.4 ND +++++ ND 
1.5 ND + ND 
1.6 ND ND 0.01 
1.7 ND ND >10000 
1.8 ND ND >10000 
1.9  ND ND >10000 
Tag Jurkat = T lymphocyte cells. MCF7 = human breast adenocarcinoma cell line. ND = not 
determined. “+” shows relative strength of activity by CMV promoter activation. 
 
The right pyran ring of FR901464 can exist in an open and close form. An initial effort to 
examine whether the open or cyclic form of the right pyran is the active form of FR901464 was 
carried out by the Jacobsen group.20 Substitution of the hydroxy group on C1 with a hydrogen 
led to an analogue that was equipotent to FR901464 (Figure 1-7, compound 1.10, Table 1-3),20 
which indicates that the active form of FR901464 is the cyclic structure of the right pyran ring. 
Furthermore, Kitahara and colleagues efforts were successful after replacing the hydroxy group 
on C1 with a methoxy group, which led to the birth of spliceostatin A, 1.4 (Figure 1-7), a more 
stable analogue than FR901464, with enhanced potency in a CMV promoter activation assay, 
although quantitative data were not available (Table 1-3).23 Later, the Koide group replaced the 
hydroxy group on C1 with a methyl group, in effort to further stabilize the right pyran ring and 
encourage hydrophobic interactions with the target biomolecule.25 This modification yielded an 
analogue that was 100 times more potent than FR901464 in MCF-7 cells (GI50 = 10 pM), named 
meayamycin, 1.6 (Figure 1-7). Meayamycin’s right pyran unit was indeed more stable than 
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FR901464’s right pyran unit, with an improvement of half-life in phosphate buffers from 4 – 8 h 
to 48 h.25  
 
 
Figure 1-7 Chemical structures of the C1 analogues of FR901464. 
 
Table 1-3 Antiproliferative activity of C1 analogues of FR901464. 
  IC50 (nM)  
compound Tag Jurkat cells Promoter activation MCF7 cells 
1.1 2 ++++ 1.1 
1.10 1.6 +++++ ND 
1.4 ND ND ND 
1.6 ND ND 0.01 
ND = not determined. “+” shows relative strength of activity by CMV  
promoter activation. 
 
Initial modifications around the C2´ - C4´ unit by the Jacobsen group strongly suggest 
that the potent anticancer property of FR901464 is not as sensitive to modifications around that 
unit as compared to the epoxide moiety. More specifically, eliminating the α,β-unsaturated 
amide moiety in the side chain led to a decrease in activity by 3 orders of magnitude when 
compared to FR901464 in Tag Jurkat cells, demonstrating the importance of that unit, 1.12 
(Figure 1-8, Table 1-4).20 Furthermore, the epimer on C4´, 1.11 (Figure 1-8), led to a reduction in 
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potency (15-fold loss).20 To advance the efforts of the Jacobsen group probing C4´, the Koide 
group probed this site. Koide group’s hypothesis was that due to the 1,3-allylic strain, the 
hydrogen on C4´ is likely on the same plane as the enamide, and that the epimer of C4´ would 
place the acetoxy and/or methyl substituent on the wrong face of the molecule, thereby 
explaining the decrease in activity of the C4´-epimer analogue by Jacobsen and coworkers.24 To 
probe this phenomenon, the Koide group prepared 4´-desacetyl-meayamycin 1.13 and epi-4´-
desacetyl-meayamycin 1.14. 4´-Desacetyl-meayamycin was 50 times lower in activity relative to 
meayamycin in MCF-7 cells, while epi-4´-desacetyl-meayamycin was 150 times lower in 
activity, and ~1 order of magnitude less active than 4´-desacetyl-meayamycin, indicating that the 
acetyl group is important for FR901464’s antiproliferative activity (Table 1-4).24 That was 
followed by their effort towards functionalizing C4´; the rationale for installing a carbamate 
group in place of the acetate was because the acetate is prone to esterases-mediated hydrolysis 
under physiological conditions. Replacement of the methyl group on C2´´ with a morpholine 
group led to an analogue that was 4 times more active, on the average, than meayamycin, named 
meayamycin B, 1.15 (Figure 1-8, Table 1-4). As hypothesized, meayamycin B exhibited a 





Figure 1-8 Chemical structures of the C2´-C4´ analogues of FR901464. 
 
Table 1-4 Antiproliferative activity of C1 analogues of FR901464. 
 IC50 (nM) 
compound Tag Jurkat cells MCF-7 cells 
1.1 2 1.1 
1.11 30 ND 
1.12 1700 ND 
1.6 ND 0.02 
1.13 ND 0.48 
1.14 ND 4.7 
1.15 ND 0.008 
  ND = not determined. 
 
Takahashi and coworkers prepared FR901464 derivatives to conjugate to affinity 
nanoparticle beads for biochemical studies. They demonstrated that attaching a long aliphatic 
carbamate chain on C4´ instead of an acetate led to a 40-fold decrease in activity in EL4 murine 
lymphoma cells, while the same carbamate group attached on C4 led to a 250-fold reduction in 
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activity, demonstrating the sensitivity of C4-hydroxy group towards functionalization with large 
groups (Figure 1-9 and Table 1-5).26  
 
 
Figure 1-9 Chemical structures of the C4 and C4´ analogues of FR901464. 
 
Table 1-5 Antiproliferative activity of C4 and C4´ analogues of FR901464. 
 IC50 (nM) 
compound EL4 cells MCF7 cells 
1.1 2 1 
1.16 83 ND 
1.17 500 ND 
EL4 = mouse lymphoma cells. ND = not determined. 
 
Extensive efforts by the Koide group were devoted towards analogues of the left pyran, 
in optimism of identifying the ideal conformer of the pyran in cells and also develop an 
alternative simpler structure to assemble rather than the current left pyran of FR901464. Several 
acetal derivatives were prepared and tested in MCF-7 cells (Figure 1-10).24 Their 
antiproliferative activity (Table 1-6) indicates that the loss of hydrophobicity may be the primary 




Figure 1-10 Chemical structures of the left pyran analogues of FR901464. 
 
Table 1-6 Antiproliferative activity of C1 analogues of FR901464. 
 IC50 (nM) 







Finally, the Koide group also probed the significance of the diene moiety by preparing 
two cyclopropyl derivatives, 1.20 and 1.21 (Figure 1-11), due to the encouraging precedence of 
the use of cyclopropanes as alkene bioisosteres in cancer chemotherapy,27 and also aiming to 
decrease the potential of rapid metabolism. The two derivatives were approximately only one 
order of magnitude lower in potency than the parent compound, which implies that the C8-C9 
alkene remains trans, though the cis geometry needs to be prepared in order to further validate 









Figure 1-12 Overview of the published data on the SAR for FR901464. 
 
1.2.3 FR901464 targets pre-mRNA splicing  
Studies by Minoru Yoshida and coworkers were conducted to identify the molecular 
target of FR901464 and spliceostatin A, and a biotin derivative was developed for this purpose 
(Figure 1-13).7  
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Figure 1-13 Chemical structure of the biotin derivative of spliceostatin A. 
 
The biotinylated analogue of spliceostatin A was incubated with HeLa cells and 
subsequent streptavidin-mediated purification revealed that spliceosome-associated protein 155 
(SAP155), SAP145 and SAP130 as candidates, all components of splicing factor (SF) 3b (SF3b 
is a subunit of U2 snRNP). SiRNA (si = small interfering) experiments did not pin point the 
exact identity of the target, because siRNA against all three isolated proteins showed similar 
phenotype to the compound-treated one.7 However, because SAP155 was the last protein eluted 
from the streptavidin column, reportedly due to a strong interaction with the biotinylated 
derivative, it is proposed to be the actual target.7 Later on, Valcarcel and coworkers showed that 
SAP155 knockdown in HeLa cells displayed similar alternative splicing patterns to spliceostatin 
A-treated cells, which indicated that SAP155 might be an actual target.28 Finally, it was shown 
that spliceostatin A inhibits pre-mRNA splicing in HeLa cells in a concentration-dependent 
fashion and causes enlargement of the nuclear speckles, due to the accumulation of unspliced 
pre-mRNA. Exactly how interfering with pre-mRNA splicing confers to cytotoxicity remains 
unknown, but it is likely that truncated proteins resulting from the translation of unspliced pre-
mRNA or alteration of alterative splicing of apoptosis related genes are the cause. There may be 
additional cellular targets of FR901464 responsible for the observed cytotoxicity effects.  
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Figure 1-14 The step where FR901464 targets the pre-mRNA splicing process. 
 
1.2.4 Meayamycin’s preliminary biological studies by Koide and coworkers  
When the Koide group examined the antiproliferative activity of meayamycin B against 
various human cancer cells, the MDA-MB231 and MCF-7 breast cancer cell lines were among 
the most responsive (GI50 = 8 – 15 pM),
24 in addition to the multidrug resistant (MDR) cell line 
VCRd5L (DC3F is transformed Chinese hamster cells and VCRd5L is their multidrug-resistant 
counterpart) being equally responsive (GI50 = 0.67 nM, Table 1-7).
29 Additionally, meayamycin 
did not show significant toxicity against nontumorigenic human lung fibroblasts IMR-90, while 
toxicity was retained in A549 cells. At the present time, it is not clear whether pre-mRNA 
splicing inhibition is the reason for this observed specificity.29 Furthermore, the Koide group 
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asked whether the electrophilic epoxide present in meayamycin, which has the potential of 
covalently labeling the biomolecule, manifests reversible or irreversible growth inhibition. The 
assay designed to address this question was based on transient exposure of meayamycin to cells, 
and washing away any unbound meayamycin, then allowing the assay to continue for a total of 
three days. If reversible growth inhibition is the case, cells should begin to grow after removal of 
meayamycin. Alternatively, if irreversible growth inhibition is the case, cells will remain 
senescent after removal of meayamycin. They illustrated that meayamycin inhibited the 
proliferation of A549, MCF-7 and HeLa cells irreversibly, which could mean that meayamycin 
binds to SF3b irreversibly or induces irreversible cell growth arrest.29 Finally, the same group 
demonstrated that meayamycin inhibited pre-mRNA splicing in HEK-293 cells at a 





















MCF-7 = earlier passage of breast cancer cell line, estrogen receptor-positive. MDA-MB231 = 
breast cancer cell line, estrogen receptor-negative. A549 = lung carcinoma cells, wild-type p53. 
DU-145 = prostate carcinoma cells. H1299 = lung carcinoma cells, p53-deficient. PC-3 = colon 
carcinoma cells, p53-deficient. HCT116 = colon carcinoma cells, wild-type p53.  
 
1.2.5 Additional natural products that inhibit pre-mRNA splicing by targeting the 
spliceosome: pladienolide and herboxidiene (GEX1A)  
In 2004, Eisai Corporation discovered seven pladienolides.30 Their discovery was the 
result of the development of a cell-based assay designed to identify small molecules that block 
the hypoxia inducible factor (HIF-1) transcription factor pathway and thus expression of vascular 
endothelial growth factor (VEGF) genes. This pathway is critical to the growth of tumors in their 
common low oxygen (hypoxic) environment, because VEGF stimulates the recruitment of new 
blood vessels to the tumors, a process known as angiogenesis.31,32 In addition to powerful anti-
VEGF activity, the pladienolides displayed a broad range of in vitro cytotoxicity against a panel 
 GI50 (nM) 
Cell line Meayamycin  Meayamycin B 
MCF-7 0.020 0.008 
MDA-MB231 0.070 0.015 
A549 0.26 0.18 
DU-145 1.2 0.21 
HCT116 0.16 0.004 
H1299 0.84 0.15 
PC-3 0.2 0.10 
VCRd5L 0.67 ND 
DC-3F 0.42 ND 
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of 39 tumor cell lines.31,32 Exposure of colorectal adenocarcinoma WiDr cells to pladienolides 
resulted in cell cycle arrest at the G1 and G2/M phase, and the cell cycle arrest profile of the 
pladienolides did not correlate well with 5-fluorouracil, vincristine, or taxol. Thus, the cellular 
target of these angiogenesis inhibitors was thought to be new for antitumor agent development. 
Initial in vivo activity results were promising; in particular, pladienolide B demonstrated potent 
activity in six different mouse xenograft models, slowing tumor growth in five and causing 
complete regression in one.33 The most important SAR result from the isolation of the 
pladienolides was the finding that the acetate at C-7 is critical for anti-VEGF activity, while the 
non-acetylated derivative are much less active. Much of the subsequent semi-synthetic medicinal 
chemistry on the pladienolides by the Eisai Corporation was done by making various esters and 
carbamates at C-7 of pladienolide D. These efforts led to a urethane derivative of pladienolide D, 
with 7-(4-cycloheptylpiperazin-1-yl) substituted for the 7-acetyl group was identified with 
complete retention of anti-VEGF activity and in vivo antitumor activity.34,35 This derivative, with 
enhanced in vivo potency and pharmacokinetic properties, was denoted E7107 (Figure 1-15) and 
entered phase I clinical trials for several cancer treatments in 2007.36 Several chemical biology 
experiments at the Eisai Corporation were conducted using photoaffinity-labeled probe 
experiments identified that the molecular target of pladienolide B to be SAP130, a subunit of 
SF3b.37 In 2011, the same group used a radiolabeled-probe and pladienolide-resistant cell lines to 
discover that the compound also binds to SAP155, which led to a proposed model suggesting 
that the compound binds to an interface between the two proteins (SAP130 and SAP155).38 
E7107 is presumably the first pre-mRNA splicing inhibitor to be clinically tested in humans.36,39 
These data suggest that the pladienolides are members of a new class of spliceosome targeting 




Figure 1-15 Chemical structures of pladienolides, and their biological activity. U-251 = 
glioblastoma-derived human cell line. 
 
Another antitumor agent found to be a pre-mRNA splicing inhibitor is 
herboxidiene/GEX1A (also known as anti-tumor agent TAN-1069), which was originally 
isolated from a fermentation broth of Streptomyces sp. A7847 in 1992 by Isaac and coworkers at 
Monsanto.40 In 2002, Yoshida and coworkers, during their screening of natural products that 
activate luciferase gene under the control of the SV40 promoter (a similar screening method that 
allowed for the discovery of FR901464), they discovered and re-isolated herboxidiene, termed 
GEX1A (Figure 1-16).41,42 This compound was found to be a novel polyketide that exhibited in 
vitro cytotoxicity against several human tumor cell lines, including epidermoid carcinoma A431 
cells, human lung carcinoma A549 cells, human colon carcinoma DLD-1 cells, and human 
normal fibroblast WI-38 cells with IC50 values ranging from 3.7 to 51 nM (Figure 1-16). 
Recently, T. Mizukami and colleagues determined that GEX1A inhibits the splicing of pre-




Figure 1-16 Chemical structure of herboxidiene and its antiproliferative activity. 
 
 
Figure 1-17 Biological targets of pladienolide and herboxidiene (not drawn to scale). 
1.2.6 SAR and preliminary biological studies of FR901464-pladienolide type compounds 
by Webb coworkers  
FR901464 and pladienolide B share the same molecular target yet differ in their chemical 
structure and their ability to inhibit a diverse collection of human tumor lines. It is likely that 
these molecules share the same mechanism of inhibition given that they share a hypothetical 
consensus pharmacophore structure as proposed by Webb and coworkers.44 Based on structural 
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overlays of features known to be critical for the activity of FR901464 and pladienolide B, Webb 
and colleagues synthesized lead compounds to try to identify a minimal pharmacophore and 
assayed the ability of these molecules to inhibit proliferation of cells and pre-mRNA splicing 
(Figure 1-18 and Table 1-8). Building on the previously SAR data acquired by others, the Webb 
group proceeded to further reduce the structural complexity of the left tetrahydropyran, the 1,3-
conjugated diene, and the right tetrahydropyran by eliminating the C4 hydroxy group.44  
More specifically, by focusing their efforts on reducing the number of stereocenters on 
the left pyran, the Webb group developed cyclohexyl 1.23 (Figure 1-18), which exhibits GI50 
values in the range of 0.1 – 4 µM in various mammalian cancer cell lines, with Jeko-1 and JVM-
2 being the most responsive (Table 1-8). They also demonstrated that the diene portion of their 
scaffold was sensitive to substitution by heteroatoms (carbamate 1.24 and carbonate 1.25, Table 
1-8). Further efforts on 1.23 focused on developing analogues that be both resistant to esterase-
mediated hydrolysis and more water-soluble.4 Analogues 1.27, 1.28, 1.29, 1.30 showed no 
antiproliferative activity, except for isobutyl ester 1.26, with GI50 values similar to the acetate 
derivative 1.23 (Table 1-8). According to NCI standards, T/C ≤ 42% is the minimum 
requirement for activity.45 The in vivo efficacy of 1.26 in mice bearing Jeko-1 was promising 
(T/C = 35%). In addition, the aqueous solubility of 1.26 was less than 1 µM in phosphate 
buffered saline (PBS) buffer. To improve the solubility of 1.26, acetal 1.31 was prepared (Figure 
1-18), and had approximately a 50-fold increase solubility in aqueous PBS (47 µM in PBS) and 
its in vivo anticancer activity was comparable to 1.26. In summary, in addition to being powerful 
tools to investigate spliceosome mechanics and structure, FR901464 and its derivatives present a 
















Table 1-8 Antiproliferative activity of Thomas Webb’s analogues. 
 IC50 (µM) 
compound JeKo-1 JVM-2 PC-3 WiDr A549 MCF-7 
FR901464 ND ND ND ND 0.0013 0.0018 
1.23 0.1 0.13 2.1 2.0 4.65 2.29 
1.24 ND ND ND >5.0 >5.0 >5.0 
1.25 ND ND ND ND >5.0 >5.0 
1.26 0.12 0.19 2.2 0.91 ND ND 
1.27 >0.5 >0.5 >2.5 >1.25 ND ND 
1.28 >0.5 >0.5 >2.5 >1.25 ND ND 
1.29 ND >1.0 >5.0 4-5 ND ND 
1.30 >0.5 >0.5 >2.5 >1.25 ND ND 
JeKo-1 and JVM-2 = mantle cell lymphoma cells. ND = not determined. 
 
Later on, a combined effort between T. Webb and P. M. Potter was directed towards 
further understanding the mode of action of these newly developed simplified FR901464 
analogues. Their efforts demonstrated that analogues 1.26 and 1.31 are capable of modulating 
alternative splicing of MDM2 and caspase 2 and 9 in human cells. mRNA levels of alternative 
splicing were increased in tumor cells relative to normal cells, and these modifications were also 
observed in human tumor xenografts in vivo following exposure of animals to 1.26 and 1.31. 
There studies suggest that modulation of alternative splicing may be directly related to the 
antitumor activity of their FR901464 analogues. 
1.2.7 Significance  
Targeting the spliceosome and inhibiting pre-mRNA splicing with FR901464 analogues 
represents a new approach for the treatment of cancer.46,47 Support of pre-mRNA splicing 
inhibition as a potential method for cancer therapy has been furthered by the many examples of 
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cancer-associated alterations in splicing and mutations in the splicing machinery.13 Two of the 
most recent examples include mutations of the splicing machinery in myelodysplasia (blood-type 
cancer)48 and the development of BRAF splicing variants (BRAF is a kinase involved in the 
ERK signaling pathway) in mammalian melanomas which are responsible for developed 
resistance to clinically used vemurafenib (Zelboraf ®).49 
In the first example, a group led by Seishi Ogawa reported the first results that provide 
evidence of genetic alterations of the major splicing components in myelodysplasia.48 Through 
genome-sequence analysis of 29 patients with myelodysplasia, they discovered mutations in 
multiple components of the pre-mRNA splicing machinery, including U2AF25, ZRSR2, SRSF2 
and SF3B1 (one of FR901464’s target). These mutations were found in 45 to 85% of patients 
with myelodysplasia. Most of the reported mutations affect genes involved in splice site 
recognition during pre-mRNA processing and which eventually lead to human diseases. 
Subsequently, investigators in the Wellcome Trust Institute in the United Kingdom and the 
Cleveland Clinic in the United States reported similar findings.50,51 
In the second example, a group led by David B. Solit at Memorial Sloan-Kettering 
Cancer Center, discovered that patients with melanoma developed resistance to vemurafenib, is 
due to aberrantly spliced BRAF.49 When BRAF is mutated, ERK signaling pathway is 
hyperactive in melanoma cells. Vemurafenib specifically targets the mutated BRAF form, and 
account for vemurafenib’s remarkable clinical activity. However, an aberrantly spliced version 
of BRAF that developed after exposure to vemurafenib, also led to accelerated tumor growth, 
and resistance to vemurafenib therapy quickly developed. This suggests that combination 
treatment with splicing modulators such as pre-mRNA splicing inhibitors could be tested to 
overcome BRAF inhibitor-mediated resistance.  
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Accumulating data shows that these cancer-specific splice variants could be involved in 
the development of diseases or predict sensitivity to certain drugs. Targeting the pre-mRNA 
splicing process as an effective approach to combat cancer could be following a similar path to 
the approach of anticancer drugs targeting microtubules. The successful development of taxane 
class of antimicrotuble chemotherapy agents represents one of the breakthroughs in cancer 
chemotherapy.52 However, it took 16 years after the elucidation of taxol’s mode of action in 
197953 until other compounds acting through a similar mechanism were identified.54  
As new tools and new information on RNA biology in tumors emerge, scientists expect 
new and better insights into the still under-explored world of the spliceosome and pre-mRNA 
splicing and its potential to provide novel avenues for molecular targeted cancer treatment(s). It 
is evident that FR901464 analogues will bring the potential cures to the treatment of cancer by 
targeting the pre-mRNA splicing process as supported by the numerous pre-mRNA splicing 
assays in development to screen and identify new pre-mRNA splicing inhibitors.55-57  
 
1.3 TOOLS THAT MODULATE PRE-MRNA SPLICING 
1.3.1 Challenges to studying the spliceosome 
One challenge in studying the human spliceosome is a lack of tools for arresting the 
splicing machinery at specific stages during its dynamic assembly pathway. Each spliceosome 
protein has unique inter-molecular interactions and presumably specific function. A highly 
coordinated exchange of these factors is essential for spliceosome activity. During spliceosome 
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assembly, each U snRNA (U1, U2, U4, U5 and U6) interacts with a defined set of proteins and 
makes critical base pair interactions within and between themselves and pre-mRNA, while 
undergoing extensive structural rearrangements.8 The current model of spliceosome assembly 
suggests that the complex transitions through several stable intermediate assemblies: early 
complex (E) → pre-spliceosome (A) → fully assembled spliceosome (B) → catalytically active 
spliceosome (C) (Figure 1-3).8 Given the dynamic nature of the spliceosome, it is likely that 
many other assemblies remain to be identified. Therefore, the discovery and characterization of 
small molecules directed against enzymatic chemistries, targeting crucial protein-protein 
interactions or disrupting protein-RNA interactions will be instrumental for studying the 
spliceosome. 
The potency of characterized small molecule splicing inhibitors ranges in IC50 value from 
the nanomolar range, for FR901464-like compounds,6,7,29 to the millimolar range, for the histone 
deacetylase inhibitor suberoylanilide hydroxamic acid, termed SAHA (to be discussed in the 
following sections).58 The molecular targets and direct mechanism of most splicing inhibitors 
remain to be determined, and many splicing inhibitors may act indirectly. For example, some 
antibiotics interfere with splicing by sequestering required Mg2+ ions while other small 
molecules interfere with RNA transcription or alter mRNA stability, which would affect events 
proceeding or following splicing, but not the spliceosome directly.59,60 To improve the current 
collection of tools, screening methods to identify novel inhibitors of general splicing events as 
well as inhibitors of transcript-specific splicing are being developed.55,56,60,61 
For the purpose of this discussion, pre-mRNA splicing modulators will be classified into 
three general categories: 1) general splicing inhibitors, 2) intron-specific modulators, i.e. 
 33 
inhibitors that modulate the splicing of a specific intron, and 3) spliceosome inhibitors, i.e. those 
which directly interfere with spliceosome assembly.  
1.3.2 General splicing inhibitors 
1.3.2.1 Antibiotics 
Antibiotics have proven to be powerful tools to study the function and structure of 
macromolecular complexes, such as ribosomes.62 Furthermore, antibiotics have been shown to 
play a role in the pre-mRNA splicing process.59 Splicing activity of a pre-mRNA substrate was 
potently inhibited when HeLa cells were treated with erythromycin, CI-tetracycline or 
streptomycin (IC50 = 160 mM, 180 mM and 230 mM, respectively). However, given the 
relatively high concentration of antibiotic needed to inhibit splicing, it is difficult to determine 
whether the mechanism of inhibition is direct. Cl-tetracycline caused 60% reduction in splicing 
in addition to a considerable accumulation of pre-mRNA suggesting that this inhibition precedes 
the first step of splicing. Furthermore, erythromycin (500 µM) inhibited 95% of splicing and a 
lariat intermediate was accumulated, suggesting that erythromycin inhibits a step between the 
two steps of trans-esterification. Reactions treated with streptomycin revealed splicing inhibition 
prior to the first step of the splicing chemistry. However, this inhibition was subsequently shown 
to be dependent on the concentration of Mg2+ ions in the assay suggesting that the observed 
inhibition might be due to an indirect mechanism. Overall, the use of antibiotics to inhibit 




Figure 1-19 Chemical structures of erythromycin, Cl-tetracycline and streptomycin. 
 
1.3.2.2 Inhibitors of histone acetylation 
Recently, histone acetyltransferases (HATs) and histone deacetylases (HDACs) were 
identified as targets of small-molecule splicing inhibitors. In 2008, Kuhn and colleagues 
investigated the origin of the splicing interference, protein and/or snRNA composition, and 
blockade of spliceosome assembly of eight small molecule inhibitors of protein acetylation and 
deacetylation.58 They found that the compounds SAHA, splitomicin, dihydrocoumarin, and 
butyrolactone inhibit splicing chemistry, but not the formation of C complex spliceosomes. Two 
compounds, anacardic acid and garcinal inhibit spliceosome assembly by accumulating an A-like 
complex. Collectively, anacardic acid and garcinal appear to inhibit the transition of A to B 
complex spliceosomes. These results suggest a role for acetylation in the stability or assembly of 
B complex spliceosomes and further support that the current model of spliceosome assembly is 
incomplete. However, relatively high concentrations of these inhibitors are required for the 
observed loss of splicing. Additionally, because the targets of acetylation are currently 
undetermined, it is difficult to identify the mechanism or target of pre-mRNA splicing inhibition. 
However, blocking post-translation modifiers could be a viable approach to identify the enzymes 




Figure 1-20 Chemical structures of SAHA, splitomicin, dihydrocoumarin, butyrolactone-3, 
anacardic acid and garcinol. 
 
1.3.2.3 Peptides 
The use of peptides designed to bind to specific proteins allows for a more targeted 
mechanism to isolate stalled mammalian spliceosomes. By interfering with facial interactions, 
essential rearrangements within the spliceosome can be blocked. Additionally, the use of 
interfering peptides can inform when a specific interaction is important during spliceosome 
assembly. For example, Parker and Steitz employed peptides that bind to Ca2+-calmodulin-
dependent protein kinase II (CaMK II) in an effort to explore the role of CaMK II-like proteins 
in spliceosome assembly.63 Two peptides, one that binds the N-terminus of glycogen synthase 
(GS) and another that interacts with the calmodulin binding domain (CBD) of CaMK II were 
identified as inhibitors of in vitro splicing and spliceosome assembly. Both peptides blocked 
splicing chemistry before the first trans-esterification step. Data from Parker and Steitz revealed 
that while the CBD peptide blocks C complex formation, the GS peptide appears to slow the 
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transition of B complex to C complex spliceosomes. In addition, splicing reactions 
complemented with recombinant bovine brain calmodulin (CBD-treated extracts) or with 
purified rat brain CaMK II (GS-treated extracts) were able to recover some splicing activity. 
However, reactions extended even to 3 h were unable to overcome inhibition of splicing when no 
additional protein was added. These findings support a role for CaM kinase in the formation of C 
complex spliceosomes that is not explained by the current model of spliceosome assembly.  
Continuing in the design of peptide-based pre-mRNA splicing inhibitors, Ajuh and 
Lamond designed peptides derived from the spliceosome proteins CDC5L and one of its 
interacting partners, PLRG1.64 CDC5L and PLRG1 are both spliceosomal proteins that are 
conserved across species, and have shown to be essential for pre-mRNA splicing in humans. A 
specific domain on PLRG1, termed WD40, and a C-terminal domain on CDC5L, mediates 
CDC5L and PLRG1 interaction.64 Peptides were designed to interfere with either the WD40 
domains in PLRG1 or the C-terminus of CDC5L. The PLRG1 peptides bound to CDC5L without 
disrupting the interaction between the two proteins and did not inhibit splicing. A subset of 
CDC5L-derived peptides bound to PLRG1 and had an inhibitory effect on splicing and 
spliceosome assembly in a transcript independent manner. Gel analyses of inhibited reactions 
revealed that there was no inhibition of spliceosome assembly, suggesting that these peptides 
may interfere with the catalytic activity rather than assembly of spliceosomes. The design of 
potential peptide inhibitors is complicated by the lack of information concerning the complex 
architecture and detailed interactions of the spliceosome. 
1.3.2.4 Isoginkgetin 
A report in 2008 by Moore and coworkers described the design of mammalian cell lines 
for the identification of small molecule inhibitors of pre-mRNA splicing.55 This group tested 
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approximately 8,000 natural compounds and identified the biflavonoid isoginkgetin as a general 
inhibitor of pre-mRNA splicing (IC50 = 30 µM). In addition to its role as an antitumor 
compound, isoginkgetin was shown to directly inhibit the transition of A complex to B complex 
spliceosomes. However, its molecular target and mechanism of inhibition were not reported.  
 
 
Figure 1-21 Chemical structure of isoginkgetin. 
1.3.3 Intron specific modulators 
1.3.3.1 Small molecules 
Borrelidin, a polyketide natural product, is a potent inhibitor of angiogenesis. A group led 
by B. Wilkinson reported the biosynthesis of a new analogue of borrelidin, 1.32 (Figure 1-22) 
using genetically engineered bacterial strains of Streptomyces parvulus.65 This analogue was first 
shown to exhibit anti-bacterial and anti-angiogenic actions. To further clarifying the molecular 
targets of 1.32, a biotin derivative was prepared, and, through phage display experiments, the 
target was found to be splicing factor FB21. Later, Wilkinson and coworkers demonstrated that 
1.32 exhibits alternative splicing activity towards the VEGF transcript. Specifically, a C-terminal 
splicing event in the VEGF mRNA results in production of two VEGF isoforms: VEGFxxx, 
which is pro-angiogenic, and VEGFxxxb, which has anti-angiogenic activity. These two isoforms 
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are formed by the use of alternate 3’ splice sites in exons. Concentrations of 0.5 – 5 µM 
decreased expression of VEGFxxx and increased expression of VEGFxxxb, in a manner that was 
sufficient to completely block angiogenesis. 
Later, Younis and colleagues described a high-throughput assay that allowed for rapid 
detection of potential inhibitors of splicing.61 From a screen of nearly 23,000 molecules, three 
splicing inhibitors were identified, namely clotrimazole, chlorhexidine and flunarizine. All three 
therapeutic agents were shown to alter the splicing and alternative splice site use of specific 
transcripts rather than to be general inhibitors of splicing chemistry. These findings revealed 
unexpected activities of clinically used drugs in alternative splicing.  
 
Figure 1-22 Chemical structures of 1.32, flunarizine, chlorhexidine and clotrimazole. 
 
Along the same lines as Younis’s work, Stoilov and colleagues developed a two-color 
fluorescent reporter construct for high-throughput screens to identify bioactive compounds that 
modulated alternative splicing.60 Two libraries were screened which included FDA-approved 
drugs, enzyme inhibitors and ion-channel antagonists. Neuroblastoma cells treated with 
Tyrphostin-9, digoxin or 5-iodotubercidin revealed differential alternative pre-mRNA splicing 
patterns of the experimental substrate, leading this group to propose that each compound 




Figure 1-23 Chemical structures of tyrphostin-9, 5-iodotubercidin and digoxin. 
 
From a screen of 220 indole derivatives 1.33, 1.34 and 1.35 (Figure 1-24) were identified 
as inhibitors of HIV-1 pre-mRNA splicing in vivo.66 Compound 1.34 led to changes in the 
alternative splicing of HIV-1 RNA, which resulted in the accumulation of larger transcripts 
(~800 base pairs) and depletion of smaller ones (~200 base pairs). Similar alternative splicing 
pattern were observed with 1.33 and 1.35. This alteration in splicing indicates that the 
compounds are inhibiting several weak 3’ splice sites upstream of key regulators of viral proteins 
Tat, Rev, Vpu, Env and Nef. Collectively, these studies suggest that targeting of spliceosomal 
proteins by small molecule inhibitors may be a potential target for anti-HIV therapies. 
Additionally, because these indole derivatives do not inhibit all splicing events, it is a powerful 
mechanism to specifically target HIV-infected cells. While these data reveal a promise for 
targeting specific disease transcripts, their mechanism in general splicing mechanism remains 




Figure 1-24 Chemical structures of 1.33, 1.34, and 1.35. 
1.3.3.2 Antisense Oligonucleotides 
Another targeted approach to modulate splicing, in addition to peptides, is through the 
use of antisense oligonucleotides (AONs). These AONs can be synthesized to complement a 
specific RNA sequence transcribed from a gene. Designed AONs that bind to specific splice sites 
or to enhancer or silencer sequences within the pre-mRNA, the splicing mechanism can be 
altered precisely; i.e. exon skipping or inclusion (Figure 1-25).67  
 
Figure 1-25 Illustration of exon skipping mediated by targeted AON. 
 
An advanced example of using this technology therapeutically was against Duchenne 
muscular dystrophy (DMD). This disorder is characterized by progressive muscle weakness in 
childhood and eventually leads to death during early adulthood.68 The defect is due to DNA 
mutation of the dystrophin gene, leading to the absence of the functional dystrophin protein. To 
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restore functional dystrophin, targeted AON were designed and synthesized to inhibit the 
inclusion of a specific exon during the splicing process.69 The resulting mRNA, although shorter, 
retained the functionally important terminal domains.  
1.3.4 Spliceosome inhibitors (FR901464, pladienolide and herboxidiene) 
The pre-mRNA splicing inhibitors FR901464, pladienolide, and herboxidiene are 
examples of compounds with known molecular targets.6,7,43 These compounds were discovered 
when groups in Japan independently identified natural products from different organisms that 
inhibited proliferation of cancer cells and pre-mRNA splicing.5,17,18,31,33,40-42 Modified derivatives 
of these compounds have since been shown to target the SF3b sub-complex of U2 snRNPs.6,7,43 
SF3b is essential for branch-point adenosine identification and plays an essential role in the 
assembly of the pre-spliceosome.70,71 Taken together, these results suggest that SF3b plays a 
direct role in the anticancer properties of these inhibitors, in addition to its established role in U2 
snRNP recruitment to the pre-spliceosome. 
1.3.5 Development of future tools 
In order to probe the structure and molecular composition of precise intermediates of the 
spliceosome, it is necessary that preparations of the spliceosomal complex be homogeneous. 
Therefore, tools must be designed to interfere and arrest spliceosome assembly at a stable and 
distinct stage. While mutational analysis of pre-mRNA substrates has allowed for the isolation of 
several now established bona fide spliceosome intermediates,72-76 new tools are being developed 
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to further elucidate the mechanism of pre-mRNA splicing and the connection to 
cancer.7,28,29,37,48,50,77-80  
 In the case of the ribosome, another highly complex ribonucleoprotein machinery, the use 
of antibiotics to capture distinct conformations has been crucial in understanding the dynamics of 
translation.62 Similarly, small molecule inhibitors of pre-mRNA splicing will be critical for 
elucidating spliceosome structure and function. Small molecules can bind to specific targets, 
thereby allowing for the characterization of a blocked spliceosome complex as well as the 
investigation of the function of the targeted spliceosome component. 
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2.0  CHEMICAL AND BIOLOGICAL STUDIES OF FR901464 ANALOGUES 
2.1 SIDE CHAIN ANALOGUES 
 
Based on detailed SAR and stability studies, our group recently developed one of the most potent 
analogues of FR901464, meayamycin B. An interesting feature of the structure of meayamycin B 
and FR901464 is the presence of a cis-enamide at C2´-C3´. This enamide may be prone to 
nucleophilic addition in biological environments, which is illustrated in selected bioactive natural 
products with similar electrophilic enamides.81,82 These electrophilic enamides are critical for the 
bioactivity of the molecules because this electrophile allows for labeling the target protein. In 
addition, designed acrylamide-based kinase inhibitors react irreversibly with glutathione,83 and 
may react with proteins other than the desired target;84 such off-target reactions are undesirable. 
Thus, current drug discovery efforts mostly aim to avoid the formation of irreversible covalent 
adducts.85  
With these considerations in mind, we tested whether the electrophilic enamide present in 
meayamycin B is in fact crucial for its bioactivity. We prepared the trans-enamide isomer of 
meayamycin B to examine the necessity of the cis-enamide configuration and the non-enamide 
analogue of meayamycin B to probe the presence of the electrophilic enamide (Figure 2-1). 
Although early SAR studies have suggested that eliminating the C1´-C5´ unit is critical for 
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maintenance of biological activity, certain modifications within this unit have yielded potent 
analogues (Figure 1-8, 1-9, 1-18).20,24  
 
 
Figure 2-1 Chemical structures of meayamycin B side-chain analogues to be prepared. 
 
2.1.1 Trans C2´-C3´ analogue 
The synthesis of the C2´-C3´ trans-isomer analogue is shown in Scheme 2-1A and 
Scheme 2-2, with the amide-bond forming reaction as a key step in the synthesis of 2.1. 
Although amide-bond forming reactions have been shown to yield both cis- and trans-isomers,86 
it was applied as a key step here considering the outcome diversity would be beneficial to this 
project. Specifically, we exploited the facile cis to trans isomerization of the HATU-activated 
acid 2.3-I prior to coupling with the amine resulting from 2.4 (Scheme 2-1). Previously, during 
this step, in route to preparing meayamycin, minor amounts, approximately 10% of trans-isomer 










Scheme 2-1 (A) Synthesis of alkene 2.6 through isomerization. (B) Mechanism of isomerization 
of 2.3 during the amide-bond forming reaction. 
 
To exploit on this observation, acid 2.3 was pre-mixed with HATU and iPr2NEt to 
deliberately isomerize the HATU-activated acid 2.3-I to the trans form prior to addition of amine 
2.4-I to deliver 2.5 in 56% yield and 2.6 in 43% yield (Scheme 2-1). Transformation of 2.6 into 
carbamate 2.8 was accomplished through methanolysis of the acetate, and the resulting alcohol 
was treated with CDI followed by morpholine (Scheme 2-2). The resulting intermediate olefin 
2.8 was exposed to methacrolein and ruthenium complex Ru-187 to furnish aldehyde 2.9 via a 
cross metathesis reaction. The Wittig reaction was then used to convert aldehyde 2.9 to diene 
2.10. The trans-side chain analogue 2.1 was then completed by exposure of diene 2.10 to alkene 
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2.11 in the presence of pre-catalyst Ru-1 in 46% yield, after two recycling steps of the starting 
materials, 2.10 and 2.11.    
 
 
Scheme 2-2 Synthesis of trans- C2´-C3´ meayamycin B 2.1. 
2.1.2 Saturated C2´-C3´ analogue 
The synthesis of the saturated C2´-C3´ isomer analogue of meayamycin B is illustrated in 
Scheme 2-3. The synthesis of the key carboxylic acid followed standard procedures, as 
summarized in Scheme 2-3. Commercially available (S)-ethyl lactate was transformed to 
carbamate 2.13, followed by reduction to yield the aldehyde derivative. This aldehyde was 
coupled with Ph3P=CHCO2Me via a Wittig reaction, followed by palladium-catalyzed 
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hydrogenation and subsequent hydrolysis to yield the key acid 2.14 in 46% yield over three 
steps.  
Analogue 2.2 was then furnished as follows: protected amine 2.4 was converted to the 
free amine by exposure to TFA, then further coupled to acid 2.14 in the presence of HATU and 
iPr2NEt to yield alkene 2.15. Treatment of alkene 2.15 with methacrolein and catalyst Ru-1 
afforded aldehyde 2.16. The diene fragment 2.17, constructed via the Wittig reaction from 2.16, 
was subjected to olefin metathesis reaction with 2.11 and Ru-1 to afford the saturated C2´-C3´ 
analogue 2.2 in 36% yield.  
 
 
Scheme 2-3 Synthesis of saturated- C2´-C3´ meayamycin B 2.2. 
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2.1.3 Antiproliferative evaluation of the trans C2´-C3´ and saturated C2´-C3´ analogues 
The antiproliferative activities of the trans C2´-C3´ isomer 2.1 and saturated C2´-C3´ 
isomer 2.2 were evaluated in the MCF-7 breast cancer cell line. Growth inhibition was 
determined with the commercial 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt (MTS) dye reduction assay at a cell density of 4 × 103 cells per 
well. It is important to note that this assay involves the ability of these compounds to inhibit the 
growth of whole cells and that changes in biological activity may be unrelated to the ability of 
the compounds to interact with the target of FR901464.  
We would expect to see a drop in antiproliferative activity of 2.2 to a similar degree as 
the non-epoxy analogues 1.3, 1.5, 1.7, 1.8, 1.9 (Figure 1-6, Table 1-2) if the enamide is a crucial 
electrophile as the epoxide. However, results showed that analogue 2.1 and 2.2 showed 3- and 4-
orders of magnitude loss in potency, respectively, when compared to meayamycin B. 
Comparison of the GI50 values between FR901464 and epi-C4´-FR901464 (Jacobsen’s 
analogue), show approximately 1-order of magnitude difference in activity, Figure 2-2. 
Likewise, 4´-desacetyl-meayamycin and epi-4´-desacetyl-meayamycin had a 1-order of 
magnitude difference in activity. Meanwhile, analogues 2.1 and 2.2 were 3- and 4-orders of 
magnitude difference in activity relative to meayamycin B, respectively. The drastic shift in 
orientation of C3´-C5´ in analogue 2.1 and the flexible nature of C2´-C5´ in analogue 2.2 is 
likely to explain the prominently reduced activity when comparing the epi-C4´-analogues to their 




Figure 2-2 Chemical structures of the C2´-C5´ analogues unit of FR901464 and their 
corresponding antiproliferative activity, GI50, and the cell-type tested. 
 
2.1.4 Summary 
The results from these studies, combined with the available SAR data addressing C1´-C5´ unit, 
strongly indicates that the side chain unit is sensitive to the positioning of the C4´-Me and C4´-
H. These results also suggest that the cis C2´-C3´ enamide is not an electrophile but, rather, 
could be a structural requirement for optimum binding to the target biomolecule, though a 
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spliceosomal-binding assay is necessary to understand if the analogues exhibit strong or weak 
binding to the spliceosome.  
2.2 EVALUATION OF MEAYAMYCIN AND ANALOGUES IN VIVO1 
Although FR901464 was tested in xenograft models prior to the pladienolides, its progress in 
terms of drug development lags behind. Studies of FR901464 and its analogues through total 
chemical syntheses and biological analyses have provided substantial insights into the SAR of 
FR901464. Here, is reported preliminary studies of meayamycins in vivo in collaboration with 
Southern Research Institute. 
2.2.1 Antiproliferative activity of meayamycin and meayamycin B 
Working together with Nancy Czaicki, Brian Albert and Dr. Miaosheng Li (previous 
members of the Koide group), the antiproliferative activities of meayamycin and meayamycin B 
were determined against various human cell lines. Meayamycin was found to inhibit the growth 
of all of the tumor cell lines tested, with GI50 values ranging from 10 pM to 1230 pM (Table 2-
1).29 The antiproliferative activity of meayamycin was also seen in the nontumorigenic cell lines 
NHDF, NHFL, HMEC and HUVEC (Table 2-1). On the other hand, the more biologically stable 
analogue, meayamycin B, was 3.1 ± 1.9 times more potent than meayamycin against MCF-7, 
MDA-MB231, A549, DU145, HCT-116, H1299, and PC-3 cell lines.24  
                                                 
1 This section was published in: S. Osman, W. R. Waud, G. S. Gorman, B. W. Day, K. Koide, Med. Chem. Commun. 
2011, 2, 38. 
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Table 2-1 Antiproliferative activity of Meayamycin, Meayamycin B, Meayamycin C, 
Doxorubicin and Bortezomib. 
 GI50 (nM) 
Cell line Meayamycin Meayamycin B Meayamycin C Doxorubicin Bortezomib 
MCF-7 0.020 0.0080 0.4 ND ND 
MDA-MB231 0.070 0.015 1.1 ND ND 
A549 0.26 0.18 ND ND ND 
DU145 1.2 0.2 ND ND ND 
H1299 0.84 0.15 ND ND ND 
PC3 0.20 0.10 ND ND ND 
HCT-116 0.070 0.0040 1.4 70 5 
NHDF 0.44 ND 39 462 334 
NHLF 0.91 ND 12 223 1.7 
HMEC 0.11 ND 9 276 3.5 
HUVEC 0.060 ND 4 109 1.1 
NHDF = normal human dermal fibroblasts. NHLF = normal human lung fibroblasts. HMEC = 
human mammary epithelial cells. HUVEC = human vein endothelial cells. ND = not determined. 
2.2.2 Evaluation of meayamycins’ in vivo 
Subsequently, an in vivo study was initiated with Southern Research Institute to 
determine whether the compounds could inhibit tumor growth in HCT-116 and PC-3 xenograft 
models.88 First, maximum tolerated doses of meayamycin and meayamycin B were determined. 
Doses for both compounds ranged from 0.03 to 3 mg kg–1/inj administered intravenously on a 
Q4D×3 schedule (Figure 2-3A and B). The treated animals were monitored for weight loss and 
mortality. No considerable weight loss or deaths were observed in any of the mice during or after 
treatment, except that a maximum average body weight loss of 11% was observed with 
meayamycin B at a dose of 3 mg kg–1/inj (Figure 2-3B). Meayamycin B was also tolerated at a 
 52 
different dosing schedule, Q1D×5, at doses of 0.5 and 1.0 mg kg–1/inj. A dose of 1.0 mg kg–1/inj 
led to only a maximum average body weight loss of 10%. Higher doses (1.5–6.0 mg kg–1/inj) 
were lethal for mice (Figure 2-3C). Webb and coworkers designed structurally simpler analogues 
that were tolerated at much higher doses (≤50 mg kg–1 at a Q1D×5 schedule), but that may be 
attributed to the lower antiproliferative activity (GI50 were at high nM to single-digit µM).
4 
These data show that doses of meayamycin and meayamycin B can be administered safely by the 




Figure 2-3 Dose tolerance of meayamycin and meayamycin B in mice. 
(A) Tolerance of meayamycin in male athymic nude mice Q4D×3. (B) Tolerance of meayamycin 
B in male athymic nude mice Q4D×3. (C) Tolerance of meayamycin B in male athymic nude 
mice Q1D×5. n = 3. 
 
The in vivo antitumor activity of meayamycin and meayamycin B was initially evaluated 
in the HCT-116 xenograft model in mice. Dosing schedule studies revealed that intravenously 
administered meayamycin and meayamycin B achieved inhibition rate (IR = [1-(median tumor 
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weight treated/median tumor weight control)] × 100%) values of 24% (Day 41) and 41% (Day 
41), respectively, using a Q4D×3 dosing schedule (Figure 2-4A and B). With the low IR values 
of both meayamycin and meayamycin B, we decided to increase the frequency of injections. We 
chose meayamycin B for this experiment because meayamycin B was more stable than 
meayamycin in mouse serum (t1/2 = 13 h vs. 2 h).24 Due to the availability of xenograft models at 
the time, we switched from HCT-116 to PC-3 in the next study. Against the PC-3 tumor 
xenograft, meayamycin B elicited an IR of 26% on Day 22 using a Q1D×5 dosing schedule 
(Figure 2-4C). A higher dose was lethal to mice at this injection frequency, which limited our 
window of optimizations. In HCT-116 tumor xenografts, paclitaxel exhibited an IR of 81% on 


















Figure 2-4 Activity of meayamycin, meayamycin B and paclitaxel in human tumor models. 
(A) Response of HCT-116 tumor implanted subcutaneously to treatment with meayamycin (Day 
16) and paclitaxel (Day 16). (B) Response of HCT-116 tumor implanted subcutaneously to 
treatment with meayamycin B (Day 16) and paclitaxel (Day 16). (C) Response of PC-3 tumor 
implanted subcutaneously to treatment with meayamycin B (Day 11). Statistical significance was 
evaluated by comparing the time to 2 tumor mass doubling values of vehicle-treated groups to 
drug-treated groups. P values of less than 0.05 were considered statistically significant. * 
signifies 0.05<p0.8 (statistically not significant), and ** signifies p<0.05. n = 10. 
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Unlike E7107, meayamycin and meayamycin B did not show clear-cut antitumor activity 
in xenograft models. It was questioned if the compound achieved an adequate plasma 
concentration in mice. A single dose of meayamycin B (1 mg/kg) was intravenously 
administered to female non-tumor-bearing athymic nude mice. The study illustrated that less 
than 1% of the injected meayamycin B was found in plasma within 30 minutes after 
administration (Figure 2-5). A glucuronidated meayamycin B metabolite exhibited the strongest 
signal in the mass spectrometric evaluations when compared to other detected metabolites. This 
result led to the hypothesis that meayamycin C, an alkylated derivative of meayamycin B, might 
be resistant to glucuronidation.  
 
 
Figure 2-5 Plasma mean concentration time profiles of meayamycin B and meayamycin C in 
plasma of female non-tumor bearing athymic nude mice. n = 3 for each time point. 
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2.2.3 Meayamycin C 
4-O-Alkyl FR901464 analogues were prepared and evaluated by others.26 However it was 
not clear whether the loss of activity was due to the large alkyl groups or the loss of a hydrogen 
bond donor. To answer this question, meayamycin C was synthesized as illustrated in Scheme 2-
4. Methylation of alcohol 2.11 followed by cross metathesis yielded meayamycin C. On a side 
note, it is noteworthy to mention that the olefin cross metathesis of 2.19 with 2.18 was 
reproducibly higher yielding than that with 2.11, mostly because 2.18 showed minimal 
homodimerization while 2.11 always presented substantial homodimerized product. This 
difference proved to be crucial in the preparation of C8-C9-cyclopropyl analogues by Yangping 
Wang in our research group.24 
 
 
Scheme 2-4 Synthesis of meayamycin C. 
 
Meayamycin C displayed sub- to single-digit nanomolar GI50 values against MCF-7, 
MDA-MB231 and HCT-116 cancer cell lines (Table 2-1). Meayamycin C retained potency to a 
slightly lesser extent against the normal cell lines NHDF, NHLF, HMEC and HUVEC with GI50 
values ranging from 4 to 39 nM (Table 2-1). These results, together with previously reported 
 58 
data, showed that all the FR901464 derivatives used in this study exhibited strong 
antiproliferative activity against these cell lines. The order of potency was meayamycin B > 
meayamycin > meayamycin C. Despite the potency of meayamycin and meayamycin C in cancer 
and non-cancerous cells, the therapeutic index increased from meayamycin to meayamycin C (if, 
e.g., one compares GI50 in the HCT-116 cell line and the non-cancerous cell lines in Table 2-1). 
The therapeutic index for meayamycin is 6 (NHDF cell line), 2.7 (NHLF cell line), 1.6 (HMEC 
cell line), and 1 (HUVEC cell line). On the other hand, the therapeutic index for meayamycin C 
is 15 (NHDF cell line), 4.6 (NHLF cell line), 3.5 (HMEC cell line), and 1.5 (HUVEC cell line). 
This indicates that there is some degree of selectivity of meayamycin C towards the HCT-116 
cancer cell line. This quantitative analysis should be met with caution because the margin of 
error could be greater when the growth inhibition of nontumorigenic cells was measured. 
Doxorubicin inhibited HCT-116 cancer cell proliferation with a GI50 of 70 nM, while in the 
normal cell lines NHDF, NHLF, HMEC, and HUVEC, its GI50 ranged from 109 to 462 nM 
(Table 2-1). Velcade displayed single digit nanomolar GI50 against these cancer and normal cell 
lines, except towards NHDF cell line, which was less sensitive (Table 2-1). Taken together, the 
data from these cell lines demonstrated that all of the meayamycin derivatives retained potent 
antiproliferative activity in tumor cells derived from a variety of organs and showed similar in 
vitro selectivity to the clinically used anticancer drugs doxorubicin and bortezomib.  
Meayamycin C’s plasma concentrations were evaluated by Southern Research Institute in 
female non-tumor-bearing mice after intravenous administration. The plasma concentrations of 
meayamycin C fell quickly within 1 h after injection and remained below 10 ng/mL for the next 
4 h, suggesting that the glucuronidation of meayamycin B was not the major reason for its poor 




In summary, the meayamycins displayed broad-spectrum antiproliferative activity, and 
meayamycin B exhibited minimal antitumor efficacy with Q4D×3 and Q1D×5 dosing schedules 
and no noticeable side effects in the HCT-116 and PC-3 xenograft models. The minimal 
antitumor efficacy of meayamycin B may be attributed to the poor PK profiles of meayamycin B 
and C in mice. The mechanism underlying this observation is unclear. Further pharmacokinetics, 
antitumor efficacy, and toxicological studies are needed to evaluate this promising new avenue in 
cancer treatment.  
2.3 SYNTETHIC EFFORTS TOWARDS A REVERSIBLE GROWTH INHIBITOR 
BASED OF MEAYAMYCIN B 
Splicing inhibitors based on the structure of FR901464, exemplified by meayamycin B 
(Figure 1-8), are generally believed to exert their biological effects through targeting SF3b. SAR 
studies on FR901464 have revealed that the presence of the spiroepoxide moiety is required. In 
addition, the epoxide might be a reactive moiety necessary for covalently modifying irreversibly 
a nucleophilic residue at the active site of SF3b, but epoxides are also, in general, prone to 
hydrolysis in a reaction catalyzed by epoxide hydrolases in vivo.  
The possible irreversible binding of FR901464-type compounds to SF3b could also lead 
to possible dose-limiting side effects. An example of such a case is an analogue of fumagillin, 
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TNP-470, that contains a crucial spiroepoxide, which has undergone clinical studies for a variety 
of cancers.89 TNP-470 is a type 2-methionine aminopeptidase (MetAP2) inhibitor. Although 
TNP-470 has shown therapeutic benefits in clinical studies, toxic side effects are a serious 
limiting factor. It has been reasoned that these unwanted side effects are partly linked to the 
irreversible character of the inhibition and the presence of reactive groups in the molecule 
(Figure 2-6).89 As a result, a MetAP2 reversible inhibitor, fumagalone, was prepared. Through 
semi-synthesis the spiroepoxide in fumagillin responsible for covalent modification of MetAP2 




Figure 2-6 General mechanism of MetAP2 with fumagillin and analogues. 
(top) Representation of fumagillin and TNP-470 irreversibly labeling the active site of MetAP2. 
(bottom) Representation of fumagalone reversibly labeling the active site of MetAP2. 
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As part of an ongoing program aimed at developing new FR901464-based anticancer 
compounds with pre-mRNA splicing inhibition and different pharmacological properties, a 
similar approach was used for the medicinal chemistry of fumagillin. The synthetic efforts in this 
area include a reversible inhibitor of SF3b based on FR901464/meayamycin B, which became 
not only an interesting intellectual challenge but also a good candidate for developing new pre-
mRNA splicing inhibitors that are likely to be less toxic than meayamycin B. As a first step 
toward a reversible pre-mRNA splicing inhibitor, the spiroepoxide in meayamycin B, 
presumably responsible for covalent modification of SF3b, was changed to an aldehyde. Because 
the spiroepoxide group in FR901464 and meayamycin B can react with a nucleophilic residue, it 
was reasoned that the replacement of the spiroepoxide with an aldehyde would retain the 
electrophilicity at C18, and it was anticipated that the nucleophilic residue would react with the 
aldehyde in a reversible fashion. 
2.3.1 Efforts towards an aldehyde derivative of meayamycin B 
Synthetic efforts began with an epoxide rearrangement to an aldehyde strategy, which 
was successfully applied to similar spiroepoxides in complex molecules.90,91 The decision to use 
a protected derivative of 2.11 was based on the observation that 2.11 would undergo ring 




Scheme 2-5 Retrosynthetic approach to prepare the aldehyde derivative of meayamycin B. 
 
Therefore, it was anticipating that 2.24 would not undergo this undesired reaction. A 
Lewis acid should open epoxide 2.24 to generate a tertiary cation, which could then undergo a 
1,2 hydride shift to form aldehyde 2.22. However, when 2.24 was treated with a variety of Lewis 
acids, only decomposition or formation of the ring contracted product 2.23 were obtained, and no 
1,2-hydride-shift product was isolated (Scheme 2-6, Table 2-2). At this point, we learned that 
ring contraction was highly favored over the hydride shift, which required for a different strategy 
to generate the desired aldehyde, or a new compound all together. Further attempting to promote 







Scheme 2-6 Synthetic efforts to prepare 2.22. 
 
Table 2-2 Conditions for the rearrangement of 2.24. 
  Yield (%) 
Entry Conditions 2.22  2.23 
 1 BF3•OEt2, benzene, 0 °C  not detected 95% 
2 BF3•OEt2, toluene, -78 °C,  not detected quantitative 
3 Cp2ZrCl2, AgOTf, CH2Cl2, 25 °C not detected 50%  
4 TiCl4, CH2Cl2, -78 °C  not detected 66%  
 
2.3.2 Ketone derivative of meayamycin B 
The spiroepoxide was replaced with a carbonyl to yield a ketone derivative of 
meayamycin B. The rationale was that with this type of replacement, the electrophilicity is 
retained and that the anticipated nucleophile would react reversibly. It was not certain, however, 
whether the electrophilic carbon at a different position would diminish the activity. Based on 
previous SAR data generated by Jacobsen and coworkers,20 the diastereomeric epoxide was only 
2-fold less active than the natural epimer, which indicates that there is no stringent spatial 
orientation for the electrophilic carbon to label the nucleophilic residue on the biomolecule.  
The synthesis of the ketone-variant of meayamycin B, 2.26, commenced with the 
preparation of ketone 2.25. For a detailed discussion of how 2.25 was prepared, please refer to 




Scheme 2-7 Synthesis of ketone derivative of meayamycin B, 2.26. 
 
The ability of ketone 2.26 to inhibit the growth of human cancer cells was assessed in a 
cell-based proliferation assay using MTS as an estimate of relative viable cells. The GI50 values 
were interpolated from 10-point (minimum) dose-response curves. Treatment with ketone 2.26 
resulted in GI50 values of sub-single digit nM against proliferating A549 and HCT-116 cell lines, 
and 1 – 20 nM against various human head and neck cancer cell lines, Table 2-3 (the data in 
Table 2-3 was generated with a combined effort of Ms. Yang Gao - Ph.D. candidate in the Koide 
group - and myself). Overall, ketone 2.26 is approximately 1 – 2 orders of magnitude less active 










Table 2-3 Antiproliferative activity of 2.26 and meayamycin B. 
 GI50 (nM) 
Cell line 2.26 meayamycin B 
A549 0.24 ± 1.30 0.18 ± 0.02 
HCT-116 0.20 ± 0.10 0.0040 ± 0.0043 
UD-SSC2 1.54 ± 0.30 0.23 ± 0.21 
UPCI-SSC90 3.2 ± 4.10 0.13 ± 0.11 
93-VU-147T 7.3 ± 4.80 0.34 ± 0.26 
UM-22B 26.0 ± 26.0 2.9 ± 3.3 
UM-SSC47 1.90 ± 1.40 0.15 ± 0.02 
PCI-30 20.5 ± 12.1 0.94 ± 1.00 
PCI-13 12.1 ± 11.3 ≤4.8 
JHU-020 11.3 ± 3.00 0.31 ± 0.14 
UD-SSC2, UPCI-SSC90, 93-VU-147T, UM-22B, UM-SSC47, PCI-30, PCI-13, JHU-020 are all 
variants of human head and neck cancer cell lines.  
For A549, vincristine displayed GI50 = 35 ± 3.2 nM. For HCT-116, cisplatin displayed GI50 = 3.9 
± 1.4 µM. For all head and neck cancer cell line, 5-FU displayed GI50 in the range between 12 ± 
12 µM and 0.15 ± 0.2 µM. All the growth inhibtion assays in the table were performed in 
parallel. 
 
To determine whether ketone 2.26 reversibly inhibits growth of cancer cells, studies 
using transient exposure of ketone 2.26 followed by outgrowth in the absence of the compound 
were performed (Figure 2-7, 2-8).29,55 Cells were exposed to ketone 2.26 at approximately GI90 
(10 nM) for the indicated times (Figure 2-7B), followed by outgrowth in the absence of the 
compound for a total of 5 days. Transient exposure (HeLa cells requires 24 h, A549 and MDA-
MB231 cells require 8 h) to 10 nM ketone 2.26 results in complete inhibition of outgrowth of the 
HeLa, A549 and MDA-MB231 cell poplulation. Additionally, after exposure of ketone 2.26 or 
vehicle to A549 cells for 8 h then removal of 2.26 or vehicle, followed by continuous monitoring 
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of cell growth, virtually no cell proliferation was recovered for 2.26-treated cells (Figure 2-8). 





   
Figure 2-7 Reversibility test. 
(A) Representation of growth inhibition reversibility experiment design. (B) Exposure time-
dependent growth inhibition of cells (HeLa, A549, and MDA-MB231) in the presence of 2.26 at 
10 nM for the indicated periods of time. Cell viability was measured on day 5 by MTS assay. 
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Figure 2-8 A549 cell growth upon treatment with DMSO (circles, dashed line) or 10 nM 2.26 
(squares, solid line). Number of viable cells was measured by MTS assay. 
 
2.3.3 Summary 
Results from this study demonstrate that transient treatment of MDA-MB231, A549 and HeLa 
cells with ketone 2.26 shows growth inhibition profiles similar to those seen with cells treated 
with ketone 2.26 for 5 days. These data suggest that in these cell lines, 2.26 might bind 
irreversibly to its target biomolecule. On the other hand, 2.26 might bind reversibly and induce 
irreversible cell growth arrest. Detailed binding assay studies are needed to precisely determine 
the nature of the interaction of 2.26 with its biological target.  
While the decrease in potency upon replacement of an epoxide with a ketone, a 
potentially reversible spliceosome inhibitor, may be an inevitable sacrifice, there is a relatively 
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large margin to accommodate such a loss in activity, given the extremely high potency of the 
epoxide-containing precursors. On the basis of the results reported here, we have begun to 
synthesize the second generation of non-epoxy meayamycin B derivatives to further probe the 
structure-activity relationship of this new class of pre-mRNA splicing inhibitors. To correlate the 
effects of ketone 2.26 on cell growth and survival with specific biochemical effects, we began 
investigating pre-mRNA splicing kinetics interrupted by ketone 2.26. It will be interesting to 
determine whether meayamycin B-based none-epoxy containing compounds will have improved 
pharmacological properties in comparison with meayamycin B. 
2.4 TEGYLATED ANALOGUES OF MEAYAMYCIN WITH UNEXPECTED 
POTENCIES 
A long-term goal in the Koide group is to develop FR901464-based probes through conjugation 
chemistry to study FR901464’s biological properties and SF3b. Toward this goal, incorporation 
of an azide functionality within meayamycin was planned due to the bioorthogonal reactivity of 
azides with alkynes. 
2.4.1 TEGylated meayamycin 
These efforts began with trying to install a triethylene glycol containing terminal azide at 
the C4´-hydroxy group. This site was chosen because the available SAR data indicate this site is 
more tolerable to large groups relative to the C4-hydroxy group. 
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Acetate 2.27 was hydrolyzed and then treated with CDI followed by amine 2.29 to 
deliver azide 2.30. Cross metathesis between 2.30 and 2.11 failed under various heating and 
different solvent conditions (Scheme 2-8, Table 2-4). It was not clear from these data whether the 
azide of the triethylene glycol chain was to blame for this unsuccessful transformation. In order 
to partially address this concern, azide 2.33 was prepared through exposing allylic alcohol-2.32 
to diphenylphosphorylazide and diisopropylazodicarboxylate. Efforts to couple 2.33 with 2.11 
failed to deliver 2.34 (Scheme 2-9A). In the literature there are no examples that illustrate the 
success of the olefin cross metathesis in the presence of an azide functionality, except for an 
isolated example by Seeberger and coworkers.92 Seeberger and coworkers’ transformation was 
successful likely because the azide is relatively hindered, thereby not capable of reaching the 
ruthenium pre-catalyst (through personal communication, Professor Verdine and coworkers 
experienced similar difficulties with their olefin cross metathesis in the presence of azide 
groups). A control experiment (Scheme 2-9B) between alkene 2.35 and acetate 2.36 failed to 
deliver cross coupled products neither isomerization (91% of the azide was recovered), which 
indicated that the azide is responsible for the unsuccessful transformation in Scheme 2-8 and 





Scheme 2-8 Efforts toward the synthesis of carbamate 2.31. 
 
 
Table 2-4 Cross metathesis conditions attempted in efforts to prepare 2.31. 
Additive Solvent Temperature (°C) 
none 1,2-dichloroethane 50  80 
Ti(OiPr)4 1,2-dichloroethane 50  70 
none THF 50  70 
none MeOH 50  70 














Scheme 2-9 (A) Efforts towards the preparation of azide 2.34. (B) Control experiment for the 
effect of the azide group in the cross metathesis reaction. 
 
Based on the above data, a different strategy was taken. It was decided to prepare a 
derivative of meayamycin C, where the C4-hydroxy group is already protected, and the C4´ is 
available for functionalization. Methyl ether 2.18 was coupled with allylic alcohol 2.28 to yield 
desacetyl-meayamycin C 2.39 in 35% yield after 2 recycling steps. Purification of this product 
was very laborious and yield of this transformation was lower than usual, hence the two 
recycling rounds. The low yield could be partially attributed to significant amount of trans-C2´-
C3´ derivative of either 2.28 or 2.39 observed by the 1H NMR spectrum of the crude reaction 
mixture (Figure 2-9). However, enough amounts of pure 2.39 were isolated in attempts to 
functionalize C4´-OH. Attempts to functionalize 2.39 either with CDI then amine 2.29, or 
isocyanate 2.41 all failed to deliver 2.40 (Scheme 2-10). The results were either no reaction, or 
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after harsher conditions (i.e., heating) led to numerous by-products as judged by TLC analysis 
and loss of the epoxide after 1H NMR analysis. Since efforts to install an azide functionality on 
the 4´-hydroxy group of 4´-desacetyl meayamycin failed, our attention was turned to the 4-
hydroxy group. There was skepticism about this approach because the aforementioned SAR data 
predicted that functionalizing 4-hydroxy group would diminish the potency of meayamycin.24,26 
Nonetheless, meayamycin was treated with NaH and tosylate 2.42 to form tetraethylene 
glycolated (TEGylated) meayamycin 2.43 (Scheme 2-11). Pleasant surprise was that this new 
analogue 2.43 was nearly as potent as meayamycin (Table 2-5). 
 
 
Scheme 2-10 Efforts towards the synthesis of carbamate 2.40. 
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Figure 2-9 1H NMR spectrum of crude 2.39. 
  
 
Scheme 2-11 Preparation of TEGylated meayamycin 2.43. 
 
Splicing inhibition by TEGylated meayamycin 2.43 was evaluated by Ms. Yang Gao in 
the Koide research group using the published HEK-293-II cell-based assay. In short, luciferase 
expression increases when pre-mRNA splicing is inhibited.55 In this assay, TEGylated 
meayamycin 2.43 exhibited a dose-dependent inhibitory activity towards pre-mRNA splicing 
after a 16-h treatment (IC50 = 2.4 nM; average of three independent experiments). The RT-PCR 
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analysis of the total RNA extracted from 2.43-, meayamycin- and DMSO-treated cells further 
validated that the new analogue 2.43 inhibited pre-mRNA splicing. Pre-mRNA splicing 
inhibition by 2.43 was examined in HEK-293-II cells over 72 h. The splicing inhibition, in the 
2.43-treated HEK-293-II cells persisted for 48 h, which was different from that in the 
meayamycin-treated cells (Figure 2-10). Because others have used meayamycin and related 
compounds to study pre-mRNA splicing over time,79,93-100 the availability of distinctly temporal 
splicing inhibitors may prove useful in such mechanistic studies. 
2.4.2 Simplified derivatives of TEGylated meayamycin 
To further investigate the effect of the TEG-N3 chain on the 4-hydroxy group of 
meayamycin, the same TEG-N3 chain on the corresponding hydroxy group of the right fragment 
2.11 (Scheme 2-12A) was installed to form 2.44. The TEGylated right fragment 2.44 was found 
to inhibit HCT-116 proliferation with a GI50 of 1.5 µM (Table 2-5). The right fragment 2.11 
exhibited no antiproliferation activity even at 200 µM. Based on the unexpected antiproliferative 
activity of 2.44 as well as the SAR data indicating the importance of the epoxide moiety,20,23-26,29 
In collaboration with Mr. Matthew Zhu (a researcher in the Koide laboratory), its simplified 
derivatives 2.46 and 2.47 (Scheme 2-12B) were prepared. These analogues 2.46 and 2.47 did not 
exhibit growth inhibition against HCT-116. This indicates that the epoxide coupled to the TEG-
N3 group is not sufficient for antiproliferative activity. The activity of 2.44 could be attributed to 




















Table 2-5 The Gi50 values of meayamycin and analogues. 
 GI50 (nM)
a 
Cell line meayamycin 2.43 2.44 vincristine 
HCT-116 0.038 ± 0.030 0.10 ± 1.4 1.5 × 103 ± 0.14 × 103 0.90 ± 0.3 
MCF7* 0.80 ± 1.6 2.4 ± 1.6 ND 1.1 ± 0.5 
HEK-293-II 7.8 ± 3.0 46 ± 1.3 8.9 × 103 ± 1.2 × 103 20 ± 0.7 
MDA-MB231 0.070 ± 0.06 ND 1.4 × 103 ± 1.4 × 103 3.0 ± 1.2 
A549 0.26 ± 0.30 ND 2.2 × 103 ± 1.15 × 103 35.0 ± 1.4 
PCI 13 4.8 ± 1.2 ND 3.7 × 103 ± 1.1 × 103  12 ± 5 
JHU 012 4.7 ± 1.1 ND 2.0 × 103 ± 1.3 × 103 17.0 ± 3.9 
a Each experiment consists of twelve data points (twelve different concentrations). ND = not 
determined. *This MCF7 was a later passage from the American Type Culture Collection.  
Growth inhibition assays of 2.43 and meayamycin were always performed in parallel. 
 
Figure 2-10 Luciferase activity versus time for HEK-293-II cells treated with 2.43, meayamycin, 
and 2.44. 
 
The antiproliferative activity of the TEGylated right fragment 2.44 against human cells is 
shown in Table 2-5. The TEGylated right fragment 2.44 displayed low micromolar GI50 values 
against cancerous cells, while the non-cancerous cell line (HEK-293-II) was less responsive. 
Consequently, it was determined if 2.44 inhibits pre-mRNA splicing in cells. The pre-mRNA 
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splicing assays were performed by Ms. Yang Gao. This analogue inhibited pre-mRNA splicing in 
HEK-293-II cells in a dose-dependant manner (IC50 = 3 µM). Pre-mRNA splicing inhibition by 
the same analogue (25 µM) peaked at 16 h (Figure 2-10). A semi-quantitative RT-PCR 
experiment showed that unspliced pre-mRNA increased relative to spliced RNA in HEK-293-II 
cells after a 16-h treatment with the TEGylated right fragment 2.44 at 20 μM (spliced:unspliced 
= 0.98 ± 0.3 in 2.44-treated cells and 7.4 ± 1.9 in DMSO-treated). 
2.4.3 Summary 
In summary, serendipitously discovered new pre-mRNA splicing inhibitor 2.43 and rationally 
designed 2.44 based on 2.43. These analogues also exhibited antiproliferative activity towards 
human tumor cell lines. The TEGylated meayamycin 2.43 represents potential for conjugatable 
FR901464 analogues, in addition to being used for identifying and studying the elusive target 
protein(s) of FR901464. The right half of this analogue (i.e., 2.44) was sufficient for 
antiproliferative activity and splicing inhibition, potentially facilitating the development of 
FR901464-based drugs. It is possible that the TEG chain alters the cellular distribution of the 
meayamycin derivatives, thereby leading to better nuclear entry, or the TEG chain mimics the 
left part of meayamycin. Based on these considerations, synthesis of modified TEG chains that 
incorporate various functional groups in order to optimize for potency was begun.    
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2.5 EFFORTS TOWARDS THE DEVELOPMENT OF A PRACTICAL APPROACH 
TO SYNTHESIZE MEAYAMYCIN 
The potency of meayamycin towards inhibiting pre-mRNA splicing and cancer-cell 
growth demonstrates that derivatives of this compound can be designed to improve upon or alter 
its pharmacological properties. In order to ensure a consistent supply of meayamycin and 
sufficient material for further biological testing, a practical synthesis (i.e. safe, shortened 
operations, scalable and economical) is required. Such a synthesis is also needed to provide 
advanced intermediates that could be used to create new analogues of meayamycin. 
Meayamycin was initially generated from intermediate 2.11 and diene 2.27.25 
Modifications of diene 2.27 generated all the nM analogues.24 In designing a new synthetic 
scheme, intermediate 2.11 (right fragment) was chosen a target. The previous approach to 
generate epoxy alcohol 2.11 was 12 steps long and provided sufficient material for biological 
assays. When performed on the larger scales required for generation of sufficient amounts of 
2.11, several problems were uncovered, which limited the practicality of the synthesis. Notable 
scale-related difficulties of the route, as described in Scheme 2-13, include the following: 
 Aldehyde 2.52 was found to be unstable for storage. 
 The alkynalation of 2.52 to form alcohol 2.54 and Mislow-Evans rearrangement using 
selenide 2.56 to form allylic alcohol 2.57 provided a mixture of diastereomers.  
 2-Nitrophenyl selenocyanate is $70 per gram, and is costly in larger quantities. 
 Hg-mediated cyclization of 2.57 to generate geminal-dimethyl 2.58 produced low yields 
of 2.58 on larger scales, often accompanied by significant amount of unreacted 2.57.  
 Preparation of 2.11 required 12 steps and 10 separate flash chromatographies. 




Scheme 2-13 Previous synthetic approach to prepare 2.11. 
 
Based on the difficulties outlined above, efforts were focused on making the preparation 
of 2.11 more practical. Because this intermediate is a key fragment of all the Koide group’s 
meayamycin derivatives, and is more stable than FR901464’s right fragment, it is important that 
the production of 2.11 be cost-effective, reproducible and safe.  
2.5.1 Preparation of racemic spiroepoxide 2.11 
Initial efforts focused on a racemic preparation of 2.11 (referred to as racemic-2.11). The 
chosen approach used an acid-mediated endo cyclization of an epoxy-alkene derivative to 
generate the pyran unit (Scheme 2-14). This approach was inspired by Nicolaou’s work on their 
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synthetic studies towards the pyran units of brevetoxin.101 This strategy to generate racemic-2.11 
required the key intermediate 2.61.  
 
 
Scheme 2-14 Our new strategy to prepare 2.60. 
 
Synthesis of 2.61 began with ketone 2.62. An aldol reaction between acrolein and 2.62 
followed by dehydration provided diene 2.64 in approximately 20% yield, with higher yields of 
the triene 2.65. Attempts to improve the yield by protecting the tertiary hydroxy on 2.62, in 
hopes of reducing the potential retro-aldol reaction, led to no improvement in yield. The use of 
LDA in the aldol reaction produced large amounts of a polymeric material, believed to be from 
the use of acrolein, which complicated the workup and purification of diene 2.64. Unfortunately, 
other conditions avoiding the use of LDA, illustrated in Table 2-6, resulted in drastically reduced 
yields of diene 2.64. As a result, optimization of the aldol reaction was postponed until the 
success of the synthetic sequence was validated.  
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Table 2-6 Aldol reaction conditions to prepare 2.63 and 2.64. 
 
  Yield (%) 
Entry Conditions 2.63 2.64 2.65 
1 1. LDA, -78 °C 2. Ac2O, NaOAc, r.t.; 100 °C 0 20 35 
2 NaOH, THF/H2O (1:4), 0 to 24 °C 0 12 0 
3 NaH, THF, 0 to 24 °C 0 0 0 
4 tBuOK, THF, 0 to 24 °C 0 0 0 
5 Cs2CO3, THF, 0 to 24 °C 0 9 0 
6 Bu2BOTf, 
iPr2NEt, CH2Cl2, -78 °C 0 trace 0 
7 BCl3, 
iPr2NEt, CH2Cl2, -78 °C 0 0 81% 
8 pyrrolidine, THF or DMSO, 24 to 60 °C 0 trace 0 
9 Cy2BCl, Et3N, CH2Cl2, -78 °C 0 trace 0 
10 L-proline, DMSO or DMF 0 0 0 
“trace” = less than 5% yield. 
 
Treatment of diene 2.64 with nucleophilic –OOH generated epoxy ketone 2.61, which 
was cyclized to racemic-2.25 via treatment with CSA. The anti-relationship between the hydroxy 
and vinyl group was confirmed by 1H NMR analysis (J value between C4-H and C5-H was 9.9 
Hz). Upon treatment of racemic-2.25 with nBuLi and dibromomethane, the spiroepoxide 
racemic-2.11 was produced in 73% as a single diastereomer. The rationale for the excellent 
diastereoselectivity is because one equivalent of nBuLi will deprotonate the hydroxy group and 
the lithiated alkoxide can coordinate with the oxygen atom on the carbonyl, thereby, shielding 
one face of the carbonyl and allowing only the other face prone to attack, thus leading to the 
epoxide illustrated in Scheme 2-15. Confident with the bond connectivity and relative 
stereochemistry using our new scheme, we proceeded to optimize the conditions and address the 
asymmetric variant of this scheme. 
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Scheme 2-15 Preparation of racemic-2.11. 
2.5.2 Optimization of the aldol reaction to prepare 2.63 
The aldol and dehydration reaction between 2.62 and acrolein to yield diene 2.64 
proceeded in poor yield (less than 20%), though the desired material was pure enough for use in 
subsequent reactions. When the LDA-mediated aldol reaction was attempted using more than 20 
grams of ketone 2.62, several difficulties emerged. In addition, the yield from the reaction 
decreased and became unpredictable, which was accompanied by the generation of significant 
amounts of a yellowish polymer by-product. Also, large amounts of LDA were needed for this 
transformation, in addition to the difficulties associated with maintaining the temperature of the 
reaction below -70 ºC. Besides the lower and variability of the yields, and increased amount of 
by-products on larger scale, the reaction did not proceed to completion, despite several hours of 
incubation and warming. Finally, quenching the reaction is exothermic at larger scales (>10 g), 
and the formation of polymeric by-products proportionally increases with the scale of the 
reaction, leading to difficulties purifying the desired product. Furthermore, the magnitude of 
these difficulties increases with the reaction scale, which makes the reaction difficult to perform 
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when using more than 20 g of ketone 2.62. However, the effectiveness of the reaction in 
producing the desired diene in good purity made the requirements for replacement conditions 
demanding.  
Alternative conditions should provide a good yield of 2.64 (>60%), be operationally 
simple, and generate material of sufficient purity to be used directly in the subsequent step. With 
these criteria in mind, an amine-promoted aldol reaction between 2.62 and acrolein was 
attempted. A variety of reaction conditions were further explored to identify a method for the 
conversion of 2.62 to 2.64. The initial screen was carried out on a 96-well plate, using 0.2 M of 
substrate 2.62, to provide a qualitative assessment of a few conditions capable of promoting the 
aldol reaction between 2.62 and acrolein (Figure 2-11). In terms of providing the desired 
product, as determined by TLC analysis, the most promising conditions was the use of DBU as a 
base in iPrOH, EtOH, 1,2-dichloroethane and no solvent at room temperature (Figure 2-11). 
 
 
Figure 2-11 Screening results. 1.0 equivalent of acrolein, 2.0 equivalent of 2.62 and greater than 
5 equivalent of amines. Black-filled circles indicate presence of product(s) as judged by TLC. 
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The conditions found in the initial screen were further explored to determine the effects 
of temperature, time and stochiometry on promoting the aldol reaction between 2.62 and 
acrolein. However, treatment of 2.62 and acrolein with DBU at -5 ºC deemed ineffective in 
promoting the reaction, although warming the reaction slowly showed signs of product and also 
an increase in the presence of polymeric material exponentially. As a result, the desired product 
was isolated in 8% yield (Scheme 2-16). Varying the solvent did not affect the reaction outcome. 
Performing the reaction in the absence of solvent led to the formation of a predominantly 
polymeric material. In a separate experiment, treatment of acrolein with all of the bases 
mentioned above showed the presence of the same polymeric material I observed during the 
optimization studies, whereas, the same test with ketone 2.62 was negative. This finding 
indicates that acrolein is responsible for the formation of the polymeric substance.  
 
 
Scheme 2-16 Aldol reaction efforts to prepare 2.64. 
 
Based on these results, acidic conditions were used to promote the aldol reaction, and a 
Mukaiyama aldol reaction between derivative of ketone 2.62 and acrolein was attempted. In 
collaboration with Mr. Alexander Krisko (a researcher in the Koide laboratory), silyl enol ether 
2.66 was prepared in two different ways (Table 2-7). The first approach (method A) involved 
using stoichiometric amounts of NaI, Et3N, TMSCl in MeCN.
102 Prior to performing this 
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process, the NaI needed to be dried thoroughly because the process of preparing 2.66 is very 
water sensitive, most likely because of the hydrolysis of in situ generated TMSI. The use of 2.62, 
NaI, Et3N, TMSCl in MeCN yielded 2.66 in 70 – 90% yield. The second approach to prepare 
2.66 (method B) involved the replacement of NaI with LiI. The solvent is also switched from 
MeCN to CHCl3. After rigorously drying LiI, followed by dissolving it in CHCl3 then treatment 
with 2.62, Et3N and TMSCl, the enol ether 2.66 was once again isolated in high yields, listed in 
Table 2-7. Methods A and B both provided the desired product in excellent yields and no 
purifications beyond aqueous extractions were required. While both methods (A and B, Table 2-
7) to prepare enol 2.66 were very efficient, method B (LiI) was slightly easier to work up due to 
the reduced volume of water needed at the end, during the workup procedure. However, from a 
cost-analysis standpoint (cost analysis for chemicals, workup and extraction solvents was 
performed), the approximate cost to prepare 25 grams of 2.66 using method B is $153, which is 
reduced to $46 using method A. For that cost saving reason, method A was used. Using method 
A, prior to starting the reaction, NaI must be dissolve in MeCN, which is time-consuming and 
requires a large volume of MeCN, e.g. 71 g of NaI needs 800 mL MeCN. Therefore, the quantity 
of NaI was reduced from 2.7 equivalents to less than 1.0 equivalent. Also, from a mechanistic 
standpoint, NaI should be catalytic during the process of generating enol 2.66; the in situ 
generated TMSI activates the carbonyl, followed by deprotonation using Et3N and generation of 
TMS-enol ether, and I– is reformed to regenerate TMSI (Scheme 2-17). Based on this hypothesis, 
0.3 equivalent of NaI was used. Performing the reaction with less NaI than the original protocol 
required drastically reduced the yield to almost half. Therefore, we proceeded with the original 
protocol and used 2.7 equivalents of NaI. Although this protocol requires careful addition of a 
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solution of NaI in MeCN and monitoring the temperature, the large scale production of 2.66 
yielded more than 80 g in a single transformation without a consequent loss in yield.  
 
Table 2-7 Conditions to prepare silyl enol ether 2.66. 
 
Method Conditions Yield (%) 
A TMSCl (2.3 equiv), Et3N (2.5 equiv), NaI (2.6 equiv), CH3CN, 40 to 25 °C 86 
B TMSCl (2.7 equiv), LiI (2.7 equiv), Et3N (2.7 equiv), CHCl3, 25 °C 99 
 
 
Scheme 2-17 Mechanistic rationale for the use of less NaI towards the preparation of 2.66. 
 
A variety of reaction conditions have been explored to determine an optimal method for 
the merge of 2.66 with acrolein. The TMS enol ether 2.66 was prone to desilylation, and 
formation of undesired ketone 2.62 was often the sole reaction pathway when attempting 
Mukaiyama aldol reaction103 with commonly used Lewis acids (such as SnCl4, AlCl3, Sc(OTf)3, 
BF3•OEt2, MgBr2•OEt2), even when performed under strictly anhydrous conditions (Table 2-8). 
Although 1H NMR analysis showed the showed the crude silyl enol ether 2.66 was pure, we 
asked whether impurities not observable by spectroscopic methods could be responsible for the 
diminished yields for 2.63. However, applying the conditions of the Mukaiyama aldol (Table 2-
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8, entries 1-5) to the distilled batch of 2.66 led no improvement in yield. Therefore, the poor 
yields of the Mukaiyama aldol reaction were not the result of an impure silyl enol ether 2.66. The 
next step, applying Kobayashi conditions104 with 10 mol% Yb(OTf)3 in 1:10:4 H2O:EtOH:PhMe 
generated the corresponding aldol product in ~70% yield. Chromatographic purification was 
relatively straightforward, even on larger scales (e.g. 30 g), due to the lack of close-running 
impurities. While the original Kobayashi protocol104 indicates the possibility of recycling of 
Yb(OTf)3, this approach was not successful due to the partial solubility of product 2.63 in the 
aqueous layer. 
 
Table 2-8 Mukaiyama aldol reaction conditions towards the preparation of 2.63. 
 
  Yield (%) 
Entry Conditions 2.63  2.62  
1 BF3•OEt2, CH2Cl2, -78 °C 25 – 43 50 – 70  
2 Sc(OTf)3, CH2Cl2, -78 °C 18 75 
3 MgBr2•OEt2, CH2Cl2, -78 °C; 0 °C 0 92 
4 SnCl4, CH2Cl2, -78 °C 20 68 
5 AlCl3, CH2Cl2, -78 °C 23 65 
6 Yb(OTf)3 (10 mol%), H2O/EtOH/toluene (1:10:4), 0 °C 72 0 
 
The next step in the preparation of 2.64 was the conversion of the allylic alcohol 2.63 to 
diene 2.64. The original protocol to prepare 2.64 described above (Section 2.5.1, Table 2-6, entry 
1) specifies mixing the allylic alcohol with sodium acetate and acetic anhydride at room 
temperature for 12 h then heating to 100 °C for 1 h. Although this protocol is effective on a small 
scale (e.g. 2 g), we experienced difficulties when we scaled up the reaction to greater than 5 g. 
Purification of the desired product 2.64 was tedious due to numerous inseparable by-products 
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during flash chromatography, such as the major by-product triene 2.65. One additional note is 
that, during the progress of the reaction, the rate of product formation as determined by TLC 
analysis varied between experiments, most likely due to the heterogeneous nature of the reaction 
mixture. The concentration of the reaction was, therefore, decreased to 0.5 M upon addition of 
solvent, as opposed to the original reaction conditions, which was run without a solvent. We also 
decreased the prolonged reaction time at room temperature due to the slow reaction progress 
observed by TLC. As a result, running the reaction in a solvent (0.50 M) such as 1,2-
dichloroethane at 50 °C for 6 – 7 h led to reproducible yields (60 – 70%), without any by-product 
formation.  
 
Scheme 2-18 Preparation of 2.64 from 2.63. 
 
2.5.3 Preparation of chiral 2.11 
The above sequence established the relative stereochemistry of 2.11. Therefore, it was 
envisioned that possible routes to control the absolute stereochemistry of 2.11 were asymmetric 
epoxidation of 2.64, kinetic resolution to cyclize epoxide 2.61 to ketone 2.25, or enzymatic 
kinetic resolution of racemic-2.25 or racemic-2.11. Epoxidation of enone 2.64 was explored as a 
possible route to prepare chiral variant of 2.61. As shown in Scheme 2-19, attempts to epoxidize 




Scheme 2-19 Effort towards the asymmetric synthesis of 2.61 using cinchona alkaloid 2.73. 
 
Enantioselective epoxidation using metals was tested as an alternative to the 
organocatalyst procedure. However, treatment of 2.64 with La-BINOL (generated in situ), 
Ph3As=O and t-butyl hydrogen peroxide106 led to no product formation. The possibility of the 
tertiary hydroxy group in 2.64 to coordinate the Ph3As=O-La-BINOL/OOtBu complex is likely 
to displace Ph3As=O, 
–OOtBu or BINOL before the complex can undergo conjugate addition to 
the enone. This hypothesis is supported by the observation that the reaction provided the desired 
product with the protected derivative of 2.64, THP 2.75 (Scheme 2-20). However, after 
cyclization, the %ee was found to be only 70%. The ee of ketone 2.25 was established upon 
treatment of 2.25 with (S)-(+)-Mosher’s acid to afford 2.77. The diastereomers of this compound 
were sufficiently resolved in the 1H NMR spectrum to permit analysis. Efforts to apply Deng’s 




Scheme 2-20 Asymmetric synthesis of ketone 2.25 from 2.75. 
 
 
Scheme 2-21 Efforts towards the asymmetric synthesis of 2.83 using chiral phase-transfer 
catalyst 2.81. 
 
Enantioselective cyclization of epoxyalcohol 2.61 failed to convert racemic-2.61 to chiral 
2.25 under Jacobsen’s developed conditions, Scheme 2-22A.108 Furthermore, Jacobsen’s kinetic 
resolution of racemic epoxides protocol using catalyst 2.87 also failed to open the racemic 
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spiroepoxide 2.86 (Scheme 2-22 B).109 These failures prompted exploration of a new area of 
chiral Brønsted acid catalyzed reactions.110,111 After preparation and silica gel chromatography 
purification of chiral phorsphoric acid 2.85, epoxide 2.61 was converted to ketone 2.25 in ~32% 
yield with an ee of >90%. However, this transformation was not reproducible, as different 
batches of phosphoric acid 2.85 produced different results. The poor reproducibility may stem 
from metal impurities.112 Specifically, a fraction of the phosphoric acid might be protonated and 
the remainder is in the phosphoroxide state coordinated to metals. To ensure that we produced 
the Brønsted acid after chromatography purification, the isolated product was washed with 
aqueous hydrochloric acid.112 However, this workup to provide 2.85 did not aid in delivering 
enantiomerically enriched ketone 2.25. This poor reproducibility prompted us to prepare a 
variety of metal-phosphoric Lewis acid compounds (Table 2-9). There is precedence in the 
literature that the corresponding metal salt of the Brønsted acid is responsible for the asymmetric 
catalysis.112 In our studies, the most promising outcome was Mg-2.88, though extensive efforts 















Scheme 2-22 (A) Efforts towards the kinetic resolution of epoxy alcohol 2.61. (B) Efforts 







Table 2-9 Efforts towards the kinetic resolution of 2.61 using phosphoric acid and phosphoric 
acid salt. 
 
Entry R M+ Yield (%) % ee (Mosher ester) 
1 Ph H 35 0 
2 H Ba 34 0 
3 H Ca 17 0 
4 H Mg 26 43 
5 H K 9 0 
6 H Na 0 0 
7 H Co 0 0 
8 H Sr 43 0 
 
Since the presented work had already established a protocol to prepare racemic-2.11, 
enzymatic kinetic resolution of secondary alcohols 2.25 and 2.11 was explred. The lipase B 
strain is known to resolve secondary allylic alcohols containing a variety of functional.113 The 
other strain, Candida antarctica lipase A, also acylates secondary allylic alcohols, but of 
sterically demanding substrates. Attempts to resolve ketone racemic-2.25 and epoxide racemic-
2.11 using both strains of the enzymes failed to produce any acylated product. Additionally, 




Scheme 2-23 Efforts towards the kinetic resolution of racemic-2.25 and racemic-2.11 using 
enzymes. 
 
A different strategy to prepare chiral 2.11 was employed, which required additional steps 
in the synthesis. A 1,2-reduction of ketone 2.64 without CeCl3 provided allylic alcohol 2.89. We 
were able to synthesize epoxide 2.61 via a kinetic resolution reaction on 2.89.114 However, the 
product of the Sharpless epoxidation step contained impurity, which was difficult to separate 
from the desired product. Rigorous purification always resulted in a lower percentage of the 
isolated product. Therefore, it was more advantageous to avoid the laborious purification and 
isolation of this substrate, and continue to the oxidation step. Oxidation using catalytic TPAP and 
stochiometric NMO115 delivered 2.61 (Scheme 2-24A). Other oxidation methods, e.g. Dess-
Martin periodane,116 Parikh-Doering,117 Swern oxidation,118 failed to deliver the desired product. 
Using the standard workup conditions employed in TPAP/NMO oxidation, filtration and 
chromatography purification, afforded some loss of product due to decomposition and volatility 
of 2.61. To avoid this loss, it was discovered that the reaction mixture could be directly filtered 
through a short silica gel plug to remove the ruthenium species and any remaining polar 
impurities from the two prior reactions, allowing the use of impure 2.61 as a starting material 
without a measurable decrease in yield of 2.25. The filtrate was directly treated with CSA, then 
Et3N to afford ketone 2.25 in greater than 90% ee (Scheme 2-24A). 
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Due to the rigorous workup needed after the Sharpless epoxidation conditions, attempts 
were made to use Hisashi Yamamoto’s epoxidation method.119 Treatment of crude allylic alcohol 
2.89 with VO(OiPr)3 and the N-hydroxyamide ligand A in CH2Cl2 formed the desired epoxide. 
Following the same procedure as reported above: TPAP/NMO mediated oxidation and 
cyclization using CSA yield ketone 2.25 (Scheme 2-24B). Mosher ester analysis of 2.77 revealed 
that the epoxidation was not enantioselective. Towards this end, it was opted to proceed with the 























Scheme 2-24 (A) Preparation of chiral 2.25 using Sharpless asymmetric epoxidation kinetic 
resolution. (B) Preparation of chiral 2.25 using Yamamoto’s asymmetric epoxidation kinetic 
resolution method. 
 
2.5.4 Generation of meayamycin from FR901464 
It was realized that meayamycin could be prepared from FR901464 by interchanging the 
stable fragment of meayamycin, 2.11, with that of the unstable counter part of FR901464 
(Scheme 2-25B, blue fragment). We exploited of the reversibility of the 1,3-diene-ene cross 
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metathesis using a ruthenium-based catalyst. This was thought to be a viable approach for the 
two following reasons:  
 The reaction of the ruthenium catalyst would preferentially react with 2.91 to form 
alkylidene 2.94, followed by formation of 2.95. This process is reversible. 
 Eventually, alkylidene 2.94 would react with the sterically more accessible alkene of 
diene 2.90 to form alkylidene 2.96, thereby forming meayamycin. 
 
This fragment interchange strategy was tested by treating FR901464 with excess 2.11 in 
1,2-dichloroethane and Ru-1 in 40 ºC for 14 h to produce meayamycin. Meayamycin formation 
was validated by the similar retention times to authentic meayamycin and 1H NMR analysis 
(Figure 2-12B). This is probably the most concise approach to produce meayamycin in a short 
term as long as FR901464 can be supplied. Another potential use of this interchange strategy, 
although not tested, is the bubbling of ethylene in a mixture of FR901464 and the ruthenium 
















Scheme 2-25 (A) The cross metathesis interchange strategy to prepare meayamycin from 























Figure 2-12 (A) HPLC chromatogram of the reaction mixture from Scheme 2-25. (B) 1H NMR 
of pure meayamycin. (C) 1H NMR of meayamycin from the synthesis using the cross metathesis 
interchange strategy shown in Scheme 2-25. 
 
 The interchange strategy could be a convenient approach to prepare 2.27 and further 
allow for diversifying C4´. In addition, the process could lead to a cleaner reaction with less by-
products formed due to the dramatic reduction of intermediates present in the reaction mixture. A 
potential disadvantage of this strategy would be the contamination of meayamycin with 
ruthenium by-products. However, there are many methods for removing ruthenium including 
activated charcoal,120 Ph3P=O,
121 Pb(OAc)4,
122 and the most convenient method being to use 
commercial thiol- or thiourea-based resin scavengers. 
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2.5.5 Summary 
The synthetic route to produce intermediate 2.11, originally developed in the Koide research 
group, required 12 steps. To improve this approach, using the new scheme, 2.11 was prepared in 
8 steps and five separate chromatographic purifications. Furthermore, meayamycin was prepared 
through one-step reaction from 2.11 and FR901464, contingent on a continuous supply of 
FR901464 continues. Future improvements directed towards the practical preparation of 
meayamycin and its derivatives should be focused on identifying alternate coupling strategies to 
cross metathesis, due to the tedious and rigorous purification efforts continuously invested to 
yield meayamycin-type compounds. Additionally, it would be advantageous to revisit the chiral 
Brønsted acid kinetic resolution method to convert 2.61 to 2.25, which would lead to a 6-step 
synthesis of intermediate 2.11.  
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3.0  CHEMICAL AND BIOLOGICAL STUDIES OF TMC-205 AND ITS 
ANALOGUES 
3.1 BACKGROUND 
Irregular gene expression disrupts homeostasis and is often a cause and/or consequence of 
diseases.123 Thus, exogenous means to regulate gene expression could be a powerful approach to 
changing the course of cells’ homeostasis. As a research tool, the combination of tetracycline or 
doxycycline and their responsive promoter has been used successfully in vitro and in vivo to 
activate a specific gene.124,125–126-130 An alternative approach using reporter gene systems has 
been pursued in the quest for natural products that regulate genes, in which the SV40 promoter 
was commonly used. These efforts have resulted in the discoveries of natural products such as 
azelaic bishydroxamic acid,131 trichostatin A,132 FR901228,133 herboxidiene134,135 and 
FR901464.136-138 Mechanistic studies of trichostatin A and FR901464 impacted chemistry, 
biology, and medicine because these small molecules demonstrated that the inhibitions of histone 
deacetylases and spliceosome were new approaches to tackle cancer.7,46,139-142,143 In sum, 
discoveries and development of small molecules that activate the SV40 promoter is a fruitful 




Figure 3-1 Chemical structures of natural products that upregulate the SV40 promoter. 
 
TMC-205 was isolated from a fermentation broth of an unidentified fungal strain TC 
1630. The natural product activated an SV40 promoter and was cytotoxic against various human 
cancer cell lines in the 52–203 µM range as GI50 values.144 Despite the modest potency, TMC-
205 may be an attractive lead compound to develop new transcriptional modulators, considering 
the recent history of the SV40 promoter-activating natural products. Moreover, TMC-205 was 
found to be light sensitive, and only 3.3 mg of TMC-205 was isolated, necessitating better access 
to this natural product. Here, we report our synthetic and biological studies of TMC-205 and its 
analogues. 
3.2 SYNTHESIS OF TMC-205 
It was important to devise a concise synthesis for subsequent biological studies. An 
obvious convergent approach was the C6-C9 bond formation toward the end of the synthesis 
via a cross-coupling reaction (Scheme 3-1). We planned to examine two different strategies: 
 104 
Stille coupling145 and Suzuki-Miyaura coupling146 reactions (Scheme 3-1). 
 
 
Scheme 3-1 Structure and retrosynthetic analysis of TMC-205. 
 
Treatment of 6-bromoindole (3.4) with (CF3CO)2O followed by aqueous NaOH 
afforded carboxylic acid 3.6 in 97% yield over 2 steps  (Scheme 3-2A).147 Boronic ester 3.2 
was prepared by the hydroboration of 2-methylbut-1-en-3-yne with catecholborane (Scheme 
3-2B).148,149 Treatment of boronic ester 3.2 with bromide 3.6 in the presence of Pd(PPh3)4 
and Cs2CO3 failed to produce the target molecule 3.1 (Scheme 3-2A).150 With the known 
organostannane 3.3 prepared from 2-methylbut-1-en-3-yne according to the literature,151,152 a 
Stille coupling reaction was examined to convert bromide 3.6 to TMC-205. However, this 
transformation provided the natural product only in 10% yield, prompting us to seek an 
alternative approach.  
Both of the cross-coupling experiments described above suffered from the poor solubility 
of carboxylic acid 3.6 in various solvents (THF, MeOH, DMSO, and 1,4-dioxane). The more 
soluble methyl ester 3.7 was prepared in 65% overall yield from 3.4 (Scheme 3-2C). This ester 
was subjected to the Suzuki-Miyaura coupling conditions with boronic ester 2 to form methyl 
ester 3.8 in 98% yield. Finally, treatment of this methyl ester with NaOH followed by 
acidification with KHSO4 afforded TMC-205 in 88% yield. Therefore, the total synthesis of 
TMC-205 was accomplished in 5 steps in the longest linear sequence (6 total steps) from the 
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commercially available bromide 3.4 in 64% overall yield. The GI50 value of the synthetic TMC-























Scheme 3-2 (A) Efforts towards the preparation of TMC-205 using Suzuki-Miyaura and Stille 
reaction. (B) Preparation of boronic ester 3.2 and organostannane 3.3. (C) Preparation of 3.1 
using Suzuki-Miyaura cross-coupling reaction on ester 3.7. 
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3.3 STABILITY OF TMC-205 
During our synthesis and structure characterization of TMC-205, this natural product in 
MeOH and DMSO decomposed noticeably in less than 24 h after being stored under ordinary 
laboratory visible light and air. HPLC analysis of 16 h-old TMC-205 solutions in MeOH and 
DMSO showed that the decomposition was not solvent-dependent (Figure 3-2). The 1H NMR 
spectrum of the CD3OD solution (Figure 3-3) revealed the presence of an enone group, possibly 
from enone 3.I (Figure 3-4) or its derivative in which the indole ring was oxidized (carboxylic 
acid 3.III), and a formyl group resulting from either the oxidation of the C9-C10 and/or the C2-
C3 bond (carboxylic acid 3.II, formyl 3.IV, or formyl 3.V; Figure 3-4). LC-MS analysis was 
performed on the decomposed TMC-205 to reveal m/z peaks indicating enone 3.I (m/z = 271 
[M+CH3CN+H]











(A)                                                                           (B) 
      
Figure 3-2 HPLC chromatograms of TMC-205 after being exposed to light and air for 16 h.  
(A) Experiment performed with TMC-205 in MeOH. (B) Experiment performed with TMC-205 
in DMSO. (A) and (B): x-axis: elution time (min). y-axis: absorption at 276 nm. Elution 
conditions: flow rate = 1.0 mL/min. Gradient: 10→95% MeCN in water (containing 0.1% 
HCOOH) over 20 min. Column: C18 XDB 4.6 mm × 7.5 cm. T = 24 °C. 
 
 





Figure 3-4 (A) Structures of possible byproducts of decomposed TMC-205 (B) Selective 
oxidation of TMC-205 with singlet oxygen. 
 
Following these analysis, we chose to see which reactive oxygen species (ROS) was 
responsible for the oxidized by-products of TMC-205. After exposure of synthetic TMC-205 to 
various cocktails that produce specific ROS (singlet oxygen, superoxide, hydrogen peroxide and 
hydroxyl radical),153 we discovered that singlet oxygen was primarily responsible for the 
decomposition of TMC-205. Treatment with NaN3, a widely used singlet oxygen scavenger, 









(A)                                                                                   (B) 
                            
 
(C)                                                                                      (D) 
         
Figure 3-5 HPLC chromatograms (A–D) of the reaction between singlet oxygen and TMC-205 
or N,N-dimethyl nitrosoaniline. 
(A) and (B): reaction of TMC-205 (without or with NaN3) with singlet oxygen. Exposure of 
TMC-205 to other ROS species (hydroxyl radical, superoxide and hydrogen peroxide) showed 
no sign of reaction. Exposure of ketone 3.13 to any of the ROS species showed no sign of 




3.4 SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY OF TMC-205 
ANALOGUES  
A notable functional group in TMC-205 is the carboxy group. As such, we prepared the 
decarboxylated analogue 3.9 and alcohol 3.10 (Scheme 3-3A). Alcohol 3.10, prepared by 
reducing methyl ester 3.8 using DIBALH, was more sensitive to light, air and heat than TMC-
205. The cytotoxicity assay with HCT-116 cells showed that decarboxylated analogue 3.10 was 
~3 times less potent than TMC-205 (Table 3-1). Alcohol 3.10 and TMC-205 were equipotent, 
indicating that the negative charge of the carboxy group is not important. 
Next, we addressed the importance of the 1,3-diene moiety by comparing TMC-205 and 
3.12 (Scheme 3-3). The alkane analogue 3.12, assembled by hydrogenation of 3.8 followed by 
ester hydrolysis, did not show cytotoxicity even at 500 µM, indicating the significance of the 
diene moiety. On a side note, alkane 3.12 was found to be stable in light and air, unlike TMC-












Scheme 3-3 Preparation of analogues 3.9, 3.10, and 3.12. 
 
During these structure-activity relationship studies, it became apparent that the instability 
of TMC-205 and its analogues could be detrimental to the biological experiments in our 
research. In order to improve the stability of TMC-205, we decided to introduce an electron-
withdrawing group to the natural product, yielding ketone 3.13 (Scheme 3-4). Indeed, this 
analogue was completely stable under room light and air than TMC-205. Moreover, analogue 
3.13 was nearly twice as potent as TMC-205, with a GI50 value of 39 µM against HCT-116 cells 
(Table 3-1).  
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N-Methylated analogue 3.14 (Scheme 3-4) was less cytotoxic than analogue 3.13, 
implying that the N-H group may serve as a hydrogen bonding donor or that a putative binding 
pocket for this functional group may not tolerate additional steric bulk. 
 
 
Scheme 3-4 Preparation of analogues 3.13 and 3.14. 
 
The improved stability of analogue 3.13 enabled us to revisit the question about the 1,3-
diene moiety. The air-oxidation of TMC-205 described above might occur in cellular 
environment to yield an enone functionality that could be the bona fide bioactive species.154 
Thus, we asked whether the oxidized product could be relevant to the biological activity of 
TMC-205. The synthesis of analogue 3.18 began with intermediate 3.5 (Scheme 3-5A). A Heck 
cross-coupling155 between 3.5 and methyl vinyl ketone using Pd(OAc)2 and P(tBu)3HBF4 at 45 
°C delivered only the conjugate addition product 3.16, indicating that the oxidative insertion of 
Pd(0) into the C-Br bond did not occur. At 100 °C, the Heck reaction of 3.15 proceeded, but 
concomitant deprotection-conjugate addition at the NH group occurred to give undesired product 
3.17 in 50 – 80% yields (Scheme 3-5A). Attempts to convert 3.17 to 3.18 under basic conditions 
met with no success, resulting in the recovery of the starting material.  
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These failures prompted us to undertake a different approach towards 3.20. A Stille 
coupling between 3.5 and nBu3SnCH=CH2 yielded C6-vinylated product 3.19 in 72% yield 
(Scheme 3-5B). Indole 3.19 was treated with methyl vinyl ketone in the presence of Ru-1 to 
form the enone analogue 3.20 in 30% yield. Enone 3.20 was 3 and 5 times more potent than 1,3-
diene 3.13 and TMC-205, respectively, with a GI50 value of 14 µM (Table 3-1). Thus, we asked 
whether the electrophilicity was of any significance for the activity of this enone. The syntheses 
of the two allylic alcohols 3.21 and 3.22, are illustrated in Scheme 3-5B. The secondary allylic 
alcohol 3.21 was equipotent to enone 3.20 (Table 3-1), suggesting that 3.21 might be oxidized to 
3.20, although this hypothesis warrants further investigation. The tertiary allylic alcohol 3.22 was 
far less potent, which could imply that the additional methyl group might be too bulky for a 















Scheme 3-5 (A) Failed attempts to form enone 3.18. (B) Preparation of analogues 3.20, 3.21, and 
3.22. 
 
After improving the activity of TMC-205 by 8 fold, we prepared readily conjugatable 
analogues 3.26 and 3.27 (Scheme 3-6) for further studies. These two analogues exhibited 
significantly reduced antiproliferative activity against HCT-116 cell line (Table 3-1). These 
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results imply that an aromatic C-H bond may need to be derivatized to insert a handle without 













Table 3-1 Antiproliferative activity of TMC-205 and its analogues against HCT-116 cells. 
Vincrstine was used a control, displayed GI50 values between 0.20 ± 0.22 and 0.3 ± 0.1 nM. 
Compound GI50 (µM)
[a] 
3.1 68 ± 3 
3.9  147 ± 10 
3.10 79 ± 15 
3.12 >500 
3.13 39 ± 12 
3.14 >500 
3.20 14 ± 4 
3.21 8 ± 6 
3.22 >500 
3.26 >100 
3.27  >99  
[a] Each experiment consists of twelve data points (twelve different concentrations).  
3.5 GENE EXPRESSION STUDIES OF TMC-205 AND ANALOGUES 
Previously, TMC-205 was found to activate luciferase gene driven by an SV40 promoter 
in an SV40 enhancer-dependent manner using the pGL3-control Luciferase Vector 
(Promega).144 The activation of the luciferase gene driven by the SV40 promoter without the 
SV40 enhancer (pGL3-promoter Luciferase Vector, Promega) was negligible in the presence 
of TMC-205.144 Due to the lack of details for dose-dependence, first we determined the TMC-
205-concentration dependence with these two commercially available vectors transiently 
transfected in HeLa cells. All the gene expression experiments were performed by Ms. Yang Gao 
in our research group. The natural product activated the luciferase expression in a dose-
dependent manner independent of an SV40 enhancer (Figure 3-6A and 3-6B). A significant and 
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unexpected discovery from this experiment is that there is a range of concentrations (0.1–1 µM) 
in which TMC-205 activates the SV40:luciferase without inhibiting cell growth (GI50 in HeLa 
cells is 157 µM).144 Analogue 3.13 and 3.21 also activated the expression of SV40:luciferase 
without inhibiting cell growth (Figure 3-6C and D). RT-PCR analysis of the total RNA extracted 
from 3.13-, meayamycin-,156 and DMSO-treated cells further validated that analogue 3.13 
upregulated the expression of luciferase. 
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Figure 3-6 Effect of TMC-205, ketone 3.13 and allylic alcohol 3.21 on luciferase expression 
regulated by an SV40 promoter. 
Signals were normalized to the samples treated with vehicle. (A) TMC-205 upregulates 
expression of luciferase gene under the control of SV40 promoter and enhancer in transiently 
transfected HeLa cells. (B) TMC-205 upregulates expression of luciferase gene under the control 
of SV40 promoter without enhancer in transiently transfected HeLa cells. (C) Ketone 3.13 
upregulates expression of luciferase gene under the control of SV40 promoter and enhancer in 
transiently transfected HeLa cells, without loss of cell viability. Data represent mean values ± 
s.d. (n = 2). (D) Allylic alcohol 3.21 upregulates expression of luciferase gene under the control 
of SV40 promoter and enhancer in transiently transfected HeLa cells, without loss of cell 
viability. Data represent mean values ± s.d. (n = 2). 
 
Subsequently, we stably transfected a HeLa cell line with the pGL3-control luciferase 
vector and were able to observe similar gene activation with TMC-205 at concentrations ranging 
from 1 to 300 µM without any loss of cell viability (EC50 = 6 µM, Figure 3-7). It should be noted 
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that the cells were treated with TMC-205 and analogues for only 24 h. The more stable and 
active analogue, 3.13, also shows a range of concentrations where activation of luciferase gene 
was observed (EC50 = 5 nM) without apparent growth inhibition (Figure 3-7B). 
 
   
Figure 3-7 Effect of TMC-205 and analogue 3.13 on luciferase expression regulated by an SV40 
promoter and enhancer, in stably transfected HeLa cells. 
Signals were normalized to the samples treated with vehicle. (A) TMC-205 upregulates 
expression of luciferase gene, without loss of cell viability. Data represent mean values ± s.d. (n 
= 4). (B) Analogue 3.13 upregulates expression of luciferase gene, without loss of cell viability. 
Data represent mean values ± s.d. (n = 2). 
3.6 SUMMARY 
In summary, the first total synthesis of TMC-205 has been accomplished. We then developed 
TMC-205 analogues that include alcohol 3.21, an eight-fold more potent analogue of TMC-205. 
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Importantly, there is a range of TMC-205 and analogue 3.13 concentrations where the 
compounds activate an SV40-controlled gene without apparent antiproliferative activity (e.g., 
EC50 for 3.13 = 5 nM). The SV40 promoter is recognized by human AP-1 and transcription 
factor Sp-1 (and related transcription factors). These transcription factors are important 
regulatory proteins in the development of organisms and cancer.156 While our studies revealed 
that changes in the expression level of genes regulated by the SV40 promoter were from 
compound treatment, it could be the outcome of multiple reasons. For instance, one of them 
being direct influence on transcription factors driving the SV40 promoter, or indirect or non-
specific effects could be operative. Further experimentation, beyond the reporter gene assay, to 
illustrate whether this observed activity is specific or not would be needed. Additionally, TMC-
205 (or its derivatives) could be used as a fluorescence quencher, since preliminary experiments 
revealed that TMC-205 decreases the fluorescence of dichlorofluorescein in a time and 






All reactions were carried out with freshly distilled solvents under anhydrous conditions, 
unless otherwise noted. All of the flasks used for carrying out reactions were dried in an oven at 
80 °C prior to use. Unless specifically stated, the temperature of a water bath during the 
evaporation of organic solvents using a rotary evaporator was 47 °C. All of the syringes in this 
study were dried in an oven at 80 °C and stored in a desiccator over Drierite®. Tetrahydrofuran 
(THF) was distilled over Na metal and benzophenone. Methylene chloride (CH2Cl2) was distilled 
over calcium hydride. Acetonitrile was distilled from CaH2 and stored over 3Å molecular sieves. 
Yields refer to chromatographically and spectroscopically (1H NMR) homogenous materials, 
unless otherwise stated. All reactions were monitored by thin-layer chromatography (TLC) 
carried out on 0.25 mm Merck silica gel plates (60F-254) using UV light (254 nm) for 
visualization or anisaldehyde in ethanol or 0.2% ninhydrin in ethanol as a developing agents and 
heat for visualization. Silica gel (230-400 mesh) was used for flash column chromatography. A 
rotary evaporator was connected to a water aspirator that produced a vacuum pressure of 
approximately 60 mmHg when it was connected to the evaporator. NMR spectra were recorded 
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on a Bruker Advance spectrometer at 300 MHz, 400 MHz, 500 MHz, 600 MHz or 700 MHz. 
The chemical shifts are given in parts per million (ppm) on a delta (δ) scale. The solvent peak 
was used as a reference value, for 1H NMR: CHCl3 = 7.27 ppm, MeOH = 3.31 ppm, DMSO = 
2.50 ppm, acetone = 2.05ppm, for 13C NMR: CDCl3 = 77.00 ppm, CD3OD = 49.00 ppm, DMSO-
d6 = 49.10 ppm and acetone-d6 = 29.40 ppm. The following abbreviations are used to indicate the 
multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; br = broad. High-
resolution mass spectra were recorded on a VG 7070 spectrometer. Low-resolution mass spectra 
[LCMS (ESI)] were recorded on a Shimadzu LCMS-2020. Infrared (IR) spectra were collected 
on a Mattson Cygnus 100 spectrometer. Samples for acquiring IR spectra were prepared as a thin 






Preparation of alkene 2.6: To a solution of 5 mL of 10% TFA in CH2Cl2 at 0 °C was added 
the Boc-protected amine 2.4 (81 mg, 0.30 mmol). The reaction was warmed to 23 °C and stirred 
for 4 h. The solvent was removed in vacuo, and the residue was diluted with EtOAc (10 mL) and 
aqueous saturated NaHCO3 (10 mL). The organic layer was separated, and the aqueous layer was 
extracted with EtOAc (2 × 10 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo, and the residue was used in the next step without 
further purification.  
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To a stirred solution of acid 2.3 (80 mg, 0.50 mmol) in MeCN (1.5 mL) at 23 °C was added 
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (152 mg, 0.40 
mmol), followed by N,N-diisopropylethylamine (194 mg, 1.50 mmol) under a nitrogen 
atmosphere. The resulting mixture was stirred for 10 min then transferred by cannula to a stirred 
solution of the amine in MeCN (1.0 mL) at the same temperature. After 15 h at 23 °C, the 
reaction was quenched with saturated aqueous NH4Cl (2 mL) and most of the organic solvent 
was removed in vacuo. The aqueous residue was extracted with EtOAc (3 × 10 mL). The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. 
The crude residue was purified by flash chromatography (7.5 to 50 % EtOAc in hexanes) on 
silica gel (25 mL) to afford the desired product 2.6 (40 mg, 43% yield) as a clear oil, and the cis 
isomer (2.5) (52 mg , 56 % yield) as a clear oil. 
Data for alkene 2.6: Rf = 0.31 (40% EtOAc in hexanes); IR (film): νmax = 3308, 2974, 2934, 
1740 (C=O), 1637 (C=O), 1530, 1446, 1240 cm-1; [α]D 
23 -1.6 (c 1.9, CHCl3); 1H NMR (300 
MHz, 293 K, 1% CD3OD in CDCl3): δ = 6.75 (dd, J = 15.3, 5.4 Hz, 1H, 3´-H), 5.94 (dd, J = 
15.3, 1.5 Hz, 1H, 2´-H), 5.81−5.73 (m, 1H, 9-H), 5.49 (qdd, J = 6.9, 5.4, 1.5 Hz, 1H, 4´-H), 5.14 
(dd, J = 17.4, 1.5 Hz, 1H, 8trans-H), 5.07 (br d, J = 10.2 Hz, 1H, 8cis-H), 4.01−3.97 (m, 1H, 14-H), 
3.65 (qd, J = 6.3, 2.0 Hz, 1H, 15-H), 3.53 (ddd, J = 7.2, 7.2, 2.7 Hz, 1H, 11-H), 2.39−2.30 (m, 
1H, 10-H), 2.24−2.13 (m, 1H, 10-H), 2.09 (s, 3H, 2´´-H), 1.95−1.93 (m, 2H, 13-H), 1.82−1.79 
(m, 1H, 12-H), 1.37 (d, J = 6.9 Hz, 3H, 5´-H), 1.15 (d, J = 6.3 Hz, 3H, 16-H), 1.04 (d, J = 7.5 
Hz, 3H, 20-H); 13C NMR (75 MHz, 293 K, CDCl3): δ = 170.0, 164.6, 142.1, 134.6, 123.5, 116.8, 
80.7, 76.0, 69.1, 47.3, 37.3, 35.8, 28.8, 21.2, 19.8, 17.9, 15.2; HRMS (EI+) calcd for 
C17H27NO4Na [M + Na]
+ 332.1838, found 332.1869. 
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Data for 2.5, see: Albert, B. J.; Sivaramakrishnan, A.; Naka, T.; Koide, K. J. Am. Chem. Soc. 
2006, 128, 2792–2793. 
 
 
Preparation of allylic alcohol 2.7: To a stirred solution of 2.6 (25 mg, 80 μmol) in MeOH 
(2.5 mL) was added K2CO3 (28 mg, 0.20 mmol) at 0 °C under an open atmosphere. After 2 h at 
the same temperature, the reaction mixture was diluted with saturated aqueous NH4Cl (3 mL) 
and H2O (7 mL), and the resulting solution was extracted with EtOAc (3 × 10 mL). The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. 
The resulting crude residue was purified by flash chromatography (20 to 90% EtAOc in hexanes) 
on silica gel (5 mL) to afford 2.7 (16 mg, 75% yield) as a colorles oil.  
Data for allylic alcohol 2.7: Rf = 0.30 (40% EtOAc in hexanes); IR (film): νmax = 3324 (br), 
3076, 2973, 2930, 1671 (C=O), 1625, 1531, 1462, 1362, 1145, 1063 cm-1; [α]D 
23 -5.2 (c 0.8, 
CHCl3); 
1H NMR (300 MHz, 293 K, 1% CD3OD in CDCl3): δ = 6.87 (dd, J = 15.3, 4.5 Hz, 1H, 
3´-H), 5.98 (dd, J = 15.3, 1.7 Hz, 1H, 2´-H), 5.87−5.73 (m, 1H, 9-H), 5.15 (dd, J = 17.4, 1.5 Hz, 
1H, 8´-H), 5.08 (dd, J = 10.2, 1.5 Hz, 1H, 8-H), 4.51 (m, 1H, 4´-H), 4.01 (ddd, J = 6.9, 2.1, 2.1 
Hz, 1H, 14-H), 3.67 (qd, J = 6.3, 2.1 Hz, 1H, 15-H), 3.56 (ddd, J = 7.2, 7.2, 2.7 Hz, 1H, 11-H), 
2.40−2.30 (m, 1H, 10-H), 2.19−2.09 (m, 1H, 10-H), 1.96−1.94 (m, 2H, 13-H), 1.83−1.77 (m, 1H, 
12-H), 1.36 (d, J = 6.9 Hz, 3H, 5´-H), 1.16 (d, J = 6.3 Hz, 3H, 16-H), 1.05 (d, J = 7.5 Hz, 3H, 
20-H); 13C NMR (75 MHz, 293 K, CDCl3): δ = 165.2, 146.7, 134.7, 121.9, 116.8, 80.8, 76.1, 
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67.2, 47.3, 37.4, 36.0, 28.9, 23.1, 17.9, 15.1; HRMS (ESI+) calcd for C15H25NO3Na [M + Na]
+ 
290.1732, found 290.1712. 
 
 
Preparation of carbamate 2.8: A stirred solution of 2.7 (24 mg, 90 μmol) in CH2Cl2 (0.5 mL) 
at 23 °C was treated with 1,1’-carbonyldiimidazole (18 mg, 0.11 mmol) under normal 
atmosphere. After 27 h, morpholine (39.2 mg, 0.450 mmol) was added, and the mixture was 
stirred at 23 °C for 16 h. The solvent was removed in vacuo, and the resulting residue was 
purified by flash chromatography (20 to 80% EtOAc in hexanes) on silica gel (5 mL) to afford 
2.8 (33.0 mg, 97% yield) as a white solid. 
Data for carbamate 2.8: mp = 161−163 °C ; Rf = 0.35 (60% EtOAc in hexanes); IR (film): 
νmax = 3304, 2968, 2930, 2858, 1704 (C=O), 1673 (C=O), 1626, 1426, 1241, 1117 cm-1; [α]D 23 
+3.53 (c 1.18, CHCl3); 1H NMR (300 MHz, 293 K, CDCl3): δ = 6.78 (dd, J = 15.3, 5.4 Hz, 1H, 
3´-H), 5.96 (dd, J = 15.3, 1.5 Hz, 1H, 2´-H), 5.81−5.74 (m, 1H, 9-H), 5.50−5.41 (m, 1H, 4´-H), 
5.15 (br d, J = 17.1, 1H, 8´-H), 5.08 (br d, J = 10.2, 1H, 8-H), 4.01−3.99 (m, 1H, 14-H), 
3.68−3.66 (m, 5H, morpholine-CH2O, 15-H), 3.56 (ddd, J = 6.9, 6.9, 2.4 Hz, 1H, 11-H), 3.48 (t, 
J = 4.7 Hz, 4H, morpholine-CH2N), 2.35 (ddd, J = 14.1, 6.9, 6.9 Hz, 1H, 10-H), 2.14 (ddd, J = 
14.1, 6.9, 6.9 Hz, 1H, 10-H), 1.94−1.93 (m, 2H, 13-H), 1.81−1.78 (m, 1H, 12-H), 1.37 (d, J = 6.6 
Hz, 3H, 5´-H), 1.16 (d, J = 6.3 Hz, 3H, 16-H), 1.04 (d, J = 7.2 Hz, 3H, 20-H); 13C NMR (75 
MHz, 293 K, CDCl3): δ = 164.7, 154.4, 142.8, 134.6,123.4, 116.8, 80.8, 76.1, 70.3, 66.6, 47.3, 
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44.1, 37.3, 35.9, 28.9, 20.2, 17.9, 15.2; HRMS (ESI+) calcd for C20H32N2O5Na [M + Na]+ 
403.2209, found 403.2209. 
 
 
Preparation of aldehyde 2.9: To a stirred solution of alkene 2.8 (60 mg, 0.16 mmol) and 
methacrolein (224 mg, 3.20 mmol) in CH2Cl2 (0.3 mL) was added Ru-1 (2.0 mg, 3.2 μmol), 
followed by p-benzoquinone (2.0 mg, 20 μmol) under open atmosphere. After 12 h at 23 °C, the 
mixture was concentrated in vacuo. The residue was purified by flash chromatography (40 to 
100% EtOAc in hexanes) on silica gel (20 mL) to afford aldehyde 2.9 (50 mg, 74% yield) as a 
dark-grey oil.  
Data for aldehyde 2.9: Rf = 0.15 (60% EtOAc in hexanes); IR (film): νmax = 3337, 2974, 
2926, 2857, 1710 (C=O), 1678 (C=O), 1637 (C=O), 1528, 1459, 1428, 1242, 1117, 1069 cm-1; 
[α]D 
23 -6.16 (c 1.4, CHCl3) 1H NMR (300 MHz, 293 K, 1% CD3OD in CDCl3): δ = 9.43 (s, 1H, 
7-H), 6.80 (dd, J = 15.3, 5.7 Hz, 1H, 3´-H) 6.54 (ddd, J = 7.5, 7.5, 1.2 Hz, 1H, 9-H), 5.94 (dd, J 
= 15.3, 1.2 Hz, 1H, 2´-H), 5.72 (br d, J = 9.0 Hz, N-H), 5.46 (dqd, J = 5.7, 6.6, 1.2 Hz, 1H, 4´-
H), 4.03 (dddd, J = 9.0, 6.6, 2.9, 2.9 Hz, 1H, 14-H), 3.74−3.66 (m, 6H, morpholine-CH2O, 15-H, 
11-H), 3.48 (t, J = 4.7, 4H, morpholine-CH2N), 2.63−2.53 (m, 1H, 10-H), 2.47−2.37 (m, 1H, 10-
H), 2.00−1.98 (m, 2H, 13-H), 1.87−1.81 (m, 1H, 12-H), 1.77 (s, 3H, 19-H), 1.38 (d, J = 6.6 Hz, 
3H, 5´-H), 1.17 (d, J = 6.6 Hz, 3H, 16-H), 1.09 (d, J = 7.5 Hz, 3H, 20-H); 13C NMR (75 MHz, 
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293 K, CDCl3): δ = 194.9, 164.7, 154.4, 150.1, 143.0, 140.6, 123.2, 79.8, 76.3, 70.3, 66.5, 47.1, 
44.1, 35.7, 32.7, 29.5, 20.2, 17.8, 15.3, 14.1; HRMS (ESI+) calcd for C22H34N2O6Na [M + Na]
+ 
445.2315, found 445.2357. 
 
 
Preparation of alkene 2.10: To a stirred suspension of methytriphenylphosphonium bromide 
(103 mg, 0.290 mmol) in THF (2.0 mL) at 0 °C was added KOtBu (30.0 mg, 0.270 mmol) under 
nitrogen atmosphere. After 30 min at 0 °C, aldehyde 2.9 (50.0 mg, 0.120 mmol) in THF (0.2 
mL) was added dropwise by cannula at the same temperature and rinsed with additional THF 
(0.1 mL). After 3 h at the same temperature, the reaction was quenched with saturated aqueous 
NH4Cl (5 mL). The mixture was extracted with EtOAc (3 × 10 mL). The combined organic 
layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude residue 
was purified by flash chromatography (30 to 90% EtOAc in heanes) on silica gel (20 mL) to 
afford the terminal alkene 2.10 (25.0 mg, 50% yield) as a colorless oil.  
Data for alkene 2.10: Rf = 0.27 (60% EtOAc in hexanes); IR (film): νmax = 3435, 2928, 1707 
(C=O), 1640 (C=O), 1456, 1375, 1242, 1118 cm-1; [α]D 
23 +4.6 (c 1.0, CHCl3); 1H NMR (300 
MHz, 293 K, CDCl3): δ = 6.79 (dd, J = 15.3, 5.4 Hz, 1H, 3´-H), 6.39 (dd, J = 17.4, 10.8 Hz, 1H, 
7-H), 5.92 (dd, J = 15.3, 1.5 Hz, 1H, 2´-H), 5.77 (br d, J = 9.0 Hz, 1H, N-H), 5.50 (m, 2H, 4´-H, 
9-H), 5.15 (br d, J = 17.4 Hz, 1H, 6´-H), 4.99 (br d, J = 10.8 Hz, 1H, 6-H), 4.01 (dddd, J = 9.0, 
6.9, 2.9, 2.9 Hz, 1H, 14-H), 3.70−3.67 (m, 5H, morpholine-CH2O, 15-H), 3.57 (ddd, J = 7.2, 7.7, 
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2.7 Hz, 1H, 11-H), 3.49 (t, J = 4.8 Hz, 4H, morpholine-CH2N), 2.46−2.37 (m, 1H, 10-H), 
2.32−2.22 (m, 1H, 10-H), 1.95 (ddd, J = 0, 3.5, 3.5 Hz, 2H, 13-H), 1.83−1.80 (m, 1H, 12-H), 
1.77 (s, 3H, 19-H), 1.40 (d, J = 6.9 Hz, 3H, 5´-H), 1.17 (d, J = 6.6 Hz, 3H, 16-H), 1.05 (d, J = 7.5 
Hz, 3H, 20-H); 13C NMR (75 MHz, 293 K, CDCl3): δ = 164.7, 154.4, 142.8, 141.2, 135.8, 127.9, 
123.4, 111.2, 80.9, 76.1, 70.3, 65.8, 47.4, 44.0, 35.9, 31.9, 29.0, 20.3, 17.9, 15.3, 12.0; HRMS 
(ESI+) calcd for C23H36N2O5Na [M + Na]
+ 443.2522, found 443.2505. 
 
 
Synthesis of 2.11, see: B. J. Albert, A. Sivaramakrishnan, T. Naka, N. L. Czaicki, K. Koide, J. 
Am. Chem. Soc. 2007, 129, 2648–2659.  
 
 
Preparation of analogue 2.1: A solution of right fragment 2.11 (14 mg, 80 μmol) was 
prepared in DCE (0.2 mL) at 23 °C under an open atmosphere. To a stirred solution of 2.10 (25 
mg, 60 µmol) in DCE (0.2 mL) was added the solution of 2.11 (0.1 mL), Ru-1 (1.5 mg, 2.2 
µmol), followed by benzoquinone (1.5 mg, 14 μmol) at 23 °C under an open atmosphere. The 
reaction mixture was then heated to 42 °C. After 2.5 h at the same temperature, additional Ru-1 
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(1.5 mg, 2.2 μmol), benzoquinone (1.5 mg, 14 μmol), and 2.11 (0.1 mL) were added. After 21.5 
total hours, the reaction mixture concentrated in vacuo. The resulting residue was purified by 
preparative-TLC (90% EtOAc in hexanes) to afford the desired product (12.0 mg, 35% yield) as 
a dark thick paste, and a mixture of 2.10 and 2.11 (9.0 mg).  
To a stirred solution of recovered 2.11 and 2.10 in DCE (0.4 mL) was added benzoquinone 
(1.5 mg, 14 µmol) and Ru-1 (1.5 mg, 2.2 µmol) at 23 °C under an open atmosphere. The 
reaction mixture was then heated to 42 °C. After an additional 21 h at the same temperature, the 
reaction was concentrated in vacuo. The resulting residue was purified by preparative-TLC (90% 
EtOAc in hexanes) to afford the desired product (3.9 mg) as a tan thick paste. The combined 
yield of 2.1 is 16 mg (46% yield).  
A portion of this material was re-purified by preparative-TLC (90% EtOAc in hexanes) and used 
for biological experiments. 
Data for analogue 2.1: Rf = 0.20 (90% EtOAc in hexanes); IR (film): νmax = 3350 (br), 2924, 
2856, 1701 (C=O), 1675 (C=O), 1635, 1527, 1436, 1378, 1276, 1242, 1190, 1118, 1062 cm-1; 
[α]D 
21 +0.7 (c 1.0, CH2Cl2); 1H NMR (300 MHz, 293 K, 1% CD3OD in CDCl3): δ = 6.74 (dd, J 
= 15.3, 5.1 Hz, 1H, 3´-H), 6.35 (d, J = 15.6 Hz, 1H, 7-H), 5.91 (dd, J = 15.3, 1.5 Hz, 1H, 2´-H), 
5.76 (br d, J = 9.0 Hz, 1H, N-H), 5.66 (dd, J = 15.6, 6.6 Hz,1H, 6-H), 5.50 (dd, J = 6.9, 6.9 Hz, 
1H, 9-H), 5.39 (qdd, J = 6.6, 5.1, 1.5 Hz, 1H, 4´-H), 3.97−3.92 (m, 2H, 5-H, 14-H), 3.65−3.60 
(m, 5H, 15-H, morpholine-CH2O), 3.54 (ddd, J = 6.3, 6.3, 3.0 Hz, 1H, 11-H), 3.46−3.43 (m, 5H, 
4-H, morpholine-CH2N), 2.94 (d, J = 4.7 Hz, 1H, 18-H), 2.45 (dd, J = 4.7, 1.5 Hz, 1H, 18-H), 
2.38−2.31 (m, 1H, 10-H), 2.26−2.21 (m, 1H, 10-H), 2.17 (d, J = 14.4 Hz, 1H, 2axial-H), 
1.99−1.95 (m, 2H, 13-H), 1.76 (s, 3H, 19-H), 1.73−1.70 (m, 1H, 12-H), 1.61 (d, J = 10.5 Hz, 1H, 
OH), 1.40 (d, J = 14.4 Hz, 1H, 2equatorial-H), 1.35 (d, J = 6.6 Hz, 3H, 5´-H), 1.33 (s, 3H, 17-H), 
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1.22 (s, 3H, 17´-H), 1.08 (d, J = 6.3 Hz, 3H, 16-H), 1.01 (d, J = 7.2 Hz, 3H, 20-H); 13C NMR 
(175 MHz, 293 K, CDCl3): δ = 165.3, 155.0, 143.3, 136.4, 134.0, 129.1, 125.6, 121.7, 80.6, 79.4, 
76.3, 73.4, 73.0, 72.0, 67.1, 56.9, 46.8, 47.0, 43.0, 36.1, 32.3, 31.3, 29.7, 29.0, 23.8, 20.1, 17.6, 
15.4, 12.0; HRMS (ESI+) calcd for C31H48N2O8Na [M + Na]
+ 599.3308, found 599.3313. 
 
 
Preparation of carbamate 2.13: To a stirred solution of 2.12 (33.8 g, 0.286 mol) in CH2Cl2 
(300 mL) was added CDI (48.7 g, 0.300 mol) in portions. The resulting mixture was stirred at 23 
°C for 20 h and then cooled to 0 °C. Morpholine (37.4 g, 0.429 mol) was added dropwise. After 
the addition, the mixture was warmed to 23 °C, stirred for an additional 2 h, and concentrated in 
vacuo. The residue was purified by dry column vacuum chromatography (10 to 70% EtOAc in 
hexanes) on silica gel (1000 mL) to afford 2.13 (62.1g, 94%) as colorless liquid.  
Data for carbamate 2.13: Rf = 0.33 (40% EtOAc in hexanes); IR (film): νmax = 3494, 2984, 
2859, 1753 (C=O), 1710 (C=O), 1430, 1371, 1302, 1277, 1245, 1203, 1113, 1048, 1021 cm-1; 
[α]D
22 +18.3 (c 1.00, CHCl3); 1H NMR (300 MHz, 293K, CDCl3) δ = 5.01 (q, 1H, J = 7.2 Hz, 4´-
H), 4.17 (q, 2H, J = 7.2 Hz, CH2CH3), 3.65 (t, 4H, J = 4.8 Hz, morpholine-CH2O), 3.48 (br s, 
4H, morpholine-CH2N), 1.45 (d, 3H, J = 6.9 Hz, 5´-H), 1.25 (t, 3H, J = 7.2 Hz, CH2CH3); 13C 
NMR (75 MHz, 293K, CDCl3) δ = 171.4, 154.5, 69.5, 66.5, 61.2, 44.3, 17.1, 14.1; HRMS (EI+) 
calcd. for C10H17NO5 [M]




Preparation of carboxylic acid 2.14: To a stirred solution of ester 2.13 (0.99 g, 4.3 mmol) in 
CH2Cl2 (7.4 mL) at -78 °C was added DIBALH (1.0 M in CH2Cl2, 4.5 mL) slowly down the 
flask side under a nitrogen atmosphere. The reaction mixture was stirred for 1 h at -78 °C before 
adding MeOH (5 mL) slowly. The mixture was stirred at the same temperature for 19 min, 
followed by the addition of THF (9 mL) and Ph3P=CHCO2Me (2.16 g, 6.45 mmol). The mixture 
was then allowed to warm to 23 °C and was stirred for 3.5 h before being quenched with aqueous 
sodium potassium tartrate (1 M, 20 mL) at the same temperature. After stirring at 23 °C for 27 
min, the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were 
washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. 
The crude mixture was purified by flash chromatography (10% to 30% EtOAc in hexanes) on 
silica gel (70 mL) to afford a mixture containing the desired product (826 mg) as a clear oil. This 
mixture was used in the next step without further purification. 
To a stirred solution of the product from the first step (826 mg) in EtOAc (10 mL) at 23 °C 
was added Pd/C (112 mg, 10% wt.%, 0.100 mmol). The flask was flushed with H2 and kept 
under hydrogen atmosphere. After stirring for 12.5 h at 23 °C, the reaction mixture was passed 
through a pad of silica and rinsed with EtOAc (7 mL). The filtrate was concentrated in vacuo. 
The residue was purified by flash chromatography (15% to 40% EtOAc in hexanes) on silica gel 
(30 mL) to afford a mixture containing the desired product (537 mg) as a clear oil. This mixture 
was used in the next step without further purification. 
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To a stirred solution of this mixture (437 mg) in MeOH (8 mL) was added aqueous NaOH (1 
M, 9 mL) at 23 °C under an air atmosphere. After 3 h at the same temperature, the reaction 
mixture was washed with CH2Cl2 (7 mL). The aqueous layer was acidified with aqueous HCl (6 
M, 10 mL) and extracted with EtOAc (3 × 5 mL). The combined organic layers was dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. Purification of the residue by flash 
chromatography (30 to 60% EtOAc in hexanes) on silica gel (50 mL) afforded acid 2.14 (452 
mg, 46% yield over 3 steps) as a colorless oil.  
Data for carboxylic acid 2.14: Rf = 0.26 (40% EtOAc in hexanes); IR (film): νmax = 3455 (br, 
O-H), 2977, 2929, 2864, 1745 (C=O), 1699 (C=O), 1434, 1248, 1115 cm-1; [α]D
21 +25.4 (c 1.0, 
CH2Cl2); 
1H NMR (300 MHz, 293 K, 1% CD3OD in CDCl3): δ = 4.91 (ddq, J = 6.3, 6.3, 6.3 Hz, 
1H, 4´-H), 3.69−3.61 (m, 4H, morpholine-CH2O), 3.48−3.3.42 (m, 4H, morpholine-CH2N), 2.43 
(dd, J = 6.3, 6.3 Hz, 2H, 2´-H), 1.93 (ddd, J = 6.3, 6.3, 6.3 Hz, 2H, 3´-H), 1.29 (d, J = 6.3 Hz, 
3H, 5´-H); 13C NMR (75 MHz, 293 K, CDCl3): δ = 177.7, 155.1, 71.3, 66.6, 44.0, 31.0, 30.0, 
20.3; HRMS (ESI+) calcd for C10H17NO5Na [M + Na]
+ 254.1004, found 254.1006. 
 
 
Preparation of alkene 2.15: To a solution of 10 mL of 10% TFA in CH2Cl2 at 0 °C was 
added the Boc-protected amine 2.4 (102 mg, 0.380 mmol). The reaction was warmed to 23 °C 
and stirred for 1 h. The solvent was removed in vacuo, and then diluted with EtOAc (5 mL) and 
saturated aqueous NaHCO3 (5 mL). The layers were separated, and the aqueous layer was 
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extracted with EtOAc (2 × 5 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo to yield the crude amine.  
To a stirred solution of acid 2.14 (11 mg, 0.51 mmol) in MeCN (1.0 mL) at 23 °C was added 
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (173 mg, 0.460 
mmol), followed by N,N-diisopropylethylamine (172 mg, 1.30 mmol) under a nitrogen 
atmosphere. To the resulting mixture was added a solution of the amine in MeCN (0.6 mL), and 
the mixture was stirred at the same temperature for 12 h. The reaction was quenched with 
saturated aqueous NH4Cl (10 mL) and most of the organic solvent was removed in vacuo. The 
aqueous residue was extracted with EtOAc (3 × 5 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by 
flash chromatography (20 to 100% EtOAc in hexanes) on silica gel (25 mL) to afford amide 2.15 
(96 mg, 66% yield) as a colorless oil.  
Data for alkene 2.15: Rf = 0.26 (70% EtOAc in hexanes); IR (film): νmax = 3342, 2962, 2927, 
2856, 1699 (C=O), 1647 (C=O), 1526, 1427, 1243, 1117, 1072 cm-1; [α]D
21 +2.23 (c 1.0, 
CH2Cl2); 
1H NMR (300 MHz, 293 K, 1% CD3OD in CDCl3): δ = 5.77 (dddd, J = 17.1, 10.2, 7.5, 
6.0 Hz, 1H, 9-H), 5.15 (dd, J = 17.1, 1.5 Hz, 1H, 8trans-H), 5.08 (br d, J = 10.2 Hz, 1H, 8cis-H), 
4.85 (app qt, J = 6.3, 6.3 Hz, 1H, 4´-H), 3.92 (m, 1H, 14-H), 3.65−3.61 (m, 5H, morpholine-
CH2O, 15-H), 3.54 (ddd, J = 7.5, 7.5, 2.7 Hz, 1H, 11-H), 3.46 (t, J = 4.5 Hz, 4H, morpholine-
CH2N), 2.40−2.26 (m, 3H, 10-H, 2´-H), 2.24−2.10 (m, 3H, 10-H, 3´-H), 1.95−1.1.87 (m, 2H, 13-
H), 1.84−1.73 (m, 1H, 12-H), 1.27 (d, J = 6.3 Hz, 3H, 5´-H), 1.14 (d, J = 6.3 Hz, 3H, 16-H), 1.04 
(d, J = 7.5 Hz, 3H, 20-H); 13C NMR (75 MHz, 293 K, CDCl3): δ = 171.7, 155.1, 134.6, 116.8, 
80.7, 76.0, 71.5, 66.6, 47.1, 44.0, 37.3, 35.9, 32.9, 32.0, 28.4, 20.4, 17.8, 15.1; HRMS (ESI+) 
calcd for C20H34N2O5Na [M + Na]




Preparation of aldehyde 2.16: To a stirred solution of alkene 2.15 (75 mg, 0.20 mmol) in 
benzene (0.4 mL) was added methacrolein (178 mg, 2.50 mmol) and Ru-1 (3.3 mg, 0.0040 
mmol) under an open atmosphere. The mixture was heated to 50 °C. After 12 h, the mixture was 
concentrated in vacuo. The residue was purified by flash chromatography (70% to 100% EtOAc 
in hexanes) on silica gel (25 mL) to afford aldehyde 2.16 (53 mg, 63% yield) as a colorless oil.  
Data for aldehyde 2.16: Rf = 0.20 (EtOAc); IR (film): νmax = 3349, 2926, 2856, 1691 (C=O), 
1640 (C=O), 1525, 1426, 1243, 1117, 1072 cm-1; [α]D
23 -2.34 (c 1.1, CH2Cl2); 1H NMR (500 
MHz, 293 K, CDCl3): δ = 9.44 (s, 1H, 7-H), 6.54 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, 9-H), 5.71 (br d, 
J = 9.0 Hz, 1H, N-H), 4.87 (qdd, J = 6.5, 6.5, 6.5 Hz, 1H, 4´-H), 3.96 (dddd, J = 9.0, 6.0, 2.5, 2.5 
Hz, 1H, 14-H), 3.68 (m, 6H, morpholine-CH2O, 15-H, 11-H), 3.46 (m, 4H, morpholine-CH2N), 
2.58 (ddd, J = 15.5, 7.5, 7.5 Hz, 1H, 10-H), 2.43 (ddd, J = 15.5, 7.5, 6.0 Hz, 1H, 10-H), 2.32 
(ddd, J = 15.0, 9.0, 7.0 Hz, 1H, 2´-H), 2.27 (ddd, J = 15.0, 9.0, 7.0 Hz, 1H, 2´-H), 2.22 (dddd, J = 
16.0, 9.0, 9.0, 6.5 Hz, 1H, 3´-H), 2.18 (dddd, J = 16.0, 9.0, 6.5, 5.0 Hz, 1H, 3´-H), 1.97−1.95 (m, 
1H, 13-H), 1.94−1.90 (m, 1H, 13-H), 1.85−1.81 (m, 1H, 12-H), 1.78 (s, 3H, 19-H), 1.28 (d, J = 
6.5 Hz, 3H, 5´-H), 1.16 (d, J = 6.5 Hz, 3H, 16-H), 1.08 (d, J = 7.5 Hz, 3H, 20-H); 13C NMR (75 
MHz, 293 K, CDCl3): δ = 195.0, 171.6, 155.2, 150.2, 140.8, 79.8, 76.2, 71.5, 66.6, 46.9, 44.1, 
35.8, 33.0, 32.8, 32.0, 29.5, 20.5, 17.8, 15.3, 9.5; HRMS (EI+) calcd for C22H36N2O6 [M]
+ 




Preparation of alkene 2.17: To a stirred suspension of methytriphenylphosphonium bromide 
(67 mg, 0.19 mmol) in THF (0.3 mL) at 0 °C was added KOtBu (20 mg, 0.18 mmol) under a 
nitrogen atmosphere. After 8 min at 0 °C, aldehyde 2.16 (32 mg, 0.075 mmol) in THF (0.7 mL) 
was added at the same temperature. The reaction mixture was stirred at the same temperature for 
43 min, then quenched with saturated aqueous NH4Cl (2 mL). The mixture was extracted with 
EtOAc (3 × 5 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (50% to 100% 
EtOAc in hexanes) on silica gel (5 mL) to afford terminal alkene 2.17 (24 mg, 76% yield) as a 
colorless oil.  
Data for alkene 2.17: Rf = 0.27 (EtOAc); IR (film): νmax = 3361, 2973, 2926, 2856, 1698 
(C=O), 1647 (C=O), 1527, 1427, 1244, 1117, 1072 cm-1; [α]D
22 -1.43 (c 1.0, CH2Cl2); 1H NMR 
(500 MHz, 293 K, CDCl3): δ = 6.38 (dd, J = 17.5, 10.5 Hz, 1H, 7-H), 5.70 (br d, J = 9.0 Hz, 1H, 
N-H), 5.46 (dd, J = 6.5, 6.5 Hz, 1H, 9-H), 5.14 (d, J = 17.5 Hz, 1H, 6trans-H), 4.98 (d, J = 10.5 
Hz, 1H, 6cis-H), 4.86 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H, 4´-H), 3.93 (dddd, J = 9.0, 5.5, 2.5, 2.5 Hz, 
1H, 14-H), 3.69−3.63 (m, 5H, morpholine-CH2O, 15-H), 3.54 (ddd, J = 7.5, 7.5, 3.0 Hz, 1H, 11-
H), 3.51−3.43 (m, 4H, morpholine-CH2N), 2.42 (ddd, J = 14.5, 6.5, 6.5 Hz, 1H, 10-H), 
2.32−2.25 (m, 3H, 10-H, 2´-H), 2.21 (ddd, J = 16.0, 9.5, 9.5, 7.0 Hz, 1H, 3´-H), 2.17 (ddd, J = 
16.0, 9.5, 6.0, 5.0 Hz, 1H, 3´-H), 1.95−1.89 (m, 2H, 13-H), 1.81−1.79 (m, 1H, 12-H), 1.77 (s, 
3H, 19-H), 1.28 (d, J = 6.0 Hz, 3H, 5´-H), 1.15 (d, J = 6.5 Hz, 3H, 16-H), 1.04 (d, J = 7.0 Hz, 
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3H, 20-H); 13C NMR (75 MHz, 293 K, CDCl3): δ = 171.6, 155.1, 141.2, 135.7, 128.0, 111.2, 
80.8, 76.0, 71.5, 66.9, 66.6, 51.9, 47.1, 35.8, 33.0, 32.2, 28.8, 20.5, 17.9, 15.2, 12.0; HRMS 
(EI+) calcd for C23H38N2O5 [M]
+ 422.2781, found 422.2778. 
 
 
Preparation of analogue 2.2: A solution of right fragment 2.11 (10 mg, 0.056 mmol) was 
prepared in DCE (0.2 mL) at 23 °C under an open atmosphere. To a stirred solution of 2.17 (18 
mg, 0.043 mmol) in DCE (0.1 mL) was added the solution of 2.11 (0.1 mL), benzoquinone (1.0 
mg, 0.0086 mmol), followed by Ru-1 (3.0 mg, 0.0045 mmol) at 23 °C under an open 
atmosphere. The reaction mixture was then heated to 50 °C. After 1.5 h at the same temperature, 
additional Ru-1 (2.8 mg, 0.0042 mmol) and 2.11 (0.1 mL) were added. After 18 total hours, the 
reaction mixture was concentrated in vacuo. The resulting residue was purified by flash 
chromatography (50% to 100% EtOAc in hexanes) on silica gel (5 mL) to afford the desired 
product (7 mg, 28% yield) as a tan oil, and a mixture of 2.11 and 2.17 (20.3 mg).  
To a stirred solution of recovered 2.11 and 2.17 in DCE (0.2 mL) was added benzoquinone 
(2.0 mg, 0.020 mmol) and Ru-1 (4.0 mg, 0.0060 mmol) at 23 °C under an open atmosphere. The 
reaction mixture was then heated to 50 °C. After an additional 18 h at the same temperature, the 
reaction mixture was concentrated in vacuo. The resulting residue as purified by flash 
chromatography (50% to 100% EtOAc in hexanes) on silica gel (5 mL) to afford the desired 
product (2.5 mg). The combined yield of 2.2 is 9.5 mg (36% yield).  
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A portion of this material was purified by preparative-TLC (EtOAc) and used for biological 
experiments. 
Data for analogue 2.2: Rf = 0.17 (EtOAc); IR (film): νmax = 3393 (br), 2924, 2854, 1696 
(C=O), 1673 (C=O), 1529, 1460, 1380, 1244, 1116 cm-1; [α]D
22 +0.15 (c 0.95, CH2Cl2); 1H NMR 
(700 MHz, 293 K, 1% CD3OD in CDCl3): δ = 6.41 (d, J = 15.0 Hz, 1H, 7-H), 5.70 (dd, J = 15.0, 
7.0 Hz, 1H, 6-H), 5.69 (br d, J = 9.1 Hz, 1H, N-H), 5.51 (dd, J = 7.0, 7.0 Hz, 1H, 9-H), 
4.88−4.86 (m, 1H, 4´-H), 4.03 (dd, J = 10.5, 7.0 Hz, 1H, 5-H), 3.95−3.92 (m, 1H, 14-H), 
3.77−3.75 (m, 1H, 15-H), 3.67−3.63 (m, 4H, morpholine-CH2O), 3.55 (dd, J = 10.5, 10.5 Hz, 
1H, 4-H), 3.52 (ddd, J = 7.0, 7.0, 2.8 Hz, 1H, 11-H), 3.48−3.44 (m, 4H, morpholine-CH2N), 3.04 
(d, J = 4.9 Hz, 1H, 18-H), 2.51 (d, J = 4.9 Hz, 1H, 18-H), 2.44−2.37 (m, 1H, 10-H), 2.32−2.29 
(m, 3H, 10-H, 2´-H), 2.78 (ddd, J = 15.4, 9.8, 9.8, 6.3 Hz, 1H, 3´-H), 2.25−2.23 (m, 1H, 3´-H), 
2.22 (d, J = 14.0 Hz, 1H, 2axial-H),1.96−1.91 (m, 2H, 13-H), 1.81−1.77 (m, 1H, 12-H), 1.79 (s, 
3H, 19-H), 1.44 (d, J = 14.0 Hz, 1H, 2equatorial-H), 1.41 (s, 3H, 17-H), 1.32 (d, J = 7.0 Hz, 3H, 5´-
H), 1.27 (s, 3H, 17´-H), 1.14 (d, J = 6.3 Hz, 3H, 16-H), 1.08 (d, J = 7.7 Hz, 3H, 20-H); 13C NMR 
(150 MHz, 293 K, CDCl3): δ = 171.7, 155.1, 138.1, 128.8, 128.3, 124.9, 80.8, 76.0, 74.7, 73.1, 
71.5, 68.1, 66.7, 57.7, 47.8, 47.1, 42.8, 35.8, 33.0, 32.0, 31.2, 29.7, 28.5, 23.6, 20.5, 17.9, 15.3, 
14.3, 12.6; HRMS (EI+) calcd for C31H50N2O8 [M]
+ 578.3553, found 578.3559. 
 
 
Preparation of epoxide 2.18: To a light-protected, stirred solution of alcohol 2.11 (20 mg, 
0.11 mmol) and MeI (78 mg, 0.55 mmol) in DMF (0.2 mL) was added Ag2O (51 mg, 0.22 
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mmol) at 23 °C under an open atmosphere.  The resulting mixture was stirred at the same 
temperature for 17 h, after which the reaction mixture was poured into H2O (5 mL), and the 
resulting mixture was extracted with Et2O (3 × 10 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo. Purification of the residue by flash 
chromatography (10 to 30% EtOAc in hexanes) on silica gel (20 mL) afforded 2.18 (19 mg, 87% 
yield) as a pale yellow oil.  
Data for epoxide 2.18: Rf = 0.3 (20% EtOAc in hexanes); IR (film): νmax = 2974, 2926, 1465, 
1370, 1126, 1195, 1127, 1060, 1026 cm-1; [α]D
21 +42.7 (c 1.13, CH2Cl2); 1H NMR (300 MHz, 
293 K, CDCl3): δ = 5.93 (ddd, J = 17.1, 10.2, 6.6 Hz, 1H, 6-H), 5.46 (ddd, J = 17.1, 1.5, 1.5 Hz, 
1H, 7trans-H), 5.28 (ddd, J = 10.2, 1.5, 0.6 Hz, 1H, 7cis-H), 4.17 (dd, J = 9.9, 6.6 Hz, 1H, 5-H), 
3.38 (s, 3H, OCH3), 3.14 (d, J = 9.9 Hz, 1H, 4-H), 2.91 (d, J = 4.8 Hz, 1H, 18-H), 2.49 (d, J = 
4.8 Hz, 1H, 18-H), 2.13 (d, J = 14.1 Hz, 1H, 2axial-H), 1.40 (s, 3H, 17-H), 1.38 (d, J = 14.1 Hz, 
1H, 2equatorial-H), 1.26 (s, 3H, 17´-H); 
13C NMR (175 MHz, 293 K, CDCl3): δ = 136.4, 118.0, 
78.5, 73.2, 73.1, 61.0, 56.8, 47.5, 43.2, 31.0, 23.7; HRMS (EI+) calcd for C10H15O3 [M – CH3]+ 
183.1021, found 183.1023. 
 
 
Preparation of meayamycin C (2.20): A solution of 2.18 (18 mg, 0.091 mmol) was prepared 
in DCE (0.2 mL) at 23 °C under an open atmosphere. A stirred solution of 2.19 (26 mg, 0.062 
mmol) in DCE (0.2 mL) was treated with an aliquot of solution of 2.18 (0.1 mL), benzoquinone 
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(1.5 mg, 0.014 mmol), followed by Ru-1 (1.5 mg, 2.2 µmol) at 23 °C under an open atmosphere. 
The reaction mixture was then heated to 42 °C. After 2.5 h at the same temperature, additional 
Ru-1 (1.5 mg, 2.2 µmol) and remaining aliquot of solution of 2.18 (0.1 mL) were added. After 
17 total hours, the reaction was concentrated in vacuo. The resulting residue was purified by 
flash chromatography (10 to 100% EtOAc in hexanes) on silica gel (5 mL) to afford the desired 
product (16 mg, 44% yield), and a mixture of 2.18 and 2.19 (14 mg).  
To a stirred solution of recovered 2.18 and 2.19 in DCE (0.2 mL) was added benzoquinone 
(1.0 mg, 9.3 µmol) and Ru-1 (2.0 mg, 3.0 µmol) at 23 °C under an open atmosphere. The 
reaction mixture was then heated to 42 °C. After an additional 22 h at the same temperature, the 
reaction was concentrated in vacuo. The resulting residue was purified by flash chromatography 
(10 to 100% EtOAc in hexanes) on silica gel (5 mL) to afford the desired product (5.0 mg) as a 
clear oil. The combined yield of 2.20 is 21 mg (57%).   
A portion of this material was purified by preparative-TLC (80% EtOAc in hexanes) and 
used for biological experiments. 
Data for meayamycin C (2.20): Rf = 0.20 (80% EtOAc in hexanes); IR (film): νmax = 3366, 
2925, 2855, 1700 (C=O), 1632 (C=O), 1515, 1426, 1277, 1241, 1119, 1071 cm-1; [α]D
21 +1.5 (c 
1.04, CH2Cl2); 
1H NMR (700 MHz, 293 K, CD2Cl2): δ = 6.35 (d, J = 16.1 Hz, 1H, 7-H), 
6.14−6.10 (m, 2H, 4´-H, N-H), 5.89 (dd, J = 11.9, 7.7 Hz, 1H, 3´-H), 5.68 (dd, J = 11.9, 1.4 Hz, 
1H, 2´-H), 5.61 (dd, J = 16.1, 7.0 Hz, 1H, 6-H), 5.51 (br t, J = 7.0, 1H, 9-H), 4.11 (dd, J = 9.1, 
7.0 Hz, 1H, 5-H), 3.89−3.87 (m, 1H, 14-H), 3.65 (qd, J = 7.0, 2.1 Hz, 1H, 15-H), 3.60−3.57 (m, 
4H, morpholine-CH2O), 3.51 (ddd, J = 7.7, 7.7, 2.8 Hz, 1H, 11-H), 3.42−3.38 (m, 4H, 
morpholine-CH2N), 3.28 (s, 3H, OCH3), 3.08 (d, J = 9.1 Hz, 1H, 4-H), 2.80 (d, J = 4.9 Hz, 1H, 
18-H), 2.39 (d, J = 4.9 Hz, 1H, 18-H), 2.37−2.33 (m, 1H, 10-H), 2.21−2.17 (m, 1H, 10-H), 2.07 
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(d, J = 14.0 Hz, 1H, 2axial-H), 1.94−1.90 (m, 2H, 13-H), 1.76 (s, 3H, 19-H), 1.77−1.74 (m, 1H, 
12-H), 1.33 (s, 3H, 17-H), 1.32 (d, J = 6.3 Hz, 3H, 5´-H), 1.30 (d, J = 14.0 Hz, 1H, 2equatorial-H), 
1.20 (s, 3H, 17´-H), 1.10 (d, J = 7.0 Hz, 3H, 16-H), 1.00 (d, J = 7.7 Hz, 3H, 20-H); 13C NMR 
(175 MHz, 293 K, CD2Cl2): δ = 164.7, 154.8, 143.9, 137.1, 134.7, 128.9, 125.3, 122.2, 80.8, 
79.0, 75.9, 73.1, 73.0, 69.5, 66.5, 60.6, 56.6, 47.2, 47.0, 43.3, 35.8, 33.3, 32.0, 30.8, 29.4, 23.6, 
20.1, 17.6, 14.8, 12.4; HRMS (ESI+) calcd for C32H50N2O8Na [M + Na]




Preparation of epoxide 2.24: To a light-protected, stirred solution of alcohol 2.11 (92.6 mg, 
0.503 mmol) and PMBCl (200 µL, 1.47 mmol) in DMF (1.0 mL) was added Ag2O (174 mg, 
0.751 mmol) at 23 °C under a nitrogen atmosphere. The resulting mixture was stirred at 60 °C 
for 43 h, after which the reaction mixture was poured into H2O (25 mL), and the resulting 
mixture was extracted with Et2O (2 × 15 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. Purification of the residue by flash 
chromatography (10 to 30% EtOAc in hexanes) on silica gel (8 mL) afforded PMB ether 2.24 
(113 mg, 74%) as a colorless oil. 
Data for epoxide 2.24: Rf = 0.26 (30% EtOAc in hexanes); IR (film): νmax = 2973, 1612, 
1514, 1466, 1249, 1115, 1033, 822 cm-1; [α]D25 +40.2 (c 0.75, CHCl3); 1H NMR (300 MHz, 
293K, CDCl3) δ = 7.21 (br d, 2H, J = 8.4 Hz, Ar-H), 6.86 (br d, 2H, J = 8.4 Hz, Ar-H), 5.95 
(ddd, 1H, J = 17.3, 10.4, 6.8 Hz, 6-H), 5.47 (br d, 1H, J = 17.3 Hz, 7trans-H), 5.29 (br d, 1H, J = 
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10.4 Hz, 7cis-H), 4.57 (d, 1H, J = 11.1 Hz, ArCH2), 4.36 (d, 1H, J = 11.1 Hz, ArCH2), 4.26 (dd, 
1H, J = 9.6, 6.8 Hz, 5-H), 3.81 (s, 3H, OCH3), 3.40 (d, 1H, J = 9.6 Hz, 4-H), 2.85 (d, 1H, J = 4.9 
Hz, 18-H), 2.41 (d, 1H, J = 4.9 Hz, 18-H), 2.10 (d, 1H, J = 14.1 Hz, 2axial-H), 1.43 (s, 3H, 17-H), 
1.36 (d, 1H, J = 14.1 Hz, 2equatorial-H), 1.27 (s, 3H, 17´-H); 13C NMR (75 MHz, 293K, CDCl3) δ = 
159.4, 136.5, 130.0, 129.6, 118.1, 113.8, 75.8, 74.3, 73.5, 73.2, 57.0, 55.2, 47.5, 43.4, 31.0, 23.7; 
HRMS (EI+) calcd. for C18H24O4Na [M + Na]
+  327.1572, found 327.1556. 
 
 
Preparation of aldehyde 2.23: A 10-mL round-bottomed flask equipped with a Teflon-coated 
magnetic stir bar containing alkene 2.24 (7.0 mg, 0.023 mmol) was purged with N2. The flask 
was charged with PhH (3 mL), cooled in an ice-water bath (0 °C external temperature), then 
BF3•OEt2 (1 µL, 0.0037 mmol) was added. The mixture was stirred for 10 min, then diluted with 
H2O (0.5 mL). The mixture was extracted with EtOAc (3 × 2 mL), and the combined organic 
layer was dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified 
by flash chromatography (10→30% EtOAc in hexanes) on silica gel (2 mL) to afford aldehyde 
2.23 as a clear oil (4 mg, 95% yield). 
Data for aldehyde 2.23: Rf = 0.22 (30% EtOAc in hexanes); IR (film): νmax = 3430 (br, O-H), 
2972, 1721 (C=O), 1370, 1170, 1077, 999, 930 cm-1; 1H NMR (300 MHz, 293K, CDCl3): δ = 
9.62 (s, 1H), 5.94 (ddd, J = 17.1, 10.5, 6.2 Hz, 1H), 5.48 (ddd, J = 17.1, 1.5, 1.5 Hz, 1H), 5.31 
(ddd, J = 10.5, 1.5, 1.5 Hz, 1H), 4.51 (br ddd, J = 6.2, 1.5, 1.5 Hz, 1H), 3.91 (br d, J = 11.1 Hz, 
1H), 3.84 (br d, J = 11.1 Hz, 1H), 2.19 (d, J = 13.7 Hz, 1H), 1.97 (d, J = 13.7 Hz, 1H), 1.45 (s, 
 143 
3H), 1.37 (s, 3H); 13C NMR (75 MHz, CDCl3, 293 K): δ = 204.2, 133.4, 118.1, 82.8, 80.9, 64.4, 
63.1, 43.6, 29.6, 28.1; HRMS (EI+) calcd. for C10H16O3 [M]
+ 184.1099, found 184.1094. 
 
Preparation of ketone 2.26: A 10-mL round-bottomed flask equipped with equipped with a 
Teflon-coated magnetic stir bar containing diene 2.19 (18 mg, 0.04 mmol) and alkene 2.25 (9.1 
mg, 0.05 mmol) was charged with DCE (0.3 mL), Ru-1 (3.2 mg, 0048 mmol). The mixture was 
stirred in an oil bath for 2 h at 40 °C, then additional Ru-1 (2.1 mg, 0.0031 mmol) was added, 
and the mixture was stirred for an additional 14 h, then concentrated in vacuo. The crude residue 
was purified by flash chromatography (10→100% EtOAc in hexanes) on silica gel (5 mL) to 
afford 2.26 as an oil (8.1 mg, 36% yield). 
Some of this material was purified by preparative-TLC (EtOAc) and used for biological 
experiments. 
Data for ketone 2.26: Rf = 0.26 (70% EtOAc in hexanes); IR (film): νmax = 3341 (br, O-H), 
2973, 2923, 1734 (C=O), 1668 (C=O), 1526, 1372, 1243, 1130, 1 cm-1; [α]D 
19 +2.16 (c 0.74, 
CH2Cl2);  
1H NMR (500 MHz, 1% CD3OD in CDCl3, 293 K): δ = 6.43 (d, J = 16.0 Hz, 1, 7-H), 
6.20 (br d, J = 9.0 Hz, 1H, N-H), 6.17–6.13 (m, 1H, 4´-H), 5.94 (dd, J = 12.0, 7.5 Hz, 1H, 3´-H), 
5.74 (dd, J = 12.0, 1.0 Hz, 1H, 2´-H), 5.58 (dd, J = 16.0, 9.0 Hz, 1H, 6-H), 5.36–5.30 (m, 1H, 9-
H), 4.16 (dd, J = 9.0, 9.0 Hz, 1H, 4-H), 3.97–3.95 (m, 2H, 5-H, 14-H), 3.68–3.65 (m, 4H, 
CH2O), 3.60–3.52 (m, 2H, 15-H, 11-H), 3.50–3.48 (m, 4H, CH2N), 2.42–2.38 (m, 2H, 10-H, 
2axial-H), 2.26–2.23 (m, 1H, 10-H), 1.98–1.93 (m, 2H, 13-H), 1.88 (d, J = 14.0 Hz, 1H, 2equatorial-
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H), 1.80 (s, 3H, 19-H), 1.78–1.76 (m, 1H, 12-H), 1.48 (s, 3H, 17-H), 1.43 (d, J = 6.5 Hz, 3H, 4´-
H), 1.28 (s, 3H, 17´-H), 1.17 (d, J = 6.5 Hz, 3H, 16-H), 1.04 (d, J = 7.5 Hz, 3H, 20-H); 13C NMR 
(100 MHz, CD2Cl2, 293 K): δ = 208.2, 164.4, 154.3, 142.7, 136.5, 135.0, 131.5, 125.1, 123.2, 
83.6, 75.7, 73.8, 70.1, 66.6, 57.3, 47.0, 44.4, 35.8, 34.6, 31.6, 29.7, 22.7, 20.0, 17.4, 15.2, 13.9; 
HRMS (ESI+) calcd. for C30H46N2O8Na [M + Na]
+ 585.3152, found 585.3157. 
 
 
Preparation of allylic alcohol 2.28: To a stirred solution of 2.27 (26.5 mg, 75.8 μmol) in 
MeOH (0.38 mL) was added K2CO3 (26.3 mg, 0.190 mmol) at 0 °C under an open atmosphere. 
After 2 h at the same temperature the reaction was diluted with saturated aqueous NH4Cl (60 
µL), and the resulting mixture was stirred for 5 min. The resulting reaction mixture was dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo. The resulting residue was purified 
by flash chromatography (20 to 50% EtOAc in hexanes) on silica gel (3 mL) to give 2.28 (19.2 
mg, 82%) as a colorless oil. 
Data for allylic alcohol 2.28: Rf = 0.21 (50% EtOAc in hexanes); IR (film): νmax = 3325, 
2975, 1655 (C=O), 1621, 1522, 1456, 1116, 1062, 894 cm-1; [α]D26 +10.0 (c 0.95, CHCl3); 1H 
NMR (300 MHz, 293K, 1% CD3OD in CDCl3) δ = 6.36 (dd, 1H, J = 17.4, 10.8 Hz, 7-H), 6.16 
(dd, 1H, J = 11.9, 5.6 Hz, 3´-H), 5.74 (dd, 1H, J = 11.9, 1.3 Hz, 2´-H), 5.44 (br app t, 1H, J = 8.1 
Hz, 9-H), 5.11 (d, 1H, J = 17.4 Hz, 6trans-H), 4.96 (d, 1H, J = 10.8 Hz, 6cis-H), 4.83–4.73 (m, 1H, 
4´-H), 3.97–3.93 (m, 1H, 14-H), 3.68 (qd, 1H, J = 6.6, 2.1 Hz, 15-H), 3.55 (qd, 1H, J = 7.1, 2.5 
Hz, 11-H), 2.48–2.31 (m, 1H, 10-H), 2.31–2.13 (m, 1H, 10-H), 1.95–1.92 (m, 2H, 13-H), 1.76 
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(br s, 3H, 19-H), 1.34 (d, 3H, J = 6.6 Hz, 5´-H), 1.14 (d, 3H, J = 6.6 Hz, 16-H), 1.01 (d, 3H, J = 
7.1 Hz, 20-H); 13C NMR (125 MHz, 293K, CDCl3) δ = 166.1, 150.8, 141.2, 135.7, 127.9, 122.5, 
111.2, 80.8, 75.8, 64.6, 47.5, 35.7, 31.8, 28.8, 22.7, 17.9, 15.2, 11.9; HRMS (EI+) calcd. for 
C18H29NO3 [M]
+  307.2147, found 307.2148. 
 
 
Synthesis of 2.29, see: E. Klein, S. DeBonis, B. Theide, D. A. Skoufias, F. Kozielski, L. Frank, 
Bioorg. Med. Chem., 2007, 15, 6474–6488. 
 
 
Preparation of carbamate 2.30: A 25-mL round-bottomed flask equipped with a Teflon-
coated magnetic stir bar containing alcohol 2.28 (55 mg, 0.18 mmol) was charged with CH2Cl2 
(1.0 mL). The reaction flask was cooled in an ice-water bath (0 °C external temperature), and 
1,1′-carbonyldiimidazole (35.0 mg, 0.22 mmol) was added to the mixture. The mixture was 
stirred for 4.75 h as the ice-water bath was left to warm to 23 °C. Then a solution of amine 2.29 
(157 mg, 0.900 mmol) in CH2Cl2 (0.2 mL) was added to the mixture at 23 °C under an open 
atmosphere. The mixture was stirred for 17 h, and then the solvent was removed in vacuo. The 
residue was purified by flash chromatography (10→80% EtOAc in hexanes) on silica gel (5 mL) 
to afford carbamate 2.30 as a clear oil (53 mg, 58% yield). 
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Data for carbamate 2.30: Rf = 0.25 (60% EtOAc in hexanes); IR (film): νmax = 3340, 2927, 
2108 (N3), 1708 (C=O), 1666 (C=O), 1515, 1252 cm
-1; [α]D 
24 –14.4 (c 1.3, CHCl3); 1H NMR 
(500 MHz, 1% CD3OD in CDCl3, 293 K): δ = 6.38 (dd, J = 17.5, 11.0 Hz, 1H, 7-H), 6.18 (br d, J 
= 9.0 Hz, 1H, N-H), 6.10 (dq, J = 7.0, 7.0 Hz, 1H, 4´-H), 5.93 (dd, J = 11.5, 7.0 Hz, 1H, 3´-H), 
5.71 (br d, J = 11.5 Hz, 1H, 2´-H), 5.47 (br t, J = 7.0 Hz, 1H, 9-H), 5.25−5.17 (m 1H, N-H), 5.13 
(d, J = 17.5 Hz, 1H, 6trans-H), 4.97 (d, J = 11.0 Hz, 1H, 6cis-H), 3.95 (m, 1H, 14-H), 3.71−3.34 
(m, 14H, 15-H, 11-H, triethylene glycol-H′s), 2.42−2.37 (ddd, J = 14.8, 7.0, 7.0 Hz, 1H, 10-H), 
2.28−2.22 (ddd, J = 14.8, 7.0, 7.0 Hz, 1H, 10-H), 1.99−1.95 (m, 1H, 13-H), 1.95−1.91 (m, 1H, 
13-H), 1.80−1.78 (m, 1H, 12-H), 1.76 (s, 3H, 19-H), 1.38 (d, J = 7.0 Hz, 3H, 5´-H), 1.17 (d, J = 
6.0 Hz, 3H, 16-H), 1.04 (d, J = 7.5 Hz, 3H, 20-H); 13C NMR (75 MHz, CDCl3, 293 K): δ = 
165.0, 156.0, 144.1, 141.3, 135.6, 128.2, 122.2, 111.1, 80.8, 76.0, 70.6, 70.1, 69.3, 50.6, 47.0, 
40.7, 35.9, 31.9, 30.3, 29.7, 28.9, 20.2, 17.8, 15.0, 11.9; HRMS (ESI+) calcd. for C25H41N5O6Na 
[M + Na]+ 530.2955, found 530.2943. 
 
 
Synthesis of 2.32, see: S. Osman, B. J. Albert, Y. Wang, M. Li, N. L. Czaicki, K. Koide, Chem. –




Preparation of azide 2.33: A 10-mL round-bottomed flask equipped with a Teflon-coated 
magnetic stir bar containing alcohol 2.32 (10 mg, 0.033 mmol) was evacuated and backfilled 
with nitrogen. The flask was cooled in an ice-water bath (0 °C external temperature), then THF 
(1 mL), PPh3 (26 mg, 0.099 mmol), diisopropylazodicarboxylate (20 mg, 0.099 mmol) and 
diphenylphosphorylazide (27 mg, 0.099 mmol) were added. The mixture was stirred for 16 min, 
then diluted with saturated aqueous NaHCO3 (8 mL). The mixture was concentrated in vacuo, 
and then extracted with Et2O (10 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (5→30% EtOAc 
in hexanes) on silica gel (5 mL) to afford azide 2.33 as a clear oil (5.6 mg, 56% yield). 
Data for azide 2.33: Rf = 0.25 (20% EtOAc in hexanes); IR (film): νmax = 3397, 2924, 2110 
(N3), 1727 (C=O), 1509, 1463, 1113 cm
-1; 1H NMR (500 MHz, CDCl3, 293 K): δ = 6.38 (dd, J = 
17.0, 10.5 Hz, 1H, 7-H), 5.90 (dd, J = 11.0, 9.0 Hz, 1H, 3´-H), 5.79 (d, J = 11.0 Hz, 1H, 2´-H), 
5.53−5.51 (m, 1H, 4´-H), 5.47 (br t, J = 7.0 Hz, 1H, 9-H), 5.12 (d, J = 17.0 Hz, 1H, 6trans-H), 
4.97 (d, J = 10.5 Hz, 1H, 6cis-H), 3.96–3.93 (m, 1H, 14-H), 3.68 (qd, J = 6.5, 2.0 Hz, 1H, 15-H), 
3.56 (ddd, J = 7.0, 7.0, 3.0 Hz, 1H, 11-H), 2.44–2.38 (m, 1H, 10-H), 2.30–2.24 (m, 1H, 10-H), 
1.96–1.95 (m, 2H, 13-H), 1.84–1.80 (m, 1H, 12-H), 1.77 (s, 3H, 19-H), 1.31 (d, J = 6.5 Hz, 3H, 
5´-H), 1.16 (d, J = 6.5 Hz, 3H, 16-H), 1.04 (d, J = 7.0 Hz, 3H, 20-H); 13C NMR (150 MHz, 
CDCl3, 293 K): δ = 164.6, 143.4, 141.2, 135.8, 128.0, 123.4, 111.2, 79.7, 76.0, 57.6, 54.2, 47.4, 








Preparation of 4’-desacetyl meayamycin C 2.39: A 10-mL round-bottomed flask equipped 
with a Teflon-coated magnetic stir bar containing diene 2.28 (30 mg, 0.10 mmol) and alkene 
2.18 (25 mg, 0.14 mmol) was charged with toluene (0.3 mL), Ru-1 (5.0 mg, 0.0074 mmol) and 
benzoquinone (4.0 mg, 0.0040 mmol). The mixture was stirred in an oil bath for 22 h at 40 °C, 
then concentrated in vacuo. The crude residue was purified by flash chromatography (10→100% 
EtOAc in hexanes) on silica gel (5 mL) to afford 4´-desacetyl meayamycin C 2.39 as a dark-grey 
oil (11 mg). The recovered starting materials (2.28 and 2.18) were dissolved in DCE (0.2 mL), 
followed by addition of Ru-1 (4 mg, 0.006 mmol) and benzoquinone (3 mg, 0.03 mmol). The 
reaction mixture was stirred in a 40 °C oil bath for 21 h, then concentrated in vacuo. The crude 
residue was purified by flash chromatography (10→100% EtOAc in hexanes) on silica gel (5 
mL) to afford 4´-desacetyl meayamycin C 2.39 as a dark-grey oil (3.7 mg). The recovered 
starting materials (2.28 and 2.18) were dissolved in DCE (0.2 mL), followed by addition of Ru-1 
(3 mg, 0.004 mmol) and benzoquinone (3 mg, 0.03 mmol). The reaction mixture was stirred in 
an oil bath for 17 h at 40 °C, then concentrated in vacuo. The crude residue was purified by flash 
chromatography (10→100% EtOAc in hexanes) on silica gel (5 mL) to afford 4´-desacetyl 
meayamycin C 2.39 as a dark oil (2 mg). The total mass of 4´-desacetyl meayamycin C 2.39 is 
16.7 mg (35% yield). 
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Data for 4’-desacetyl meayamycin C 2.39: Rf = 0.3 (70% EtOAc in hexanes); IR (film): νmax 
= 3323 (br, O-H), 2975, 2930, 1656 (C=O), 1526, 1444, 1116 cm-1; [α]D 
22 –5.7 (c 0.8, CH2Cl2); 
1H NMR (500 MHz, 1% CD3OD in CDCl3, 293 K): δ = 6.42 (d, J = 15.5 Hz, 1H, 7-H), 6.19 (dd, 
J = 11.5, 5.8 Hz, 1H, 3´-H), 5.93 (br d, J = 9.0 Hz, 1H, N-H), 5.72 (d, J = 11.5 Hz, 1H, 2´-H), 
5.66 (dd, J = 15.5, 7.0 Hz, 1H, 6-H), 5.49 (br t, J = 7.0 Hz, 1H, 9-H), 4.82–4.75 (m, 1H, 4´-H), 
4.24 (dd, J = 9.5, 7.0 Hz, 1H, 5-H), 3.96–3.94 (m, 1H, 14-H), 3.68 (qd, J = 6.3, 1.8 Hz, 1H, 15-
H), 3.54 (ddd, J = 7.0, 7.0, 2.5 Hz, 1H, 11-H), 3.36 (s, 3H, 1´´-H), 3.15 (d, J = 9.5 Hz, 1H, 4-H), 
2.92 (d, J = 5.0 Hz, 1H, 18-H), 2.49 (d, J = 5.0 Hz, 1H, 18-H), 2.44–2.37 (m, 1H, 10-H), 2.26–
2.22 (m, 1H, 10-H), 2.13 (d, J = 14.0 Hz, 1H, 2axial-H), 1.99–1.92 (m, 2H, 13-H), 1.79 (s, 3H, 19-
H), 1.63–1.59 (m, 1H, 12-H), 1.43 (s, 3H, 17-H), 1.41 (d, J = 14.0 Hz, 1H, 2equatorial-H), 1.36 (d, J 
= 6.5 Hz, 3H, 5´-H), 1.28 (s, 3H, 17´-H), 1.15 (d, J = 6.3 Hz, 3H, 16-H), 1.03 (d, J = 7.0 Hz, 3H, 
20-H); 13C NMR (150 MHz, CDCl3, 293 K): δ = 166.1, 150.8, 137.7, 134.9, 128.4, 125.0, 122.6, 
80.9, 78.8, 75.8, 73.3, 64.6, 60.9, 56.8, 47.5, 43.3, 35.7, 31.9, 31.1, 29.6, 28.8, 23.8, 22.7, 17.9, 
15.3, 12.7; HRMS (ESI+) calcd. for C27H43NO6Na [M + Na]
+ 500.2988, found 500.2995. 
 
 
Synthesis of 2.41, see: K. Breitenkamp, K. N. Sill, H. Skaff, PCT Int. Appl., 2007, WO 
2007127473 A2 20071108. 
 
 
Synthesis of 2.42, see: H. S. Gill, et. al. J. Med. Chem., 2009, 52, 5816–5825. 
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Preparation of 4-TEGylated meayamycin 2.43: A 10-mL round-bottomed flask equipped 
with a Teflon-coated magnetic stir bar containing meayamycin (3.3 mg, 0.0065 mmol) was 
added THF (0.1 mL) and tosylate 2.42 (7.1 mg, 2.8 mmol). The flask was cooled in an ice-water 
bath (0 °C external temperature), then NaH (5.3 mg, 0.13 mmol) was added to the flask. The 
mixture was stirred for 7 h as the ice-water bath was left to warm to 23 °C. The mixture was 
diluted with saturated aqueous NH4Cl (2 mL), and THF was removed in vacuo. The resulting 
mixture was extracted with EtOAc (6 × 5 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo. The residue was purified by preparative-TLC (80% 
EtOAc in hexanes) to afford 4-TEGylated meayamycin 2.43 as a colorless oil (2.3 mg, 51% 
yield).  
Data for 4-TEGylated meayamycin 2.43: Rf = 0.23 (80% EtOAc in hexanes); IR (film): νmax 
= 3391, 2922, 2854, 2106 (N3), 1779 (C=O), 1598 (C=O), 1459, 1178, 1017 cm
-1; [α]D 
22 +10.2 
(c 0.23, CH2Cl2); 1H NMR (500 MHz, CDCl3, 293 K): δ = 6.40 (d, J = 15.5 Hz, 1H, 7-H), 6.27 
(m, 4´-H), 5.99 (br d, J = 9.0 Hz, 1H, N-H), 5.90 (dd, J = 11.5, 7.5 Hz, 1H, 3´-H), 5.71 (dd, J = 
11.5, 1.5 Hz, 1H, 2´-H), 5.64 (dd, J = 15.5, 7.5 Hz, 1H, 6-H), 5.48 (br t, J = 7.5 Hz, 1H, 9-H), 
4.26 (dd, J = 9.0, 7.5 Hz, 1H, 5-H), 3.97–3.93 (m, 1H, 14-H), 3.72–3.48 (m, 16H, tetraethylene 
glycol-H’s, 15-H, 11-H), 3.42–3.39 (m, 2H, N3CH2), 3.32 (d, J = 9.0 Hz, 1H, 4-H), 3.12 (d, J = 
5.5 Hz, 1H, 18-H), 2.45 (d, J = 5.5 Hz, 1H, 18-H), 2.42–2.39 (m, 1H, 10-H), 2.24–2.21 (m, 1H, 
10-H), 2.13 (d, J = 14.0 Hz, 1H, 2axial-H), 2.07 (s, 3H, 2´´-H), 1.99–1.94 (m, 2H, 13-H), 1.78 (s, 
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3H, 19-H), 1.62–1.59 (m, 1H, 12-H), 1.43 (s, 3H, 17-H), 1.40 (d, J = 6.5 Hz, 3H, 5´-H), 1.39 (d, 
J = 14.0 Hz, 1H, 2equatorial-H), 1.28 (s, 3H, 17´-H), 1.16 (d, J = 6.5 Hz, 3H, 16-H), 1.02 (d, J = 7.5 
Hz, 3H, 20-H); 13C NMR (125 MHz, CDCl3, 293 K): δ = 170.4, 164.8, 143.5, 138.1, 134.7, 
125.0, 122.5, 80.8, 77.5, 75.9, 74.6, 72.9, 70.7, 70.6, 70.1, 68.9, 68.1, 57.5, 50.7, 47.6, 47.1, 42.8, 
35.8, 31.9, 31.0, 28.9, 23.6, 21.3, 20.0, 17.8, 15.4, 12.8; HRMS (ESI+) calcd. for C36H58N4O10Na 
[M + Na]+ 729.4051, found 729.4031. 
 
 
Preparation of TEGylated right fragment 2.44: A 25-mL round-bottomed flask equipped 
with a Teflon-coated magnetic stir bar containing right fragment 2.11 (15 mg, 0.080 mmol) was 
added THF (0.6 mL) and tosylate 2.42 (45 mg, 0.12 mmol). The flask was cooled in an ice-water 
bath (0 °C external temperature) and NaH (8.2 mg, 0.32 mmol) was added to the flask. The 
mixture was stirred for 9 h as the ice-water bath was left to warm to 23 °C. The mixture was 
diluted with saturated aqueous NH4Cl (1 mL), and THF was removed in vacuo. The resulting 
mixture was extracted with EtOAc (3 × 5 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography 
(10→70% EtOAc in hexanes) on silica gel (20 mL) to afford TEGylated right fragment 2.44 as a 
colorless oil (20 mg, 67% yield). 
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Data for TEGylated right fragment 2.44: Rf = 0.3 (70% EtOAc in hexanes); IR (film): νmax = 
2919, 2970, 2104 (N3), 1457, 1299, 1123 cm
-1; [α]D
22 +42.9 (c 1.0, CH2Cl2); 1H NMR (400 MHz, 
CDCl3, 293 K): δ = 5.95 (ddd, J = 17.2, 10.4, 6.4 Hz, 1H, 6-H), 5.43 (ddd, J = 17.2, 2.8, 1.2 Hz, 
1H, 7trans-H), 5.25 (ddd, J = 10.4, 2.8, 1.2 Hz, 1H, 7cis-H), 4.21 (dd, J = 9.6, 6.4 Hz, 1H, 5-H), 
3.77–3.51 (m, 14H, tetraethylene glycol-H’s), 3.40 (t, J = 5.2 Hz, 2H, N3CH2), 3.31 (d, J = 9.6 
Hz, 1H, 4-H), 3.11 (d, J = 5.2 Hz, 1H, 18-H), 2.45 (d, J = 5.2 Hz, 1H, 18-H), 2.12 (d, J = 14.0 
Hz, 1H, 2axial-H), 1.42 (s, 3H, 17-H), 1.37 (d, J = 14.0 Hz, 1H, 2equatorial-H), 1.27 (s, 3H, 17´-H); 
13C NMR (100 MHz, CDCl3, 293 K): δ = 136.5, 117.8, 77.6, 73.3, 73.2, 72.3, 70.7, 70.6, 70.5, 
70.0, 57.0, 50.7, 47.3, 43.4, 31.1, 23.7; HRMS (ESI+) calcd. for C18H31N3O6Na [M + Na]
+ 
408.2111, found 408.2120. 
 
 
Synthesis of 2.45, see: Y. Gong, Y. Luo, D. Bong, J. Am. Chem. Soc., 2006, 128, 14430–14431. 
 
 
Preparation of epoxide 2.46: A 100-mL round-bottomed flask equipped with a Teflon-coated 
magnetic stir bar containing alcohol 2.45 (666 mg, 3.04 mmol) was added THF (10 mL). The 
flask was cooled in an ice-water bath (0 °C external temperature), then NaH (243 mg, 6.08 
mmol) and allyl chloride (349 mg, 4.56 mmol) were added to the flask. The mixture was stirred 
for 23 h as the ice-water bath was left to warm to 23 °C. The mixture was diluted with saturated 
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aqueous NH4Cl (2 mL) and H2O (10 mL), then THF was removed in vacuo. The resulting 
mixture was extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo. The crude alkene was used directly in the next step. 
A 100-mL round-bottomed flask equipped with a Teflon-coated magnetic stir bar containing 
the crude alkene, was diluted with CH2Cl2 (5 mL) then cooled in an ice-water bath (0 °C external 
temperature). Meta-chloroperoxybenzoic acid (454 mg, 2.63 mmol) was added, and the mixture 
was stirred for 17 h as the ice-water bath was left to warm to 23 °C. 2-methyl-2-butene (172 mg, 
2.46 mmol) was added followed by saturated aqueous NaHCO3 (5 mL). The organic layer was 
separated, and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic 
layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
The residue was purified by flash chromatography (70→100% EtOAc in hexanes) on silica gel 
(50 mL) to afford epoxide 2.46 as a colorless oil (182 mg, 54% yield over 2 steps). 
Data for epoxide 2.46: Rf = 0.22 (60% EtOAc in hexanes); IR (film): νmax = 2871, 2108 (N3), 
1298, 1110 cm-1; 1H NMR (300 MHz, CDCl3, 293 K): δ = 3.79 (dd, J = 11.4, 3.0 Hz, 1H, 3-H), 
3.72–3.64 (m, 14H, tetraethylene glycol-H’s), 3.43 (dd, J = 11.4, 6.0 Hz, 1H, 3-H), 3.39 (t, J = 
5.1 Hz, CH2N3), 3.19–3.14 (m, 1H, 2H), 2.79 (dd, J = 5.1, 5.1 Hz, 1H, 1-H), 2.61 (dd, J = 5.1, 
3.0 Hz, 1, 1-H); 13C NMR (100 MHz, CDCl3, 293 K): δ = 72.0, 70.7, 70.6, 70.0, 50.8, 50.7, 44.3, 
40.9; HRMS (ESI+) calcd. for  C11H21N3O5Na [M+Na]






Preparation of epoxide 2.47: A 100-mL round-bottomed flask equipped with a Teflon-coated 
magnetic stir bar containing alcohol 2.45 (809 mg, 3.69 mmol) was added THF (12 mL). The 
flask was cooled in an ice-water bath (0 °C external temperature), then NaH (295 mg, 7.38 
mmol) and methallyl bromide (747 mg, 5.54 mmol) were added to the flask. The mixture was 
stirred for 20 h as the ice-water bath was left to warm to 23 °C. The mixture was diluted with 
saturated aqueous NH4Cl (2 mL) and H2O (20 mL), then THF was removed in vacuo. The 
resulting mixture was extracted with EtOAc (3 × 50 mL). The combined organic layers were 
dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by flash 
chromatography (20→40% EtOAc in hexanes) on silica gel (50 mL) to afford the alkene as a 
colorless oil (979 mg, 97% yield). 
A 100-mL round-bottomed flask equipped with a Teflon-coated magnetic stir bar containing 
the alkene (461 mg, 1.69 mmol), was diluted with CH2Cl2 (6 mL) then cooled in an ice-water 
bath (0 °C external temperature). Meta-chloroperoxybenzoic acid (437 mg, 2.53 mmol) was 
added, and the mixture was stirred for 17 h as the ice-water bath was left to warm to 23 °C. 2-
methyl-2-butene (236 mg, 3.38 mmol) was added followed by saturated aqueous NaHCO3 (5 
mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (3 × 20 
mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. The residue was purified by flash chromatography (40→80% EtOAc 
in hexanes) on silica gel (50 mL) to afford epoxide 2.47 as a colorless oil (332 mg, 66% yield 
over 2 steps). 
Data for epoxide 2.47: Rf = 0.23 (70% EtOAc in hexanes); IR (film): νmax = 2870, 2107 (N3), 
1289, 1117 cm-1; 1H NMR (400 MHz, CDCl3, 293 K): δ = 3.69–3.64 (m, 14H, tetraethylene 
glycol-H’s), 3.61 (d, J = 11.2 Hz, 1H, 3-H), 3.44 (d, J = 11.2 Hz, 1H, 3-H), 3.39 (t, J = 4.8, 
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CH2N3), 2.74 (d, J = 4.8 Hz, 1H, 1-H), 2.62 (d, J = 4.8 Hz, 1H, 1-H), 1.37 (s, 3H, 4-H); 13C 
NMR (100 MHz, CDCl3, 293 K): δ = 74.3, 70.5, 70.4, 69.9, 55.9, 51.3, 50.5, 18.2; HRMS 
(ESI+) calcd. for  C12H23N3O5Na [M+Na]
+ 312.1535, found 312.1562. 
 
Cells and reagents: HCT-116 cells were obtained as a gift from Professor Andreas Vogt 
(University of Pittsburgh), the MCF7 cells were a gift from Professor Paul Robbins (University 
of Pittsburgh), the MDA-MB231, MCF-7, DU145, H1299 and A549 cells were a gift from 
Professor Billy Day (University of Pittsburgh), the HEK-293-II cells were a gift from Professor 
Melissa Moore (University of Massachusetts), and the PCI-13, PCI-30, UD-SSC90, 93-VU-
147T, UM-22B, UMSSC47, JHU-020 and JHU-012 cells were from Professor Robert Ferris 
(University of Pittsburgh). All cell culture media were supplemented with 10% fetal bovine 
serum, 1% L-glutamine and 1% penicillin/streptomycin. MCF7, MCF-7, DU145, H1299, MDA-
MB231 and A549 were grown in RPMI 1640 media. HCT-116 cells were grown in McCoy’s 5A 
media. HEK-293-II, PCI-13, PCI-30, UD-SSC90, 93-VU-147T, UM-22B, UMSSC47, JHU-020 
and JHU-012 were grown in DMEM media. All synthetic compounds were dissolved in dimethyl 
sulfoxide (DMSO) as stock solutions and stored at -20 °C.  
Antiproliferative activity assays: Cells were plated in a 96-well plate at an initial density of 
approximately 4 × 103 cells per well in 100 µL of cell culture medium and were incubated in an 
incubator of 37 °C in an atmosphere containing 5% carbon dioxide for 24 h prior to compound 
addition. One plate of cells was used for a time zero cell number determination, and cells in other 
plates were treated with either DMSO or a range of concentrations, in triplicate, of test agents. 
Serial three-fold dilutions were used in this experiment for the indicated ranges. The compound 
was added to the cells at the desired concentration in 100 mL medium (containing 2% DMSO). 
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Cell viability was measured spectrophotometrically using the commercial 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt 
(MTS) dye reduction assay with phenazine methosulfate (PMS) as the electron acceptor (20 μL 
per well). The absorbance (at 490 nm minus that at 650 nm) was measured using a Modulus II 
Microplate Multimode Reader (Turner BioSystem). Evaluation of analogues was performed in 
triplicate at each concentration, and the final numbers were averaged. GraphPad Prism 5.0© was 
used to generate dose-response curves and calculate GI50 values. Growth inhibition is calculated 
as defined by the National Cancer Institute [GI50 = 100 × (T – T0)/(C – T0); T0 = cell density at 
time zero; T = cell density of the test well after period of exposure to test compound; C = cell 
density of the vehicle treated] (see: http://www.dtp.nci.nih.gov/branches/btb/ivclsp.html). 
































Figure A1. A representative example of the antiproliferative dose-dependant activity of 
meayamycin and analogues in cells. 
 (A) 2.43-treated HCT-116 cells (B) 2.43-treated MCF7 cells (C) 2.43-treated HEK-293-II cells 
(D) meayamycin-treated HCT-116 cells (E) meayamycin-treated MCF7 cells (F) 2.44-treated 
HCT-116 cells (G) 2.44-treated MDA-MB231 cells (H) 2.44-treated A549 cells (I) vincristine-
treated MDA-MB231 cells (J) vincristine-treated A549 cells. (K) vincristine-treated HCT-116 
cells. (L) 2.26-treated A549 cells. (M) 2.44-treated JHU 012 cells. (N) 2.44-treated PCI 13 cells. 
(O) meayamycin-treated PCI 13 cells. (P) meayamycin B-treated JHU 020 cells. (Q) 2.26-
treated HCT-116 cells. (R) cisplatin-treated HCT-116 cells. (S) vincristine-treated HEK-293-II 
cells.  
 
Antiproliferative reversibility test: Cells were plated in a 96-well plate at an initial density 
of approximately 4 × 103 cells per well in 100 µL of medium and were incubated for 24 h prior 
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to the addition of the compound. One concentration was used in each experiment for all times 
examined. The compound was added to the cells at twice the desired concentration in 100 µL 
cell culture medium. At the desired time intervals, the medium containing the compound was 
revmoved, the wells were washed three times with new medium and 200 µL of new medium 
containing 1% DMSO was added. At the last time interval, after washing and replacing the 
medium, cell proliferation was measured using the commercial MTS solution (20 µL/well) as 
described above for the antiproliferative activity assay. 
 
 
Preparation of silyl enol ether 2.66: A 1-L round-bottomed flask equipped with a Teflon-
coated magnetic stir bar containing 4-hydroxy-4-methyl-2-pentanone (22 g, 189 mmol) was 
purged with argon. Et3N (66 mL, 435 mmol) and TMSCl (55 mL, 491 mmol) were added to the 
flask at 23 °C and the mixture was stirred at the same temperature for 30 min. A solution of NaI 
(75 g, 500 mmol) in MeCN (850 mL) was added to the reaction mixture over 1 h at the same 
temperature. The mixture was stirred for an additional 3.5 h, then diluted with ice/cold H2O (1.5 
L). The mixture was extracted with EtOAc (5 × 500 mL). The combined organic layers were 
dried over Na2SO4, filtered and concentrated in vacuo. The resulting crude residue of 2.66 (34 g, 
70% yield) was <90% pure by 1H NMR, and used directly in the next step without further 
purification.  
Data for silyl enol ether 2.66: IR (film): νmax = 2961, 1620, 1321, 1251, 1042 cm-1; 1H NMR 
(300 MHz, CDCl3, 293 K): δ = 4.08 (d, J = 3.3 Hz, 2H, 1´-, 1-H), 2.21 (s, 2H, 2-H), 1.28 (s, 6H, 
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3-H), 0.23 (s, 9H, TMS), 0.12 (s, 9H, TMS); 13C NMR (100 MHz, CDCl3, 293 K): δ = 157.0, 
92.7, 73.8, 51.8, 29.9, 2.7, 0.04;  
HRMS of compound 2.66 was not obtainable. 
 
 
Preparation of allylic alcohol 2.63: To a 1-L round-bottomed flask equipped with a Teflon-
coated magnetic stir bar containing 2.66 (1.9 g, 7.3 mmol), was added toluene (15 mL) and 
acrolein (11.6 mL, 174 mmol). The flask was cooled in an ice-water bath (0 °C external 
temperature), then a solution of Yb(OTf)3 (533 mg, 0.86 mmol) in H2O:EtOH (1:10, 4.1 mL) 
was added. The mixture was stirred at the same temperature for 24 h, then diluted with brine (30 
mL). The organic solvents were removed in vacuo, then the resulting mixture was extracted with 
EtOAc (3 × 20 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (10→80% 
EtOAc in hexanes) on silica gel (100 mL) to afford 2.63 as a clear oil (903 mg, 72% yield). 
Data for allylic alcohol 2.63: Rf = 0.18 (40% EtOAc in hexanes); IR (film): νmax = 3410 (br 
O-H), 2974, 2932, 1701 (C=O), 1378, 1144 cm-1; 1H NMR (300 MHz, 1% CD3OD in CDCl3, 
293 K): δ = 5.87 (ddd, J = 5.6, 10.4, 16.8 Hz, 1H, 2-H), 5.31 (ddd, J = 16.8, 1.2, 1.2 Hz, 1H, 
1trans-H), 5.16 (ddd, J = 10.4, 1.2, 1.2 Hz, 1H, 1cis-H), 4.61 (ddddd, J = 8.8, 6.0, 6.0, 1.2, 1.2 Hz, 
1H, 3-H), 2.73–2.63 (m, 4H, 2-H, 5-H), 1.25 (s, 6H, 6-H); 13C NMR (100 MHz, CDCl3, 293 K): 
δ = 212.5, 138.8, 115.3, 69.8, 68.6, 54.2, 50.5, 29.4; HRMS (ESI+) calcd. for C9H17O3 [M + H]
+ 




Preparation of diene 2.64: To a 250-mL round-bottomed flask equipped with a Teflon-
coated magnetic stir bar was added 2.63 (10.7 g, 62.2 mmol), DCE (40 mL), Ac2O (6.20 mL, 
62.2 mmol) and NaOAc (1.50 g, 18.7 mmol). The mixture was stirred in a 60 °C oil bath for 24 
h. The mixture was cool to 23 °C, then diluted with EtOAc (150 mL) and saturated aqueous 
sodium bicarbonate (200 mL). The organic layer was separated, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (10→50% 
EtOAc in hexanes) on silica gel (100 mL) to afford 2.64 as a clear oil (6.7 g, 70% yield). 
 
 
Preparation of diene 2.64: A 250-mL round-bottomed flask equipped with a Teflon-coated 
magnetic stir bar containing diisopropylamine (9.1 g, 90 mmol) was purged with N2. The flask 
was cooled in an ice-water bath (0 °C external temperature). nBuLi (55 mL, 90 mmol) was added 
slowly, while the mixture got viscous. THF (42 mL) was added, then the homogenous mixture 
was cooled to -78 °C. A solution of 4-hydroxy-4-methyl-2-pentanone (5.0 g, 43 mmol) in THF 
(17 mL) was added and the mixture was stirred for 50 min at the same temperature. A solution of 
acrolein (2.7 g, 47 mmol) in THF (38 mL) was added and the mixture was stirred for 1 h. The 
reaction mixture was then quenched with saturated aqueous NH4Cl (200 mL), then diluted with 
H2O (100 mL). THF was removed in vacuo, then the resulting mixture was extracted with Et2O 
(3 × 25 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, 
filtered and concentrated in vacuo. To the crude residue was added Ac2O (4.8 g, 47 mmol) and 
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NaOAc (2.3 g, 28 mmol). The mixture was stirred at 23 °C for 22 h, then heated to 100 °C, and 
stirred for 2 h. The mixture was cooled to 23 °C, diluted with saturated aqueous NaHCO3 (100 
mL) and extracted with Et2O (3 × 70 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo. The crude residue was purified by flash chromatography 
(5→30% EtOAc in hexanes) on silica gel (200 mL) to afford 2.64 as a clear oil (2.78 g, 42% 
yield). 
Data for diene 2.64: Rf = 0.33 (40% EtOAc in hexanes); IR (film): νmax = 3437 (br O-H), 
2973, 1678 (C=O), 1204, 1110 cm-1; 1H NMR (300 MHz, 1% CD3OD in CDCl3, 293 K): δ = 
7.16 (dd, J = 15.6 Hz, 10.8 Hz, 1H, 3-H), 6.48 (ddd, J = 16.8, 10.8, 10.8 Hz, 1H, 2-H), 6.18 (d, J 
= 15.6 Hz, 1H, 4-H), 5.72 (d, J = 16.8 Hz, 1H, 1trans-H), 5.60 (d, J = 10.8 Hz, 1H, 1cis-H), 2.77 (s, 
2H, 5-H), 1.29 (s, 6H, 6-H); 13C NMR (75 MHz, CDCl3, 293 K): δ = 202.0, 143.6, 135.0, 131.0, 
127.4, 69.9, 50.5, 29.4; HRMS (EI+) calcd. for C9H14O2 [M-CH3]
+ 139.0759, found 139.0756. 
 
Preparation of diene 2.75: A 250-mL round-bottomed flask equipped with a Teflon-coated 
magnetic stir bar containing 4-hydroxy-4-methyl-2-pentanone (10 g, 86 mmol) was cool in an 
ice-water bath (0 °C external temperature). 3,4-Dihydro-2H-pyran (14.5 g, 172 mmol) was added 
followed by CSA (200 mg, 0.860 mmol). The mixture was stirred for 1 h while slowly warming 
the cooling bath to 23 °C. The mixture was diluted with saturated aqueous NaHCO3 (70 mL) and 
extracted with Et2O (3 × 70 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo. The residue was purified by flash chromatography (10→30% EtOAc 
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in hexanes) on silica gel (200 mL) to afford THP-protected derivative of 2.62 as a clear liquid 
(16.4 g, 96% yield). 
A 500-mL round-bottomed flask equipped with a Teflon-coated magnetic stir bar containing 
diisopropylamine (4.2 g, 42 mmol) was purged with N2. The flask was cooled in an ice-water 
bath (0 °C external temperature). nBuLi (26.3 mL, 42 mmol) was added slowly, while the 
mixture got viscous. THF (35 mL) was added, then the homogenous mixture was cooled to -78 
°C. A solution of the THP-protected derivative of 2.62 (7 g, 35 mmol) in THF (17 mL) was 
added and the mixture was stirred for 50 min at the same temperature. A solution of acrolein (2.4 
g, 42 mmol) in THF (18 mL) was added and the mixture was stirred for 1 h. The reaction 
mixture was then quenched with saturated aqueous NH4Cl (100 mL), then diluted with H2O (100 
mL). THF was removed in vacuo, then the resulted mixture was extracted with Et2O (3 × 70 
mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. To the crude residue was added Ac2O (4 g, 39 mmol) and NaOAc 
(1.7 g, 21 mmol). The mixture was stirred at 23 °C for 21 h, then heated to 100 °C, and stirred 
for 2 h. The mixture was cooled to 23 °C, diluted with saturated aqueous sodium bicarbonate 
(100 mL) and extracted with Et2O (3 × 70 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by flash 
chromatography (2→10% EtOAc in hexanes) on silica gel (200 mL) to afford 2.75 as a clear oil 
(2 g, 24% yield). 
Data for diene 2.75: Rf = 0.25 (20% EtOAc in hexanes); IR (film): νmax = 2942, 2870, 1683 
(C=O), 1590, 1128, 1023 cm-1; 1H NMR (300 MHz, CDCl3, 293 K): δ = 7.15 (dddd, J = 15.3, 
11.7, 0.6, 0.6 Hz, 1H, 3-H), 6.30 (d, J = 15.3 Hz, 1H, 4-H), 5.65 (dddd, J = 17.1, 1.2, 0.6, 0.6 Hz, 
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1H, 1trans-H), 5.52 (dddd, J = 10, 1.2, 0.6, 0.6 Hz, 1H, 1cis-H), 4.81 (dd, J = 2.4, 2.4 Hz, 1H, 1´-
H), 3.94–3.87 (m, 1H, 5´-H), 3.48–3.40 (m, 1H, 5´-H), 2.84 (d, J = 13.5 Hz, 1H, 5-H), 2.73 (d, J 
= 13.5 Hz, 1H, 5-H), 1.85–1.40 (m, 6H, 4´-, 3´-, 2´-H), 1.37 (s, 3H, 6-H), 1.32 (s, 3H, 6-H); 13C 
NMR (75 MHz, CDCl3, 293 K): δ = 199.3, 142.4, 135.4, 131.9, 126.1, 93.8, 75.8, 63.0, 53.0, 
32.1, 27.2, 26.2, 25.4, 20.4; HRMS (EI+) calcd. for C14H22O3 [M]
+ 238.1569, found 238.1562. 
 
 
Preparation of epoxide 2.61: A 50-mL round-bottomed flask equipped with a Teflon-coated 
magnetic stir bar containing 2.64 (390 mg, 2.50 mmol) was charged with MeOH (13 mL). The 
flask was cooled in an ice-water bath (0 °C external temperature). H2O2 (30% aqueous solution, 
1 mL, 12.5 mmol) and aqueous 1M NaOH (0.46 mL, 0.5 mmol) were added to the reaction 
mixture at the same temperature. The mixture was stirred at the same temperature for 3.5 h, then 
diluted with saturated aqueous NH4Cl (10 mL). The mixture was extracted with Et2O (3 × 10 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. 
The crude residue was purified by flash chromatography (5→30% EtOAc in hexanes) on silica 
gel (25 mL) to afford 2.61 as a clear oil (309 mg, 73% yield). 
Data for epoxide 2.61: Rf = 0.33 (40% EtOAc in hexanes); IR (film): νmax = 3403 (br, O-H), 
2974, 2930, 1709 (C=O), 1442, 1199, 1135 cm-1; 1H NMR (300 MHz, CDCl3, 293 K): δ = 5.56 
(ddd, J = 17, 11, 6 Hz, 1H, 2-H), 5.55 (dd, J = 17, 2.5 Hz, 1H, 1trans-H), 5.41 (dd, J = 11, 2.5 Hz, 
1H, 1cis-H), 3.49 (dd, J = 6, 2.1 Hz, 1H, 3-H), 3.38 (d, J = 2.1 Hz, 1H, 4-H), 2.67 (d, J = 17.1 Hz, 
1H, 5-H), 2.50 (d, J = 17.1 Hz, 1H, 5-H), 1.28 (s, 3H, 6-H), 1.27 (s, 3H, 6-H); 13C NMR (175 
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MHz, CDCl3, 293 K): δ = 207.9, 133.0, 121.8, 69.8, 61.2, 57.9, 47.9, 29.5, 29.4; HRMS (EI+) 
calcd. for C9H13O2 [M-OH]
+ 153.0916, found 153.0910. 
 
 
Preparation of ketone 2.25: A 100-mL round-bottomed flask equipped with a Teflon-coated 
magnetic stir bar containing 2.61 (633 mg, 3.7 mmol) was charged with CH2Cl2 (20 mL). The 
flask was cooled in an ice-water bath (0 °C external temperature). CSA (860 mg, 3.7 mmol) was 
added, and the mixture was stirred for 19 h, while the cooling bath was left to warm to 23 °C. 
Et3N (1 mL) was added, then the mixture was concentrated in vauo. The crude residue was 
purified by flash chromatography (10→30% EtOAc in hexanes) on silica gel (50 mL) to afford 
2.25 as a clear oil (512 mg, 80% yield). 
Data for ketone 2.25: Rf = 0.35 (30% EtOAc in hexanes); IR (film): νmax = 3474 (br, O-H), 
2975, 2934, 1723 (C=O), 1374, 1240, 1107, 1080 cm-1; 1H NMR (300 MHz, 1% CD3OD in 
C6D6, 293 K): δ = 6.16 (ddd, J = 17.1, 10.5, 4.8 Hz, 1H, 2-H), 5.53 (ddd, J = 17.1, 1.8, 1.8 Hz, 
1H, 1trans-H), 5.17 (ddd, J = 10.5, 1.8, 1.8 Hz, 1H, 1cis-H), 3.86 (dd, J = 9.0, 6.8 Hz, 1H, 3-H), 
3.63 (d, J = 9.0 Hz, 1H, 4-H), 1.00 (s, 3H, 6-H), 0.75 (s, 3H, 6-H); 13C NMR (75 MHz, CDCl3, 
293 K): δ = 207.4, 135.5, 118.0, 77.9, 76.7, 76.4, 51.5, 30.8, 23.6; HRMS (ESI+) calcd. for 
C9H15O3 [M + H]




Preparation of epoxide racemic-2.11: A 25-mL round-bottomed flask equipped with a 
Teflon-coated magnetic stir bar containing 2.25 (200 mg, 1.18 mmol) was purged with N2. To 
the flask was added THF (12 mL) and CH2Br2 (246 mg, 1.42 mmol). The flask was cooled to -78 
°C, then nBuLi (1.6 mL, 2.6 mmol) was added. The mixture was stirred for 7 h, while warming 
the cooling bath to 20 °C. The reaction mixture was quenched with saturated aqueous NH4Cl (15 
mL), and THF was removed in vacuo. The resulting mixture was extracted with Et2O (3 × 15 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. 
The crude residue was purified by flash chromatography (5→30% EtOAc in hexanes) on silica 
gel (40 mL) to afford racemic-2.11 as a clear oil (157 mg, 73% yield). 
Spectroscopic data for racemic-2.11 matches B. J. Albert, A. Sivaramakrishnan, T. Naka, N. L. 
Czaicki, K. Koide, J. Am. Chem. Soc. 2007, 129, 2648–2659. 
 
 
Preparation of ketone chiral-2.25: A 500-mL round-bottomed flask equipped with a Teflon-
coated magnetic stir bar was added 2.64 (2.4 g, 15.4 mmol) and MeOH (60 mL). The mixture 
was cooled to 0 °C, then CeCl3•7H2O (11.6 g, 30.8 mmol) was added in one portion, followed by 
addition of NaBH4 (1.16 g, 30.8 mmol) added over 15 min. The mixture was stirred at the same 
temperature for 30 min, then diluted with saturated aqueous NH4Cl (50 mL). MeOH was 
removed in vacuo, then the resulting mixture was extracted with EtOAc (3 × 20 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude 
alcohol was used directly in the next step.  
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A 250-mL round-bottomed flask equipped with a Teflon-coated magnetic stir bar containing 
the crude alcohol was purged with argon. CH2Cl2 (60 mL) and 4Å M.S. (3.1 g) were added to the 
flask. The mixture was cooled to -20 °C (external temperature), then Ti(OiPr)4 (0.38 g, 1.34 
mmol), (+)-DIPT (0.5 g, 2.1 mmol) and tBuOOH solution in isoocatane (1.4 mL, 8.0 mmol) 
were added sequentially at the same temperature. The mixture was stirred at the same 
temperature for 13 h, then diluted with 1 M NaOH (50 mL), Celite ® (3.0 g), Na2SO4 (3.0 g), 
NaCl (3.0 g). The mixture was stirred for 40 min, then filtered through a pad of Celite® and 
florisil mixture. The filtrate was concentrated in vacuo, and the resulting crude residue was 
purified by flash chromatography (10→70% EtOAc in hexanes) on silica gel (200 mL) to afford 
the epoxyalcohol as a clear oil (0.8 g) with impurities of titantium and tartarate. The impure 
epoxide was used in the next step without further purification.  
To a 1-L round-bottomed flask equipped with a Teflon-coated magnetic stir bar containing 
the epoxy-alcohol (0.8 g) was added CH2Cl2 (200 mL), 4Å molecular sieves (3.3 g), TPAP (101 
mg,0.29 mmol) and NMO (2.5 g, 18.4 mmol) at 23 °C. The mixture was stirred at the same 
temperature for 40 min, then filtered through a plug of silica. The filtrate was concentrated to 
approximately 200 mL of CH2Cl2 remained in the flask. To the flask was added CSA (860 mg, 
3.7 mmol) at 23 °C. The mixture was stirred at the same temperature for 19 h, then Et3N (1 mL) 
was added. The mixture was concentrated in vacuo, and the crude residue was purified by flash 
chromatography (10→30% EtOAc in hexanes) on silica gel (50 mL) to afford chiral-2.25 as a 
clear oil (512 g, 20% yield, over 4 steps). The optical rotation of chiral-2.25 is [α]D 20 +28.1 (c 
1.0, CH2Cl2). 






Preparation of Mosher ester derivative 2.77: A 10-mL round-bottomed flask was charged 
with ketone chiral-2.25 (5.2 mg, 0.030 mmol) and CH2Cl2 (0.13 mL). The flask was cooled on 
an ice-water bath (0 °C external temperature), then (R)-(+)-Mosher’s acid (11.3 mg, 0.046 
mmol), DCC (19.1 mg, 0.090 mmol) and DMAP (4.5 mg, 0.036 mmol) were added at the same 
temperature under an open atmosphere to the flask containing the mixture. The reaction mixture 
was stirred, while warming slowly to 25 °C, for 3.5 h. The mixture was filtered through a plug of 
silica gel, and the filter cake was rinsed with CH2Cl2 (20 mL). The filtrate was concentrated in 
vacuo, and the crude residue was used without purification for analysis. The diastereomers were 
sufficiently separated in the 1H NMR spectrum such that integration could be performed. Peaks 
used for analysis: 1H NMR (300 MHz, 293K, CDCl3): δ = 5.90 (ddd, J = 17.1, 10.2, 6.6 Hz, 1H), 





Preparation of meayamycin: A 10-mL round-bottomed flask was charged with FR901464 
(3.1 mg, 0.006 mmol), 2.11 (6.2 mg, 0.034 mmol), Ru-1 (2.2 mg, 0.0030 mmol), benzoquinone 
(2.1 mg, 0.020 mmol), and DCE (0.15 mL). The flask was stirred in a 40 °C oil bath for 14 h, 
then concentrated in vacuo. The crude residue was purified by preparative TLC (70% EtOAc in 
hexanes), then the isolated semipure product was further purified by preparative HPLC 
(Absorption at 232 nm. Elution conditions: flow rate = 10.0 mL/min, gradient: 40→100% MeCN 
in water over 15 min, then 15-25 min 100% MeCN. Column: Agilent Prep-C18 column 21.2 × 





Preparation of carboxylic acid 3.6: A 10-mL round-bottomed flask was charged with 3.4 
(100 mg, 0.510 mmol) and DMF (2 mL). The flask was cooled on an ice-water bath (0 °C 
external temperature), then TFAA (118 mg, 0.561 mmol) was added at the same temperature 
under an open atmosphere to the flask containing the mixture. The reaction mixture was stirred, 
while warming slowly to 23 °C, for 15 h. The mixture was then poured into a seperatory funnel 
containing H2O (50 mL) and extracted with Et2O (2 × 20 mL). The combined organic extracts 
were dried over Na2SO4 and concentrated under reduced pressure using a rotary evaporator to 
yield a pale yellow solid. The crude solid was transferred to a 50-mL round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, then aqueous NaOH (4 M, 4 mL) was added to 
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the flask. The mixture was refluxed under an open atmosphere for 23 h, then cooled to 23 °C, 
and washed with CH2Cl2 (2 × 25 mL). The aqueous layer was then acidified with aqueous HCl (6 
M, 3 mL), and the resulting precipitate was isolated by vacuum filtration to give carboxylic acid 
3.6 as a pale yellow solid (119 mg, 97% yield) with >95% purity. 
Data for carboxylic acid 3.6: 1H NMR (300 MHz, 293K, DMSO-d6): δ = 12.07 (br s, 1H, 
OH), 11.88 (br s, 1H, N-H), 8.01 (d, J = 3.0 Hz, 1H, 2-H), 7.92 (d, J = 8.6 Hz, 1H, 4-H), 7.64 (d, 
J = 1.7 Hz, 1H, 7-H), 7.28 (dd, J = 8.6, 1.7 Hz, 1H, 5-H); HRMS (EI+) calcd for C9H6NO2Br 
[M]+ 238.9582, found 238.9585. These spectroscopic data for carboxylic acid 3.6 were consistent 
with the literature: J. Nat. Prod. 1993, 56, 1553. 
 
 
Preparation of alkenyl stannane 3.3: A 50-mL round-bottomed flask equipped with a Teflon-
coated magnetic stir bar was evacuated and backfilled with nitrogen. The flask was cooled on an 
ice-water bath and diisopropylamine (0.24 g, 2.4 mmol) was added via syringe. nBuLi (1.6 M in 
hexanes, 1.5 mL, 2.4 mmol) was slowly added using a syringe, at the same temperature under a 
nitrogen atmosphere. The mixture was stirred for 3 min, resulting in the development of a 
viscous liquid, an indication of LDA formation. The mixture was cooled to -40 °C (external 
temperature), and then THF (5 mL) followed by Bu3SnH (670 mg, 2.30 mmol) were added. The 
resulting mixture was treated with CuCN (191 mg, 2.10 mmol) via opening and closing the 
round-bottomed flask’s septa at the same temperature. A solution of 2-methylbut-1-en-3-yene 
(132 mg, 2.00 mmol) in THF (1 mL) was added to the reaction flask at the same temperature 
using a syringe. The reaction mixture was stirred at the same temperature under a nitrogen 
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atmosphere for 3 h, and then quenched with MeOH (2 mL) at the same temperature to result in a 
dark brown liquid mixture. The reaction mixture was diluted with Et2O (20 mL) and washed with 
saturated aqueous NH4Cl (2 × 20 mL) and brine (2 × 20 mL). The organic layer was dried over 
Na2SO4, filtered, and concentrated under reduced pressure using a rotary evaporator. The crude 
residue was dissolved in EtOAc (10 mL) in a 50-mL oven-dried round-bottomed flask, then 
AgOAc (1 g) was added at 23 °C under an open atmosphere. The mixture was stirred for 1 h at 
23 °C, filtered through Celite®, and concentrated under reduced pressure using a rotary 
evaporator. The resulting residue was purified by flash chromatography (3% Et3N in hexanes) on 
silica gel (50 mL) to afford alkenyl stannane 3.3 as a colorless oil (414 mg, 58% yield). 
Data for alkenyl stannane 3.3: 1H NMR (300 MHz, 293K, CDCl3): δ = 6.64 (d, J = 19.2 Hz, 
1H, 2-H), 6.21 (d, J = 19.2 Hz, 1H, 1-H), 5.01 (br s, 1H, 3-H), 4.96 (br s, 1H, 3-H), 1.86 (s, 3H, 
4-H), 1.64–1.48 (m, 6H, butyl), 1.39–1.25 (m, 12H, butyl), 1.01–0.82 (m, 9H, butyl); 13C NMR 
(75 MHz, 293 K, CDCl3): δ = 149.0, 143.7, 135.7, 115.6, 29.1, 27.7, 27.0, 18.5, 17.8, 13.6, 9.4. 
These spectroscopic data for alkenyl stannane 3.3 were consistent with literature: Tetrahedron 
1991, 47, 1163. 
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Preparation of methyl ester 3.7: Indole 3.4 (400 mg, 2.00 mmol) was dissolved in DMF (6 
mL) in a 50-mL round-bottomed flask. The mixture was cooled in an ice-water bath (0 °C), then 
TFAA (882 mg, 4.20 mmol) was added at the same temperature under an open atmosphere. The 
reaction mixture was stirred, while warming the cooling bath slowly to 23 °C, for 1 h. The 
reaction mixture was then poured into a separatory funnel containing H2O (100 mL) and 
extracted with Et2O (2 × 20 mL). The combined organic layers were concentrated under reduced 
pressure using a rotary evaporator to yield a pale yellow solid. The crude solid was transferred to 
a 50-mL round-bottomed flask and aqueous NaOH (4 M, 8 mL) was added. The mixture was 
stirred in a 100 °C oil bath for 19 h under an open atmosphere. The reaction mixture was then 
cooled to 23 °C and washed with CH2Cl2 (2 × 10 mL). The aqueous layer was acidified with 6 M 
aqueous HCl, and the resulting precipitate was isolated by vacuum filtration. The resulting solid 
was added to MeOH (4 mL) in a 50-mL oven-dried round-bottomed flask equipped with a 
Teflon-coated magnetic stir bar. TMSCHN2 (2 M in Et2O, 4.1 mL, 8.2 mmol) was added slowly 
over 7 min to the flask containing the mixture, using a syringe, at 23 °C under an open 
atmosphere. The reaction mixture was stirred for 23 min at the same temperature, after which it 
was concentrated under reduced pressure using a rotary evaporator, to afford methyl ester 3.7 as 
a pale yellow solid (330 mg, 65% yield over 3 steps) with >95% purity.  
Data for methyl ester 3.7: Rf = 0.34 (40% EtOAc in hexanes); 1H NMR (300 MHz, 293K, 
CD3OD): δ = 7.96 (d, J = 8.7 Hz, 1H, 4-H), 7.95 (s, 1H, 2-H), 7.61 (d, J = 1.8 Hz, 1H, 7-H), 7.29 
(dd, J = 8.7, 1.8 Hz, 1H, 5-H), 3.87 (s, 3H, OMe); HRMS (EI+) calcd for C10H8NO2Br [M]+ 
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252.9738, found 252.9740. These spectroscopic data for methyl ester 3.7 were consistent with 
the literature: J. Nat. Prod. 2005, 68, 1484. 
 
 
Preparation of methyl ester 3.8: A 10-mL sealed tube equipped with a Teflon-coated 
magnetic stir bar was evacuated and backfilled with nitrogen. To the sealed tube was added 
catecholborane (1.05 g, 8.80 mmol) and then 2-methylbut-1-en-3-yene (1.50 g, 22.0 mmol) via a 
syringe at 23 °C. The resulting mixture was stirred for 2 h in an 80 °C oil bath. The mixture was 
then cooled to 23 °C and an aliquot (1 drop) of the mixture was analyzed by 1H NMR to confirm 
the formation of 3.2. The mixture was then transferred, via a syringe, to a 250-mL round-
bottomed flask equipped with a Teflon-coated magnetic stir bar that had been purged with 
nitrogen before. THF (60 mL), MeOH (15 mL), Pd(PPh3)4 (173 mg, 0.0150 mmol), 3.7 (760 mg, 
3.00 mmol), and Cs2CO3 (3.0 g, 9.0 mmol) were added to the flask by opening and closing the 
round-bottomed flask’s septa at 23 °C. The resulting mixture was refluxed for 21 h under a 
nitrogen atmosphere. The reaction mixture was then cooled to 23 °C, filtered through a silica 
plug, and the filter cake was rinsed with EtOAc (200 mL). The resulting filtrate was concentrated 
under reduced pressure using a rotary evaporator. The crude residue was purified by flash 
chromatography (10→40% EtOAc in hexanes) on silica gel (100 mL) to afford methyl ester 3.8 
as a pale yellow solid (670 mg, 93% yield).  
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Data for methyl ester 3.8: m.p. = 89–90 °C; Rf = 0.37 (40% EtOAc in hexanes); IR (film): 
νmax = 3274 (N-H), 2947, 1678 (C=O), 1531, 1444, 1417, 1198, 1136, 1051 cm-1; 1H NMR (300 
MHz, 293K, CD3OD): δ = 7.97 (d, J = 8.0 Hz, 1H, 4-H), 7.93 (s, 1H, 2-H), 7.47 (br s, 1H, 7-H), 
7.35 (dd, J = 8.0, 1.2 Hz, 1H, 5-H), 6.93 (d, J = 16.0 Hz, 1H, 10-H), 6.65 (d, J = 16.0 Hz, 1H, 9-
H), 5.10 (br s, 1H, 12-H), 5.03 (br s, 1H, 12-H), 3.87 (s, 3H, OMe), 1.98 (s, 3H, 13-H); 13C NMR 
(75 MHz, 293 K, CD3OD): δ = 167.8, 143.8, 134.0, 133.9, 133.3, 132.3, 131.5, 127.1, 122.1, 




Preparation of TMC-205 (3.1): MeOH (1.5 mL) and aqueous NaOH (4 M, 2.5 mL) were 
added to a 25-mL oven-dried round-bottomed flask containing 3.8 (20 mg, 0.080 mmol) under 
an open atmosphere at 23 °C. The resulting solution was covered from light and stirred in an 80 
°C oil bath for 2.25 h. The solution was then cooled to 23 °C and steps subsequent to cooling 
were performed in a dark environment. The solution was washed with CH2Cl2 (1 mL) and then 
the aqueous layer was acidified with aqueous 3 M KHSO4 (10 mL). The aqueous layer was 
extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over Na2SO4, 
filtered, and concentrated under reduced pressure using a rotary evaporator (Twater bath = 30 °C) to 
afford 16 mg of TMC-205 (3.1) as a pale yellow solid (88% yield, >95% purity).  
Data for TMC-205 (3.1): Rf = 0.24 (40% EtOAc in hexanes); IR (film): νmax = 3432 (broad, 
O-H), 2920, 2851,1644 (C=O), 1528, 1451, 1349 cm-1; 1H NMR (500 MHz, 293K, CD3OD): δ = 
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7.99 (d, J = 8.3 Hz, 1H, 4-H), 7.92 (s, 1H, 2-H), 7.48 (br s, 1H, 7-H), 7.35 (dd, J = 8.3, 1.5 Hz, 
1H, 5-H), 6.94 (d, J = 16 Hz, 1H, 10-H), 6.67 (d, J = 16 Hz, 1H, 9-H), 5.10 (br s, 1H, 12-H), 
5.03 (br s, 1H, 12-H), 1.98 (s, 3H, 13-H); 13C NMR (75 MHz, 293 K, CD3OD): δ = 169.0, 143.7, 
139.0, 134.0, 133.8, 131.3, 130.7, 127.3, 122.1, 121.3, 116.7, 111.1, 109.9, 18.8; HRMS (EI+) 





















Table A1. Comparison of the spectral data of natural and synthetic TMC-205. δC and δH (the 









2 132.8 (d) 7.98 (1H, d, 2.7) 132.7 7.98 (1H, br s) 
3 107.6  107.5  
3a 125.8  125.5  
4 120.6 7.94 (1H, d, 8.5) 120.4 7.94 (1H, d, 8.4) 
5 119.5 7.39 (1H, dd, 8.5, 1.2) 119.3 7.39 (1H, d, 8.4) 
6 131.2  131.1  
7 110.5 7.52 (1H, br s) 110.4 7.52 (1H, br s) 
7a 136.8  136.6  
8 165.6  165.6  
9 129.6 6.69 (1H, d, 16.1) 129.4 6.69 (1H, 16.1) 
10 129.7 6.96 (1H, d, 16.1) 129.5 6.97 (1H, 16.1) 
11 141.7  141.6  
12cis 116.6 5.16 (1H, br s) 116.4 5.16 (1H, br s) 
12trans  5.05 (1H, br s)  5.05 (1H, br s) 
13 18.4 1.95 (3H, s) 18.3 1.93 (3H, s) 
1-NH  11.82 (1H, br s)  11.85 (1H, br s) 
COOH  11.88 (1H, br s)  11.96 (1H, br s) 
a M. Sakurai, J. Kohno, M. Nishio, K. Yamamoto, T. Okuda, K. Kawano, N. Nakanishi, J. 
Antibiot. 2001, 54, 628–634.  




Figure A2.  HPLC chromatogram of synthetic TMC-205. 
y-axis: Absorption at 276 nm. Elution conditions: flow rate = 1.0 mL/min, gradient: 10→95% 
MeCN in water (containing 0.1% HCOOH) over 20 min. Column: C18 XDB 4.6 mm × 7.5 cm. T 
= 24 °C. 
 
TMC-205 and Reactive Oxygen Speciesc 
Solution A: [TMC-205 (3.1)] = 1 mM in MeOH; solution B: [NaN3] = 20 mM in pH 10 
buffer; solution C: [N, N-dimethyl nitrosoanilined] = 50 mM in DMSO; solution D: [13] =1 mM 
in MeOH; solution E: [NaMoO4•2H2O] = 100 mM in pH 10 buffer; solution F: [KO2] = 100 mM 
in DMSO; solution G: [FeSO4•7H2O] = 100 mM in pH 7 buffer. These solutions were used 
immediately after preparation. 
Singlet oxygen: Solution of A or C or D ([reagent]final = 15.0 µM) with or without solution B 
[NaN3]final = 15 µM or 1 mM), solution E (40.0 µL, [NaMoO4•2H2O]final = 1.0 mM) and 30% 
H2O2 (10.0 µL, [H2O2]final = 25.0 mM) were added to a mixture of MeOH/pH 10 buffer (5:95) 
(4.0 mL), and the samples were incubated for 60 min at 37 °C. 
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Superoxide: Solution of A or D ([reagent]final = 15.0 µM) with solution F (10.0 µL, [KO2]final 
= 250 µM) were added to a mixture of MeOH/pH 7 buffer solution (5:95) (4.0 mL), and the 
samples were incubated for 60 min at 37 °C. 
Hydrogen peroxide: Solution of A or D ([reagent]final = 15.0 µM) and 30% H2O2 (10 µL, 
[H2O2]final = 25.0 mM) were added to a mixture of MeOH/pH 7 buffer solution (5:95) (4.0 mL), 
and the samples were incubated for 60 min at 37 °C. 
Hydroxyl radical: Solution of A or D ([reagent]final = 15.0 µM), solution G (10.0 µL, 
[FeSO4•7H2O]final = 250 µM) and 30% H2O2 ([H2O2]final = 250 µM) were added to a mixture of 
MeOH/pH 7 buffer solution (5:95) (4.0 mL), and the samples were incubated for 60 min at 37 
°C. 
After incubations, samples were analyzed by HPLC and low-resolution mass spectra [LC-MS 
(APCI)]. HPLC monitoring was performed on a Zorbax XDB-C18 column, 4.6 min × 7.5 cm, 1.0 
mL/min, 20% MeCN in H2O (containing 0.1% HCOOH) to 100% MeCN linear gradient elution 
from 0.5 to 20 min, followed by 100% MeCN from 20 to 25 min, followed by 100% MeCN to 
20% MeCN in H2O (containing 0.1% HCOOH) linear gradient from 25 to 30 min. 
 
cA. L. Garner, C. M. St. Croix, B. R. Pitt, G. D. Leikauf, S. Ando, K. Koide, Nat. Chem. 2009, 1, 
316. 
dN, N-Dimethyl nitrosoaniline was used to ensure singlet oxygen was efficiently generated: Shio 






Preparation of decarboxylated analogue 3.9: A 10-mL sealed tube equipped with a Teflon-
coated magnetic stir bar was evacuated and backfilled with nitrogen. To the sealed tube was 
added catecholborane (363 mg, 3.00 mmol) then 2-methylbut-1-en-3-yene (485 mg, 7.40 mmol) 
via a syringe at 23 °C. The resulting solution was stirred for 4.75 h in an 85 °C oil bath. The 
mixture was then cooled to 23 °C, and an aliquot (1 drop) of the solution was analyzed by 1H 
NMR spectroscopy to confirm the formation of 3.2. The mixture was then transferred, via a 
syringe, to a 50-mL round-bottomed flask equipped with a Teflon-coated magnetic stir bar that 
had been purged with nitrogen before. THF (4 mL), MeOH (1 mL), Pd(PPh3)4 (69 mg, 0.060 
mmol), 3.4 (118 mg, 0.600 mmol), and Cs2CO3 (586 mg, 1.80 mmol) were added to the 50-mL 
round-bottomed flask at 23 °C by opening and closing the round-bottomed flask’s septa. The 
resulting mixture was stirred in a 70 °C oil bath for 23 h under a nitrogen atmosphere. The 
reaction mixture was then cooled to 23 °C and filtered through a silica plug. The filter cake was 
rinsed with EtOAc (200 mL) and Et2O (200 mL), and the resulting filtrate was concentrated 
under reduced pressure using a rotary evaporator. The crude residue was purified by flash 
chromatography (0→20% EtOAc in hexanes) on silica gel (180 mL) to afford the 
decarboxylated analogue 3.9 as a pale yellow solid (60 mg, 55% yield).  
Data for decarboxylated analogue 3.9: m.p. = 104–106 °C; Rf = 0.32 (20% EtOAc in 
hexanes); IR (film): νmax = 3222 (N-H), 3053, 2930, 1617, 1453, 1335, 1264, 1092 cm-1; 1H 
NMR (300 MHz, 293K, CD3OD): δ = 7.49 (br d, J = 8.1 Hz, 1H, 4-H), 7.43 (s, 1H, 7-H), 
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7.23−7.18 (m, 2H, 5-H, 2-H), 6.91 (d, J = 16.0 Hz, 1H, 10-H), 6.67 (d, J = 16.0 Hz, 1H, 9-H), 
6.41 (br d, J = 2.1 Hz, 1H, 3-H), 5.07 (br s, 1H, 12-H), 5.00 (br s, 1H, 12-H), 1.99 (s, 3H, 13-H); 
13C NMR (75 MHz, 293 K, CD3OD): δ = 144.3, 138.6, 132.7, 132.0, 130.6, 129.9, 126.9, 121.7, 
119.4, 116.5, 111.1, 103.0, 19.4; ESI-MS calcd for C14H17NO [M + MeOH]+ 215.13, found 
215.10. These spectroscopic data for decarboxylated analogue 3.9 were consistent with literature: 
H. Ishii, Y. Murakami, T. Furuse, H. Takeda, N. Ikeda, Tetrahedron Lett. 1973, 14, 355. 
 
 
Preparation of alcohol 3.10: A 10-mL round-bottomed flask was charged with 3.8 (20 mg, 
0.080 mmol) at 23 °C under an open atmosphere. The flask was evacuated and backfilled with 
nitrogen. THF (1.3 mL) was added to the flask via a syringe, and the flask was cooled to -78 °C 
(external temperature). DIBALH (1 M in hexanes, 0.48 mL, 0.48 mmol) was added at -78 °C, by 
a syringe and then the mixture was stirred for 30 min at the same temperature. H2O (0.9 mL) was 
added to the reaction mixture at -78 °C, then warmed to 23 °C, filtered through Celite®, and the 
filtrate was concentrated under reduced pressure using a rotary evaporator. The crude residue 
was purified by flash chromatography (10→60% EtOAc in hexanes) on silica gel (25 mL) to 
afford alcohol 3.10 as a pale yellow solid (13 mg, 76% yield).  
Data for alcohol 3.10: m.p. = 91–92 °C; Rf = 0.36 (50% EtOAc in hexanes); IR (film): νmax = 
3370 (broad, O-H), 2923, 2854, 1724, 1457, 1377, 1073 cm-1; 1H NMR (300 MHz, 293K, 
CD3OD): δ = 7.59 (d, J = 8.0 Hz, 1H, 4-H), 7.40 (br s, 1H, 2-H), 7.22 (d, J = 8.0 Hz, 1H, 5-H), 
7.21 (s, 1H, 7-H), 6.90 (d, J = 15.9 Hz, 1H, 10-H), 6.65 (d, J = 15.9 Hz, 1H, 9-H), 5.06 (br s, 1H, 
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12-H), 4.99 (br s, 1H, 12-H), 4.82 (s, 2H, 8-H), 1.98 (s, 3H, 13-H); 13C NMR (75 MHz, 293 K, 
CD3OD): δ = 143.8, 138.7, 132.6, 131.3, 130.3, 125.5, 119.8, 119.1, 118.9, 116.7, 116.1, 110.7, 
57.2, 18.9; HRMS (EI+) calcd for C14H15NO [M]+ 213.1154, found 213.1155. 
 
 
Preparation of 3.11: MeOH (5 mL) and Pd/C (10% wt., 17 mg, 0.015 mmol) were added to a 
25 mL oven-dried round-bottomed flask containing 3.8 (73 mg, 0.30 mmol) at 23 °C under an 
open atmosphere. The flask was evacuated and backfilled with a hydrogen atmosphere using a 
balloon filled with hydrogen gas. The mixture was stirred under the hydrogen atmosphere for 
12.5 h at 23 °C, and then filtered through a plug of Celite, followed by solvent removal under 
reduced pressure using a rotary evaporator. The resulting crude residue was purified by flash 
chromatography (5→30% EtOAc in hexanes) on silica gel (40 mL) to afford 3.11 as a pale 
yellow solid (70 mg, 95% yield).  
Data for 3.11: m.p. = 97–98 °C; Rf = 0.23 (20% EtOAc in hexanes); IR (film): νmax = 3266 
(N-H), 2953, 2869, 1627 (C=O), 1534, 1446, 1369, 1200, 1149, 1051 cm-1; 1H NMR (300 MHz, 
293K, CD3OD): δ = 7.92 (d, J = 8.4 Hz, 1H, 4-H), 7.87 (d, J = 3.0 Hz, 1H, 2-H), 7.22 (d, J = 1.2 
Hz, 1H, 7-H), 7.01 (dd, J = 8.4, 1.2 Hz, 1H, 5-H), 3.85 (s, 3H, OMe), 2.68 (t, J = 7.8 Hz, 2H, 9-
H), 1.62–1.48 (m, 3H, 10-H, 11-H), 0.93 (d, J = 6.3 Hz, 6H, 12-H, 13-H); 13C NMR (75 MHz, 
293 K, CD3OD): δ = 168.1, 139.2, 138.6, 132.9, 125.4, 123.8, 121.8, 112.3, 108.3, 51.5, 42.8, 




Preparation of alkane analogue 3.12: MeOH (1.5 mL) and aqueous NaOH (6 M, 2.5 mL) 
were added to a 10-mL round-bottomed flask containing 3.11 (23 mg, 0.090 mmol) at 23 °C 
under an open atmosphere. The mixture was stirred in a 50 °C oil bath for 3.5 h and then cooled 
to 23 °C. The reaction mixture was washed with CH2Cl2 (10 mL). The aqueous layer was 
acidified with KHSO4 (3 M, 10 mL) and extracted with EtOAc (2 × 20 mL). The combined 
organic extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure using 
a rotary evaporator. The resulting residue was purified by flash chromatography (20→50% 
EtOAc in hexanes with 1% acetic acid) on silica gel (5 mL) to afford the alkane analogue 3.12 as 
a pale yellow solid (18 mg, 87% yield).  
Data for alkane analogue 3.12: m.p. = 127–129 °C; Rf = 0.33 (50% EtOAc in hexanes); IR 
(film): νmax = 3431 (broad, O-H), 3138, 2954, 2927, 1682 (C=O), 1535, 1453, 1358, 1195, 1141 
cm-1; 1H NMR (300 MHz, 293K, CD3OD): δ = 7.94 (d, J = 8.1 Hz, 1H, 4-H), 7.87 (s, 1H, 2-H), 
7.22 (br s, 1H, 7-H), 7.01 (dd, J = 8.1, 1.2 Hz, 1H, 5-H), 2.69 (t, J = 7.7 Hz, 2H, 9-H), 1.63–1.49 
(m, 3H, 10-H, 11-H), 0.93 (d, J = 6.3 Hz, 6H, 12-H, 13-H); 13C NMR (75 MHz, 293 K, CD3OD): 
δ = 169.5, 139.0, 138.7, 133.1, 125.8, 123.7, 121.9, 112.2, 108.8, 42.8, 35.2, 28.9, 23.1; HRMS 




Preparation of ketone 3.13: An oven-dried 10-mL sealed tube equipped with a Teflon-coated 
magnetic stir bar was evacuated and backfilled with nitrogen. To the sealed tube was added 
catecholborane (1.05 g, 8.80 mmol) and then 2-methylbut-1-en-3-yne (1.50 g, 22.0 mmol) via a 
syringe at 23 °C. The resulting solution was stirred for 2 h in an 80 °C oil bath. The mixture was 
then cooled to 23 °C and an aliquot (1 drop) of the mixture was analyzed by 1H NMR 
spectroscopy to confirm the formation of 3.2. The mixture was then transferred, by a syringe, to 
a 100-mL round-bottomed flask equipped with a Teflon-coated magnetic stir bar that had been 
previously purged with nitrogen. Toluene (5 mL), EtOH (5 mL), Pd2(dba)3 (192 mg, 0.21 mmol), 
PPh3 (110 mg, 0.42 mmol), 3.5 (500 mg, 1.7 mmol), and Cs2CO3 (2.0 g, 6.3 mmol) were added 
in this order to the flask by opening and closing the round-bottomed flask’s septa at 23 °C. The 
resulting mixture was stirred in a 90 °C oil bath for 9 h under a nitrogen atmosphere. The 
reaction mixture was then cooled to 23 °C, filtered through a silica plug, and the filter cake was 
rinsed with EtOAc. The resulting filtrate was concentrated under reduced pressure using a rotary 
evaporator. The crude residue was purified by flash chromatography (2.5→20% EtOAc in 
hexanes) on silica gel (40 mL) to afford ketone 3.13 as a pale yellow solid (413 mg, 87% yield).  
Data for ketone 3.13: m.p. = 76–77 °C; Rf = 0.18 (30 % EtOAc in hexanes); IR (film): νmax = 
3217 (N-H), 3094, 1635 (C=O), 1525, 1497, 1426, 1393, 1241, 1184, 1136 cm-1; 1H NMR (300 
MHz, 293K, CD3OD): δ = 8.22 (d, J = 1.8 Hz, 1H, 2-H), 8.19 (d, J = 8.4 Hz, 1H, 4-H), 7.57 (br 
s, 1H, 7-H), 7.48 (dd, J = 8.4, 0.9 Hz, 1H, 5-H), 6.99 (d, J = 16.1 Hz, 1H, 10-H), 6.68 (d, J = 
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16.1 Hz, 1H, 9-H), 5.14 (br s, 1H, 12-H), 5.07 (br s, 1H, 12-H), 1.99 (s, 3H, 13-H); 13C NMR 
(175 MHz, 293 K, CD3OD): δ = 174.7, 142.1, 137.7, 136.8, 134.3, 131.0, 128.7, 126.2, 125.0, 




Preparation of N-methylated analogue 3.14: To a 25-mL round-bottomed flask equipped 
with a Teflon-coated magnetic stir bar was added 3.13 (90 mg, 0.32 mmol), MeI (227 mg, 1.60 
mmol), DMF (1.5 mL) and Cs2CO3 (208 mg, 0.64 mmol). The mixture was stirred at 23 °C for 
1.5 h, then diluted with H2O (30 mL) and extracted with Et2O (2 × 10 mL). The combined 
organic extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure using 
a rotary evaporator. The crude residue was purified by flash chromatography (2.5→20% EtOAc 
in hexanes) on silica gel (40 mL) to afford N-methylated analogue 3.14 as a pale yellow oil (86 
mg, 92% yield). 
Data for N-methylated analogue 3.14: Rf = 0.29 (30 % EtOAc in hexanes); IR (film): νmax = 
3030, 2922, 2853, 1663 (C=O), 1530, 1466, 1376, 1289, 1177, 1135 cm-1; 1H NMR (300 MHz, 
293K, CD3OD): δ = 8.22 (d, J = 1.8 Hz, 1H, 2-H), 8.19 (d, J = 8.1 Hz, 1H, 4-H), 7.62 (br s, 1H, 
7-H), 7.51 (dd, J = 8.4, 1.2 Hz, 1H, 5-H), 7.04 (d, J = 15.9 Hz, 1H, 10-H), 6.73 (d, J = 15.9 Hz, 
1H, 9-H), 5.15 (br s, 1H, 12-H), 5.08 (br s, 1H, 12-H), 3.95 (s, 3H, 14-H), 2.00 (s, 3H, 13-H); 13C 
NMR (150 MHz, 293 K, CD3OD): δ = 174.3, 142.1, 140.1, 138.3, 134.5, 131.2, 128.6, 126.1, 
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122.2, 121.6, 118.1, 116.3, 108.8, 108.4, 32.7, 17.4; HRMS (EI+) calcd for C16H14NOF3 [M]+ 
293.1027, found 293.1015. 
 
 
Preparation of 3.16 and 3.17: An oven-dried 10-mL sealed tube purged with nitrogen was 
charged with DMF (1 mL), Pd(OAc)2 (2.000 mg, 0.007 mmol), P(tBu)3HBF4 (4.000 mg, 0.014 
mmol). The mixture was stirred in a 100 °C oil bath for 25 min, then cooled to 23 °C. To the 
mixture was added 3.5 (20 mg, 0.07 mmol), NaHCO3 (11 mg, 0.13 mmol) and methylvinyl 
ketone (49 mg, 0.70 mmol) then stirred in a 100 °C oil for an additional 25 h. The mixture was 
filtered through a pad of silica, rinsed with EtOAc, and the filtrate was concentrated under 
reduced pressure using a rotary evaporator. The crude residue was purified by flash 
chromatography (10→70% EtOAc in hexanes) on silica gel (10 mL) to afford 3.16 as a pale 
yellow viscous oil (4 mg, 15% yield) and 3.17 as a pale yellow paste (17 mg, 69% yield). 
Data for 3.16: Rf = 0.23 (20 % EtOAc in hexanes); IR (film): νmax = 3124, 2924, 1718 
(C=O), 1668 (C=O), 1527, 1394, 1288, 1183, 1144, 882 cm-1; 1H NMR (300 MHz, 293K, 
CD3OD): δ = 8.30 (d, J = 1.8 Hz, 1H, 2-H), 8.16 (d, J = 8.7 Hz, 1H, 4-H), 7.87 (d, J = 1.8 Hz, 
1H, 7-H), 7.46 (dd, J = 8.7, 1.8 Hz, 1H, 5-H), 4.52 (t, J = 6.6 Hz, 2H, 14-H), 3.11 (t, J = 6.6 Hz, 
2H, 15-H), 2.13 (s, 3H, 17-H); 13C NMR (175 MHz, 293 K, CD3OD): δ = 206.6, 174.3, 140.0, 
137.6, 126.6, 125.6, 123.0, 117.6, 116.1, 113.9, 108.8, 41.8, 41.5, 28.5; HRMS (EI+) calcd for 
C14H11NO2F3Br[M]+ 360.9925, found 360.9919.   
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Data for 3.17: Rf = 0.30 (50 % EtOAc in hexanes); IR (film): νmax = 3121, 2925, 2851, 1714 
(C=O), 1668 (C=O), 1604, 1527, 1371, 1289, 1256, 1182, 1142, 1156, 1045 cm-1; 1H NMR (700 
MHz, 293K, CD3OD): δ = 8.39 (d, J = 2.1 Hz, 1H, 2-H), 8.29 (d, J = 8.4 Hz, 1H, 4-H), 7.95 (br 
s, 1H, 7-H), 7.81 (d, J = 16.1 Hz, 1H, 9-H), 7.67 (dd, J = 8.4, 1.4 Hz, 1H, 5-H), 6.93 (d, J = 16.1 
Hz, 1H, 10-H), 4.60 (t, J = 6.3 Hz, 2H, 14-H), 3.15 (t, J = 6.3 Hz, 2H, 15-H), 2.41 (s, 3H, 13-H), 
2.14 (s, 3H, 17-H); 13C NMR (175 MHz, 293 K, CD3OD): δ = 206.4, 199.8, 174.2, 144.7, 137.0, 
131.2, 128.7, 126.2, 123.7, 123.3, 122.1, 117.8, 116.2 111.6, 41.9, 41.5, 28.5, 26.0; HRMS (EI+) 
calcd for C18H16NO3F3 [M]+ 351.1082, found 351.1078.  
 
 
Preparation of alkene 3.19: A 25-mL round-bottomed flask purged with argon was charged 
with 3.5 (406 mg, 1.40 mmol), DMF (7 mL), (PPh3)2PdCl2 (29.3 mg, 42.0 µmol), and 
vinylstannane (666 mg, 2.10 mmol) at 23 °C. The mixture was stirred in a 50 °C oil bath for 17.5 
h, then filtered through a pad of silica and rinsed with a solution of 70% EtOAc in hexanes. The 
filtrate was diluted with H2O (100 mL) and the organic layer was separated. The aqueous layer 
was extracted with a solution of 70% EtOAc in hexanes (2 ×10 mL), then the combined organic 
layers were dried over Na2SO4, filtered, and concentrated under reduced pressure using a rotary 
evaporator. The crude residue was purified by flash chromatography (10→50% EtOAc in 
hexanes) on silica gel (15 mL) to afford 3.19 as a pale yellow solid (242 mg, 72% yield).  
Data for alkene 3.19: m.p. = 153–154 °C; Rf = 0.20 (30 % EtOAc in hexanes); IR (film): νmax 
= 3221 (N-H), 2927, 1636 (C=O), 1498, 1430, 1270, 1185, 1135 cm-1; 1H NMR (400 MHz, 
 195 
293K, 1% CD3OD in acetone-d6): δ = 8.41 (d, J = 2.0 Hz, 1H, 7-H), 8.25 (d, J = 8.0 Hz, 1H, 4-
H), 7.67 (br s, 1H, 2-H), 7.54 (dd, J = 8.0, 1.2 Hz, 1H, 5-H), 6.88 (dd, J = 18.0, 11.0 Hz, 1H, 9-
H), 5.86 (d, J = 18.0 Hz, 1H, 10-Htrans), 5.26 (d, J = 11.0 Hz, 1H, 10-Hcis); 13C NMR (100 MHz, 
293 K, acetone-d6): δ = 174.3, 137.2, 137.0, 134.5, 125.9, 121.7, 121.6, 118.6, 115.8, 112.9, 
110.6, 110.0; ESI-MS calcd for C14H12F3N2O [M + CH3CN]+ 281.09, found 281.05. ESI-MS 
calcd for C12H9F3NO [M + H]+ 240.06, found 240.05. 
 
 
Preparation of enone 3.20: A 25-mL round-bottomed flask was charged with 3.5 (150 mg, 
0.63 mmol), PhH (2 mL), Ru-1 (21.5 mg, 0.0320 mmol), and methylvinyl ketone (218 mg, 3.12 
mmol) at 23 °C. The mixture was stirred at 23 °C for 26 h then concentrated under reduced 
pressure using a rotary evaporator. The crude residue was purified by flash chromatography 
(10→80% EtOAc in hexanes) on silica gel (30 mL) to afford enone 3.20 as a white solid (53.3 
mg, 30% yield).  
Data for enone 3.20: m.p. = >200 °C; Rf = 0.28 (50 % EtOAc in hexanes); IR (film): νmax = 
3212 (N-H), 2922, 1662 (C=O), 1635 (C=O), 1499, 1429, 1265, 1185, 1136 cm-1; 1H NMR (300 
MHz, 293K, CD3OD): δ = 8.33 (d, J = 1.8 Hz, 1H, 2-H), 8.30 (d, J = 8.4 Hz, 1H, 4-H), 7.82 (br 
s, 1H, 7-H), 7.79 (d, J = 16.5 Hz, 1H, 9-H), 7.65 (dd, J = 8.4, 0.9 Hz, 1H, 5-H), 6.86 (d, J = 16.5 
Hz, 1H, 10-H), 2.40 (s, 3H, 13-H); 13C NMR (175 MHz, 293 K, CD3OD): δ = 199.9, 174.7, 
144.8, 137.8, 137.1, 131.0, 128.1, 125.9, 123.0, 121.8, 117.9, 116.2, 109.9, 26.0; HRMS (EI+) 




Preparation of allylic alcohol 3.21: A 25-mL pear-shaped flask was charged with 3.5 (82 
mg, 0.34 mmol), DCE (0.4 mL), 3-buten-2-ol (123 mg, 1.70 mmol), and Ru-1 (18 mg, 0.027 
mmol) at 23 °C. The mixture was stirred in a 50 °C oil bath for 22 h, then concentrated under 
reduced pressure using a rotary evaporator. The crude residue was purified by flash 
chromatography (10→60% EtOAc in hexanes) on silica gel (30 mL) to afford allylic alcohol 
3.21 as a pale yellow oil (38 mg, 39% yield). 
Data for allylic alcohol 3.21: Rf = 0.25 (60 % EtOAc in hexanes); IR (film): νmax = 3218 
(broad, O-H), 2970, 2927, 1633 (C=O), 1498, 1443, 1265, 1185, 1134, 1091 cm-1; 1H NMR (300 
MHz, 293K, CD3OD): δ = 8.21 (d, J = 1.5 Hz, 1H, 2-H), 8.18 (d, J = 8.4 Hz, 1H, 4-H), 7.52 (br 
s, 1H, 7-H), 7.43 (dd, J = 8.4, 1.5 Hz, 1H, 5-H), 6.68 (d, J = 15.9 Hz, 1H, 9-H), 6.33 (dd, J = 
15.9, 6.3 Hz, 1H, 10-H), 4.44 (qd, J = 6.6, 6.3 Hz, 1H, 11-H), 1.34 (d, J = 6.6 Hz, 3H, 13-H); 13C 
NMR (75 MHz, 293 K, CD3OD): δ = 176.5, 138.8, 138.2, 135.5, 134.7, 130.5, 127.1, 123.3, 
122.9, 120.6, 116.8, 111.5, 69.6, 23.9; HRMS (ES+) calcd for C14H12NO2F3Na [M + Na]+ 





Preparation of allylic alcohol 3.22: A 25-mL round-bottomed flask was charged with 3.5 (75 
mg, 0.31 mmol), DCE (0.4 mL), 2-methyl-3-buten-2-ol (135 mg, 1.57 mmol), and Ru-1 (16 mg, 
0.024 mmol) at 23 °C. The mixture was stirred in a 40 °C oil bath for 22 h, then concentrated 
under reduced pressure using a rotary evaporator. The crude residue was purified by flash 
chromatography (20→80% EtOAc in hexanes) on silica gel (25 mL) to afford allylic alcohol 
3.22 as a pale yellow oil (29 mg, 32% yield).  
Data for allylic alcohol 3.22: Rf = 0.21 (50 % EtOAc in hexanes); IR (film): νmax = 3224 
(broad, O-H), 2923, 2853, 1633 (C=O), 1461, 1426, 1265, 1184, 1133, 1089 cm-1; 1H NMR (300 
MHz, 293K, 1% CD3OD in acetone-d6): δ = 8.37 (br s, 1H, 7-H), 8.21 (d, J = 8.1 Hz, 1H, 4-H), 
7.61 (d, J = 1.2 Hz, 1H, 2-H), 7.48 (dd, J = 8.1, 1.2 Hz, 1H, 5-H), 6.73 (d, J = 15.9 Hz, 1H, 9-H), 
6.49 (d, J = 15.9 Hz, 1H, 10-H), 1.38 (s, 6H, 13, 13’-H); 13C NMR (75 MHz, 293 K, acetone-d6): 
δ = 175.1, 139.6, 138.4, 137.7, 135.5, 126.6, 126.3, 122.9, 122.5, 120.1, 116.2, 111.4, 110.8, 
70.7; HRMS (EI+) calcd for C15H14NO2F3 [M]+ 297.0977, found 297.0978. 
 
 
Preparation of oxime 3.23: A 25-mL round-bottomed flask was charged with 3.20 (31 mg, 
0.11 mmol), Boc2O (37 mg, 0.13 mmol), CH2Cl2 (0.6 mL), and DMAP (7.5 mg, 0.060 mmol) at 
23 °C. The mixture was stirred at 23 °C for 1 h, then concentrated under reduced pressure. The 
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crude residue was purified by flash chromatography (2.5→30% EtOAc in hexanes) on silica gel 
(10 mL) to afford Boc-protected 3.20 (40 mg, 95% yield). 
To a 25-mL round-bottomed flask containing the Boc-protected 3.20 (40 mg, 0.10 mmol) 
was added MeOH (0.7 mL), HONH2•HCl (14 mg, 0.20 mmol), and NaOAc (21 mg, 0.25 mmol) 
at 23 °C. The mixture was stirred in a 50 °C oil bath for 19 h and then diluted with H2O (15 mL). 
The mixture was extracted with CH2Cl2 (2 × 3 mL), and the combined organic extracts were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was 
purified by flash chromatography (5→30% EtOAc in hexanes) on silica gel (10 mL) to afford 
oxime 3.23 as a pale yellow viscous oil (27 mg, 66% yield over two steps). 
Data for oxime 3.23: Rf = 0.32 (30 % EtOAc in hexanes); IR (film): νmax = 3306 (broad, O-
H), 2925, 2854, 1745 (C=O), 1698 (C=O), 1441, 1373, 1319, 1255, 1150, 1103 cm-1; 1H NMR 
(300 MHz, 293K, 1% CD3OD in acetone-d6): δ = 8.53 (d, J = 1.8 Hz, 1H, 7-H), 8.38 (d, J = 1.5 
Hz, 1H, 2-H), 8.25 (d, J = 8.4 Hz, 1H, 4-H), 7.70 (dd, J = 8.4, 1.8 Hz, 1H, 5-H), 7.16 (d, J = 16.5 
Hz, 1H, 9-H), 6.96 (d, J = 16.5 Hz, 1H, 10-H), 2.12 (s, 3H, 13-H), 1.76 (s, 9H, Boc); 13C NMR 
(100 MHz, 293 K, acetone-d6): δ = 174.1, 156.8, 155.0, 136.6, 135.4, 134.3, 132.1, 127.9, 126.8, 
124.5, 121.8, 113.6, 107.4, 98.9, 85.0, 27.3, 13.5; HRMS (EI+) calcd for C19H19N2O4F3 [M]+ 
396.1297, found 396.1290. 
 
 
Synthesis of 3.24, see: X. Qiu, G. Li, G. Wu, J. Zhu, L. Zhou, P. Chen, A. R. Chamberlin, W. 





Preparation of 3.25: A 10-mL round-bottomed flask was charged 3.23 (21 mg, 0.050 mmol), 
DMF (0.6 mL), 3.24 (26 mg, 0.080 mmol), and Cs2CO3 (17 mg, 0.050 mmol) at 23 °C. The 
mixture was stirred for 4 h at 23 °C, then diluted with saturated aqueous NH4Cl (7 mL) and H2O 
(10 mL), and the mixture was extracted with EtOAc (3 × 5 mL). The combined organic extracts 
were dried over Na2SO4, filtered, and concentrated under reduced pressure using a rotary 
evaporator. The crude residue was purified by flash chromatography (10→70% EtOAc in 
hexanes) on silica gel (8 mL) to afford 3.25 as a colorless oil (23 mg, 77% yield). 
Data for 3.25: Rf = 0.32 (70 % EtOAc in hexanes); IR (film): νmax = 3128, 2926, 2872, 2109 
(N3), 1767 (C=O), 1669 (C=O), 1527, 1453, 1289, 1191, 1152 cm
-1; 1H NMR (300 MHz, 293K, 
acetone-d6): δ = 8.44 (d, J = 1.8 Hz, 1H, 7-H), 8.30 (d, J = 8.1 Hz, 1H, 4-H), 8.11 (br s, 1H, 2-
H), 7.64 (dd, J = 8.1, 1.8 Hz, 1H, 5-H), 7.43 (d, J = 16.5 Hz, 1H, 9-H), 7.04 (d, J = 16.5 Hz, 1H, 
10-H), 4.69 (t, J = 5.1 Hz, 2H, 14-H), 3.98 (t, J = 5.1 Hz, 2H, 15-H), 3.63−3.58 (m, 5H, 
tetraethylene glycol-H’s), 3.55−3.48 (m, 5H, tetraethylene glycol-H’s), 3.32 (t, J = 5.1 Hz, 2H, 
16-H), 2.23 (s, 3H, 13-H), 1.54 (s, 9H, Boc); 13C NMR (100 MHz, 293 K, acetone-d6): δ = 174.6, 
162.1, 151.8, 141.5, 138.2, 137.8, 133.1, 128.1, 124.1, 122.4, 119.2, 116.2, 110.4, 109.3, 82.9, 
71.0, 70.9, 70.8, 70.7, 70.2, 69.6, 50.9, 47.7, 27.4, 10.9; HRMS (ES+) calcd for C27H34N5O7F3Na 




Preparation of 3.26: A 10-mL round-bottomed flask was charged with 3.25 (17 mg, 0.03 
mmol) then cooled in an ice-water bath mixture. A solution of 1:9 v/v TFA in CH2Cl2 (1 mL) 
was added to 3.25 at the same temperature, then the resulting solution was stirred at the same 
temperature for 45 min, then warmed to 23 °C, and stirred for an additional 22.5 h. The mixture 
was diluted with saturated aqueous NaHCO3 (5 mL) and then the organic layer was separated. 
The aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The combined organic extracts were 
dried over Na2SO4, filtered and concentrated under reduced pressure using a rotary evaporator. 
The crude residue was purified by flash chromatography (30→80% EtOAc in benzene) on silica 
gel (5 mL) to afford 3.26 as a pale yellow oil (13 mg, 89% yield).   
Data for 3.26: Rf = 0.27 (60 % EtOAc in hexanes); IR (film): νmax = 3396 (N-H), 2922, 2872, 
2108 (N3), 1669 (C=O), 1527, 1444, 1291, 1190, 1142 cm
-1; 1H NMR (300 MHz, 293K, 1% 
CD3OD in acetone-d6): δ = 8.40 (br s, 1H, 7-H), 8.26 (d, J = 8.1 Hz, 1H, 4-H), 7.95 (br s, 1H, 2-
H), 7.59 (d, J = 8.1 Hz, 1H, 5-H), 7.12 (d, J = 16.5 Hz, 1H, 9-H), 6.97 (d, J = 16.5 Hz, 1H, 10-
H), 4.66 (t, J = 4.8 Hz, 2H, 14-H), 3.97 (t, J = 4.8 Hz, 2H, 15-H), 3.61−3.53 (m, 4H, 
tetraethylene glycol-H’s), 3.55−3.50 (m, 6H, tetraethylene glycol-H’s), 3.32 (t, J = 4.8 Hz, 2H, 
16-H), 2.10 (s, 3H, 13-H); 13C NMR (100 MHz, 293 K, acetone-d6): δ = 174.2, 155.4, 141.0, 
138.2, 134.2, 132.4, 127.1 123.4, 122.3, 119.3, 116.3, 110.1, 109.4, 71.0, 70.9, 70.8, 70.7, 70.2, 





Preparation of 3.27: A 10-mL round-bottomed flask was charged with 3.21 (21 mg, 0.070 
mmol), MeOH (0.5 mL) and aqueous NaOH (4 M, 0.2 mL) at 23 °C. The resulting solution was 
stirred in a 40 °C oil bath for 9 h. After cooling to 24 °C, the solution was concentrated to 
remove MeOH, then the aqueous mixture was washed with CH2Cl2 (3 × 2 mL). The aqueous 
layer was acidified with aqueous HCl (4 M, 5 mL) and the aqueous layer was extracted with 
CH2Cl2 (2 × 5 mL). The combined organic extracts were dried over Na2SO4, filtered, and 
concentrated to yield the crude carboxylic acid (15.3 mg). A majority of this acid was used 
without further purification.  
A 25-mL round-bottomed flask was charged with the crude carboxylic acid (14.2 mg, 0.06 
mmol), amine 2.29 (16.9 mg, 0.090 mmol), CH2Cl2 (1 mL) and N,N’-dicyclohexylcarbodiimide 
(25 mg, 0.12 mmol) at 23 °C. The mixture was stirred at the same temperature for 4 h, then 
diluted with H2O (7 mL). The organic layer was separated and the aqueous layer was extracted 
with CH2Cl2 (5 × 5 mL). The combined organic extracts were dried over Na2SO4, filtered, and 
concentrated under reduced pressure using a rotary evaporator. The crude residue was purified 
by flash chromatography (40→100% EtOAc in hexanes) on silica gel (10 mL) to afford 3.27 as a 
pale yellow viscous oil (13 mg, 56% yield over 2 steps). 
Data for 3.27: Rf = 0.28 (100 % EtOAc); IR (film): νmax = 3233 (broad, O-H), 2926, 2106 
(N3), 1622 (C=O), 1544, 1452, 1305, 1110 cm
-1; 1H NMR (300 MHz, 293K, 1% CD3OD in 
acetone-d6): δ = 8.18 (d, J = 8.4 Hz, 1H, 4-H), 7.96 (d, J = 1.2 Hz, 1H, 7-H), 7.50 (br s, 1H, 2-
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H), 7.33 (dd, J = 8.4, 1.2 Hz, 1H, 5-H), 6.66 (d, J = 15.9 Hz, 1H, 9-H), 6.10 (dd, J = 15.9, 7.5 
Hz, 1H, 10-H), 3.89 (dq, J = 7.5, 6.3 Hz, 1H, 11-H), 3.70−3.62 (m, 8H, triethylene glycol-H’s), 
3.58 (t, J = 5.1 Hz, 2H, 14’-H), 3.36 (t, J = 5.1 Hz, 2H, 15’-H), 1.27 (d, J = 6.3 Hz, 3H, 13-H); 
13C NMR (100 MHz, 293 K, acetone-d6): δ = 164.5, 137.0, 132.0, 131.4, 129.9, 127.8, 126.1, 
121.2, 119.3, 112.1, 110.0, 77.9, 70.2, 69.9, 69.8, 55.0, 50.5, 38.8, 21.0; ESI-MS calcd for 
C21H28N6O4 [M + CH3CN]+ 428.22, found 428.20. 
 
Procedure for Pd removal: A Deloxan® MP metal scavenger (30 mg) was washed with EtOH 
(20 mL) over a C18 octadecyl column. The washed metal scavenger was added to a 10-mL 
round-bottomed flask equipped with a Teflon-coated magnetic stir bar containing TMC-205 
(12.0 mg). To the flask was added toluene (0.7 mL), using a syringe, under an open atmosphere 
at 23 °C. The mixture was shielded from light and stirred in an 80 °C oil bath for 2 h, then cooled 
to 23 °C. All steps subsequent to cooling were performed in a dark environment. The flask was 
cooled on an ice-water bath for 7 min and then the cold mixture was filtered through a filter 
paper. The filtrate was concentrated under reduced pressure using a rotary evaporator (Twater bath = 
30 °C). The crude residue was purified by preparative TLC (60% EtOAc in hexanes) to give 
TMC-205 (3.1, 11.4 mg) as a pale yellow solid. This product was used for the antiproliferative 
activity assay. All the TMC-205 analogues were purified by the same procedure prior to 
biological experiments.  
I thank Amanda L Garner in our group for analyzing the palladium content of 3.8. See: A. L. 
Garner, F. Song, K. Koide, J. Am. Chem. Soc. 2009, 131, 5163. 
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Cells and reagents: HCT-116 cells was gifts from Professor Andreas Vogt (University of 
Pittsburgh. HCT-116 cells were maintained at 37 °C in an atmosphere containing 5% carbon 
dioxide in Corning cell culture dishes (75 mm) in McCoy’s 5A cell culture medium containing 
10% fetal bovine serum, 1% L-glutamine, and 1% penicillin-streptomycin solution (Invitrogen). 
All synthetic compounds were dissolved in DMSO as stock solutions and stored at -20 °C. For 
the experiments, aliquots were thawed at room temperature in a dark environment, and diluted 
solutions were prepared in McCoy’s 5A medium containing 1% DMSO prior to addition to the 
cell culture media. 
Antiproliferative activity assay: HCT-116 cells were plated in a 96-well plate at an initial 
density of approximately 1 × 104 cells per well in McCoy’s 5A cell culture medium (135 μL) and 
were incubated in an incubator at 37 °C in an atmosphere containing 5% carbon dioxide for 24 h 
prior to compound addition. One plate of cells was used for a time zero cell number 
determination, and cells in other plates were treated for 72 h with either DMSO or a range of 
concentrations, in triplicate, of test agents. Serial two-fold dilutions were used in this experiment. 
The test compounds was added to the cells at the desired concentration in 15 μL medium 
(containing 1% DMSO). Cell proliferation was measured spectrophotometrically using the 
commercial 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS) dye reduction assay with phenazine methosulfate (PMS) as the 
electron acceptor (20 μL per well). The absorbance (at 490 nm minus that at 630 nm) was 
measured by a Spectromax M5 plate reader (Molecular Devices) or Modulus II Microplate 
Multimode Reader (Turner BioSystem). Evaluation of test compounds was performed in 
triplicate at each concentration, and the final numbers were averaged. Microsoft Excel and 
GraphPad Prism 5.0© were used to generate dose-response curves and calculate GI50 values. 
 204 
Growth inhibition was calculated as defined by the National Cancer Institute [GI50 = 100 × (T – 
T0)/(C – T0); T0 = cell density at time zero; T = cell density of the test well after period of 
exposure to test compound; C = cell density of the vehicle treated] (see: 













Figure A3. A representative example of the antiproliferative dose-dependant activity of 
TMC-205 and analogues in cells. 
 (A) 2.43-treated HCT-116 cells. (B) 3.9-treated HCT-116 cells. (C) 3.10-treated HCT-116 cells. 

































































































































































































































































































































































































































































































































































































































































Spectrum 22. 13C NMR spectrum of alkene 2.17 (75 MHz, CDCl3, 293K) 
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Spectrum 24. 13C NMR spectrum of analogue 2.2 (150 MHz, CDCl3, 293K) 
*  grease 



























































































































































































*  acetone 
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Spectrum 36. 1H NMR spectrum of allylic alcohol 2.28 (500 MHz, CDCl3, 293K) 
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Spectrum 38. 1H NMR spectrum of carbamate 2.30 (500 MHz, 1% CD3OD in CDCl3, 293K) 
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Spectrum 39. 1H NMR spectrum of carbamate 2.30 (500 MHz, 1% CD3OD in CDCl3, 293K) 
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Spectrum 40. 1H NMR spectrum of carbamate 2.30 (500 MHz, 1% CD3OD in CDCl3, 293K) 
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Spectrum 41. 13C NMR spectrum of carbamate 2.30 (75 MHz, CDCl3, 293K) 
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Spectrum 42. 1H NMR spectrum of azide 2.33 (500 MHz, CDCl3, 293K) 
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Spectrum 44. 13C NMR spectrum of azide 2.33 (150 MHz, CDCl3, 293K) 
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Spectrum 48. 13C NMR spectrum of 4’-desacetyl meayamycin C 2.39 (150 MHz, CDCl3, 293K) 
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Spectrum 49. 1H NMR spectrum of 4-TEGylated meayamycin 2.43 (500 MHz, CDCl3, 293K) 
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Spectrum 51. 1H NMR spectrum of 4-TEGylated meayamycin 2.43 (500 MHz, CDCl3, 293K) 
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Spectrum 53. 1H NMR spectrum of TEGylated right fragment 2.44 (400 MHz, CDCl3, 293K) 
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Spectrum 58. 1H NMR spectrum of epoxide 2.47 (400 MHz, CDCl3, 293K) 
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Spectrum 59. 13C NMR spectrum of epoxide 2.47 (100 MHz, CDCl3, 293K) 
 269 
 
Spectrum 60. 1H NMR spectrum of silyl enol ether 2.66 (300 MHz, CDCl3, 293K) 
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Spectrum 61. 13C NMR spectrum of silyl enol ether 2.66 (100 MHz, CDCl3, 293K) 
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Spectrum 63. 1H NMR spectrum of allylic alcohol 2.63 (100 MHz, CDCl3, 293K) 
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Spectrum 65. 13C NMR spectrum of diene 2.64 (75 MHz, CDCl3, 293K) 
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Spectrum 66. 1H NMR spectrum of diene 2.76 (300 MHz, CDCl3, 293K) 
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Spectrum 67. 13C NMR spectrum of diene 2.76 (75 MHz, CDCl3, 293K) 
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Spectrum 68. 1H NMR spectrum of epoxide 2.61 (300 MHz, CDCl3, 293K) 
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Spectrum 69. 13C NMR spectrum of epoxide 2.61 (175 MHz, CDCl3, 293K) 
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Spectrum 70. 1H NMR spectrum of ketone 2.25 (300 MHz, 1% CD3OD in C6D6, 293K) 
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Spectrum 71. 13C NMR spectrum of ketone 2.25 (75 MHz, CDCl3, 293K) 
 281 
 
Spectrum 72. 1H NMR spectrum of Mosher ester derivative 2.77 (400 MHz, CDCl3, 293K) 
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Spectrum 73. 1H NMR spectrum of Mosher ester derivative 2.77 (400 MHz, CDCl3, 293K) 
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 Spectrum 74. 1H NMR spectrum of carboxylic acid 3.6 (300 MHz, DMSO-d6, 293K) 
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Spectrum 76. 13C NMR spectrum of alkenyl stannane 3.3 (75 MHz, CDCl3, 293K) 
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Spectrum 77. 1H NMR spectrum of methyl ester 3.7 (300 MHz, CD3OD, 293K) 




Spectrum 78. 1H NMR spectrum of methyl ester 3.8 (300 MHz, CD3OD, 293K) 
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Spectrum 79. 13C NMR spectrum of methyl ester 3.8 (75 MHz, CD3OD, 293K) 
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Spectrum 80. 1H NMR spectrum of TMC-205 (3.1) (500 MHz, CD3OD, 293K) 
grease    → 
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Spectrum 81. 13C NMR spectrum of TMC-205 (3.1) (75 MHz, CD3OD, 293K) 
 291 
  
Spectrum 82. 1H NMR spectrum of TMC-205 (3.1) (700 MHz, DMSO-d6, 293K) 
impurity    → 
H2O    → 
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Spectrum 86. 13C NMR spectrum of decarboxylated analogue 3.9 (75 MHz, CD3OD, 293K) 
 296 
 














Spectrum 90. 13C NMR spectrum of 3.11 (75 MHz, CD3OD, 293K) 
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Spectrum 95. 1H NMR spectrum of N-methylated analogue 3.14 (300 MHz, CD3OD, 293K) 
grease    → 












Spectrum 98. 13C NMR spectrum of 3.16 (175 MHz, CD3OD, 293K)  
 308 
 
Spectrum 99. 1H NMR spectrum of 3.17 (700 MHz, CD3OD, 293K) 
grease    → 
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Spectrum 103. 13C NMR spectrum of alkene 3.19 (100 MHz, acetone-d6, 293K) 
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Spectrum 104. 1H NMR spectrum of enone 3.20 (300 MHz, CD3OD, 293K) 







Spectrum 105. 13C NMR spectrum of enone 3.20 (175 MHz, CD3OD, 293K) 
 315 
 




Spectrum 107. 13C NMR spectrum of allylic alcohol 3.21 (75 MHz, CD3OD, 293K) 
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Spectrum 108. 1H NMR spectrum of allylic alcohol 3.22 (300 MHz, 1%CD3OD in acetone-d6 293K) 
H2O    → 
 318 
 
Spectrum 109. 13C NMR spectrum of allylic alcohol 3.22 (75 MHz, acetone-d6, 293K) 
 319 
 
Spectrum 110. 1H NMR spectrum of oxime 3.23 (300 MHz, 1%CD3OD in acetone-d6 293K) 








Spectrum 112. 1H NMR spectrum of 3.25 (300 MHz, acetone-d6, 293K) 
H2O    → 
 322 
 




Spectrum 114. 13C NMR spectrum of 3.25 (100 MHz, acetone-d6, 293K) 
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Spectrum 115. 1H NMR spectrum of 3.26 (300 MHz, 1%CD3OD in acetone-d6 293K) 
H2O    → 


















Spectrum 118. 13C NMR spectrum of 3.26 (100 MHz, acetone-d6, 293K) 
 328 
 
Spectrum 119. 1H NMR spectrum of 3.27 (300 MHz, 1%CD3OD in acetone-d6 293K) 
 329 
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